<html>
<head><meta http-equiv=Content-Type content="text/html; charset=UTF-8">
<style type="text/css">
<!--
span.cls_003{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_003{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_004{font-family:Times,serif;font-size:18.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_004{font-family:Times,serif;font-size:18.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_005{font-family:Arial,serif;font-size:18.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_005{font-family:Arial,serif;font-size:18.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_006{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_006{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_007{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_007{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_008{font-family:Times,serif;font-size:14.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_008{font-family:Times,serif;font-size:14.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_009{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_009{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_010{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_010{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_011{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
div.cls_011{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
span.cls_012{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_012{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_002{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_002{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_013{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
div.cls_013{font-family:Times,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
span.cls_014{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_014{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_015{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_015{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_016{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
div.cls_016{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
span.cls_023{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: underline}
div.cls_023{font-family:Times,serif;font-size:11.1px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
span.cls_017{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
div.cls_017{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:bold;font-style:normal;text-decoration: none}
span.cls_018{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
div.cls_018{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:bold;font-style:italic;text-decoration: none}
span.cls_019{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_019{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_020{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
div.cls_020{font-family:Times,serif;font-size:9.3px;color:rgb(43,42,41);font-weight:normal;font-style:italic;text-decoration: none}
span.cls_021{font-family:Arial,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_021{font-family:Arial,serif;font-size:12.1px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
span.cls_022{font-family:Times,serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
div.cls_022{font-family:Times,serif;font-size:7.0px;color:rgb(43,42,41);font-weight:normal;font-style:normal;text-decoration: none}
-->
</style>
<script type="text/javascript" src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/wz_jsgraphics.js"></script>
</head>
<body>
<div style="position:absolute;left:50%;margin-left:-297px;top:0px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background01.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_003"><span class="cls_003">Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no</span></div>
<div style="position:absolute;left:28.35px;top:56.61px" class="cls_003"><span class="cls_003">responsibility for the contents of this announcement, make no representation as to its accuracy or</span></div>
<div style="position:absolute;left:28.35px;top:73.61px" class="cls_003"><span class="cls_003">completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or</span></div>
<div style="position:absolute;left:28.35px;top:90.62px" class="cls_003"><span class="cls_003">in reliance upon the whole or any part of the contents of this announcement.</span></div>
<div style="position:absolute;left:94.73px;top:203.19px" class="cls_004"><span class="cls_004">CSPC PHARMACEUTICAL GROUP LIMITED</span></div>
<div style="position:absolute;left:210.67px;top:225.20px" class="cls_005"><span class="cls_005">石藥集團有限公司</span></div>
<div style="position:absolute;left:145.61px;top:247.19px" class="cls_006"><span class="cls_006">(Incorporated in Hong Kong under the Companies Ordinance)</span></div>
<div style="position:absolute;left:246.22px;top:261.19px" class="cls_007"><span class="cls_007">(Stock code: 1093)</span></div>
<div style="position:absolute;left:230.28px;top:295.20px" class="cls_008"><span class="cls_008">ANNUAL RESULTS</span></div>
<div style="position:absolute;left:140.76px;top:314.19px" class="cls_008"><span class="cls_008">FOR THE YEAR ENDED 31 DECEMBER 2019</span></div>
<div style="position:absolute;left:34.48px;top:353.95px" class="cls_007"><span class="cls_007">FINANCIAL HIGHLIGHTS</span></div>
<div style="position:absolute;left:367.05px;top:382.89px" class="cls_009"><span class="cls_009">2019</span></div>
<div style="position:absolute;left:452.09px;top:382.89px" class="cls_010"><span class="cls_010">2018</span></div>
<div style="position:absolute;left:525.60px;top:382.89px" class="cls_010"><span class="cls_010">Change</span></div>
<div style="position:absolute;left:344.93px;top:397.89px" class="cls_011"><span class="cls_011">RMB’000</span></div>
<div style="position:absolute;left:431.69px;top:397.89px" class="cls_012"><span class="cls_012">RMB’000</span></div>
<div style="position:absolute;left:34.26px;top:427.89px" class="cls_010"><span class="cls_010">Revenue by business units:</span></div>
<div style="position:absolute;left:34.26px;top:442.89px" class="cls_010"><span class="cls_010">Finished drugs</span></div>
<div style="position:absolute;left:339.25px;top:442.89px" class="cls_009"><span class="cls_009">17,937,001</span></div>
<div style="position:absolute;left:424.29px;top:442.89px" class="cls_010"><span class="cls_010">13,503,386</span></div>
<div style="position:absolute;left:524.66px;top:442.89px" class="cls_010"><span class="cls_010">+32.8%</span></div>
<div style="position:absolute;left:34.26px;top:457.89px" class="cls_010"><span class="cls_010">Vitamin C</span></div>
<div style="position:absolute;left:344.73px;top:457.89px" class="cls_009"><span class="cls_009">1,921,704</span></div>
<div style="position:absolute;left:429.77px;top:457.89px" class="cls_010"><span class="cls_010">1,783,510</span></div>
<div style="position:absolute;left:530.14px;top:457.89px" class="cls_010"><span class="cls_010">+7.7%</span></div>
<div style="position:absolute;left:34.25px;top:472.89px" class="cls_010"><span class="cls_010">Antibiotics</span></div>
<div style="position:absolute;left:353.14px;top:472.89px" class="cls_009"><span class="cls_009">878,921</span></div>
<div style="position:absolute;left:429.76px;top:472.89px" class="cls_010"><span class="cls_010">1,086,725</span></div>
<div style="position:absolute;left:527.01px;top:472.89px" class="cls_010"><span class="cls_010">-19.1%</span></div>
<div style="position:absolute;left:34.25px;top:487.89px" class="cls_010"><span class="cls_010">Others</span></div>
<div style="position:absolute;left:344.72px;top:487.89px" class="cls_009"><span class="cls_009">1,365,566</span></div>
<div style="position:absolute;left:429.76px;top:487.89px" class="cls_010"><span class="cls_010">1,342,919</span></div>
<div style="position:absolute;left:530.13px;top:487.89px" class="cls_010"><span class="cls_010">+1.7%</span></div>
<div style="position:absolute;left:34.26px;top:520.89px" class="cls_010"><span class="cls_010">Total revenue</span></div>
<div style="position:absolute;left:339.25px;top:520.89px" class="cls_009"><span class="cls_009">22,103,192</span></div>
<div style="position:absolute;left:424.29px;top:520.89px" class="cls_010"><span class="cls_010">17,716,540</span></div>
<div style="position:absolute;left:524.66px;top:520.89px" class="cls_010"><span class="cls_010">+24.8%</span></div>
<div style="position:absolute;left:34.26px;top:558.14px" class="cls_010"><span class="cls_010">Gross profit</span></div>
<div style="position:absolute;left:339.25px;top:558.14px" class="cls_009"><span class="cls_009">15,910,981</span></div>
<div style="position:absolute;left:424.29px;top:558.14px" class="cls_010"><span class="cls_010">11,737,353</span></div>
<div style="position:absolute;left:524.66px;top:558.14px" class="cls_010"><span class="cls_010">+35.6%</span></div>
<div style="position:absolute;left:34.26px;top:588.14px" class="cls_010"><span class="cls_010">Operating profit</span></div>
<div style="position:absolute;left:344.73px;top:588.14px" class="cls_009"><span class="cls_009">4,600,181</span></div>
<div style="position:absolute;left:429.77px;top:588.14px" class="cls_010"><span class="cls_010">3,822,962</span></div>
<div style="position:absolute;left:524.66px;top:588.14px" class="cls_010"><span class="cls_010">+20.3%</span></div>
<div style="position:absolute;left:34.26px;top:618.14px" class="cls_010"><span class="cls_010">Profit attributable to shareholders</span></div>
<div style="position:absolute;left:344.73px;top:618.14px" class="cls_009"><span class="cls_009">3,714,106</span></div>
<div style="position:absolute;left:429.77px;top:618.14px" class="cls_010"><span class="cls_010">3,080,802</span></div>
<div style="position:absolute;left:524.66px;top:618.14px" class="cls_010"><span class="cls_010">+20.6%</span></div>
<div style="position:absolute;left:34.26px;top:648.14px" class="cls_010"><span class="cls_010">Basic earnings per share</span></div>
<div style="position:absolute;left:312.06px;top:648.14px" class="cls_009"><span class="cls_009">RMB59.65 cents</span><span class="cls_010">  RMB49.36 cents</span></div>
<div style="position:absolute;left:524.66px;top:648.14px" class="cls_010"><span class="cls_010">+20.8%</span></div>
<div style="position:absolute;left:34.26px;top:678.14px" class="cls_010"><span class="cls_010">Final dividend per share</span></div>
<div style="position:absolute;left:333.93px;top:678.14px" class="cls_009"><span class="cls_009">HK20 cents</span></div>
<div style="position:absolute;left:421.24px;top:678.14px" class="cls_010"><span class="cls_010">HK18 cents</span></div>
<div style="position:absolute;left:524.66px;top:678.14px" class="cls_010"><span class="cls_010">+11.1%</span></div>
<div style="position:absolute;left:34.27px;top:709.17px" class="cls_002"><span class="cls_002">The Board has also proposed a bonus issue of one new share for every five existing shares held by</span></div>
<div style="position:absolute;left:34.27px;top:726.18px" class="cls_002"><span class="cls_002">shareholders of the Company, which is subject to shareholders’ approval at the forthcoming annual</span></div>
<div style="position:absolute;left:34.27px;top:743.18px" class="cls_002"><span class="cls_002">general meeting of the Company.</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 1 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:851px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background02.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">Chairman’s Statement</span></div>
<div style="position:absolute;left:28.55px;top:73.60px" class="cls_007"><span class="cls_007">RESULTS</span></div>
<div style="position:absolute;left:28.33px;top:107.60px" class="cls_002"><span class="cls_002">For the year ended 31 December 2019, the Group achieved a revenue of RMB22,103 million, which</span></div>
<div style="position:absolute;left:28.33px;top:124.60px" class="cls_002"><span class="cls_002">was 24.8% higher than last year; and a profit attributable to shareholders of RMB3,714 million,</span></div>
<div style="position:absolute;left:28.33px;top:141.60px" class="cls_002"><span class="cls_002">which was 20.6% higher than last year. Basic earnings per share amounted to RMB59.65 cents.</span></div>
<div style="position:absolute;left:28.55px;top:175.60px" class="cls_007"><span class="cls_007">DIVIDEND</span></div>
<div style="position:absolute;left:28.33px;top:209.60px" class="cls_002"><span class="cls_002">The Board of Directors of the Company has recommended the payment of a final dividend of</span></div>
<div style="position:absolute;left:28.33px;top:226.60px" class="cls_002"><span class="cls_002">HK20 cents per share for the year ended 31 December 2019 (2018: HK18 cents per share). Subject</span></div>
<div style="position:absolute;left:28.33px;top:243.60px" class="cls_002"><span class="cls_002">to approval by the shareholders at the forthcoming annual general meeting of the Company, the</span></div>
<div style="position:absolute;left:28.33px;top:260.61px" class="cls_002"><span class="cls_002">proposed final dividend will be payable on</span></div>
<div style="position:absolute;left:276.27px;top:260.61px" class="cls_002"><span class="cls_002">3 July</span></div>
<div style="position:absolute;left:317.25px;top:260.61px" class="cls_002"><span class="cls_002">2020 to shareholders of the Company whose</span></div>
<div style="position:absolute;left:28.33px;top:277.61px" class="cls_002"><span class="cls_002">names appear on the register of members of the Company on 23 June 2020.</span></div>
<div style="position:absolute;left:28.55px;top:311.61px" class="cls_007"><span class="cls_007">BONUS ISSUE OF SHARES</span></div>
<div style="position:absolute;left:28.33px;top:345.60px" class="cls_002"><span class="cls_002">The Board has also proposed a bonus issue of one new share for every five existing shares held by</span></div>
<div style="position:absolute;left:28.33px;top:362.61px" class="cls_002"><span class="cls_002">shareholders of the Company whose names appear on the register of members of the Company on</span></div>
<div style="position:absolute;left:28.33px;top:379.61px" class="cls_002"><span class="cls_002">23 June 2020, which is subject to shareholders’ approval at the forthcoming annual general meeting</span></div>
<div style="position:absolute;left:28.33px;top:396.62px" class="cls_002"><span class="cls_002">of the Company. Details of this bonus issue will be disclosed in the circular to be published by the</span></div>
<div style="position:absolute;left:28.33px;top:413.62px" class="cls_002"><span class="cls_002">Company in due course.</span></div>
<div style="position:absolute;left:28.55px;top:447.62px" class="cls_007"><span class="cls_007">INDUSTRY REVIEW</span></div>
<div style="position:absolute;left:28.33px;top:481.61px" class="cls_002"><span class="cls_002">The year</span></div>
<div style="position:absolute;left:85.93px;top:481.61px" class="cls_002"><span class="cls_002">2019 has witnessed the continuous progress of national healthcare reform and the</span></div>
<div style="position:absolute;left:28.33px;top:498.62px" class="cls_002"><span class="cls_002">promulgation of a number of policies regulating the development of the pharmaceutical industry.</span></div>
<div style="position:absolute;left:28.33px;top:515.62px" class="cls_002"><span class="cls_002">The implementation of various important measures, including nationwide centralised procurement of</span></div>
<div style="position:absolute;left:28.33px;top:532.62px" class="cls_002"><span class="cls_002">medicines, national reimbursement drug list negotiation, key drugs for monitoring and prescription</span></div>
<div style="position:absolute;left:28.33px;top:549.63px" class="cls_002"><span class="cls_002">control, accelerating review of innovative drugs, consistency evaluations of generic drugs and</span></div>
<div style="position:absolute;left:28.33px;top:566.63px" class="cls_002"><span class="cls_002">pilot trial of Diagnosis Related Groups</span></div>
<div style="position:absolute;left:251.33px;top:566.63px" class="cls_002"><span class="cls_002">(DRGs), has profound impact on the development of the</span></div>
<div style="position:absolute;left:28.33px;top:583.64px" class="cls_002"><span class="cls_002">pharmaceutical industry. Under such policy environment, Chinese pharmaceutical enterprises will</span></div>
<div style="position:absolute;left:28.33px;top:600.64px" class="cls_002"><span class="cls_002">accelerate the transformation of development focus from generic drugs to innovative drugs. With</span></div>
<div style="position:absolute;left:28.33px;top:617.64px" class="cls_002"><span class="cls_002">the strong R&D capability of innovation, rich pipeline of products, outstanding commercialization</span></div>
<div style="position:absolute;left:28.33px;top:634.65px" class="cls_002"><span class="cls_002">capability and comprehensive productivity, the Group has fully grasped the opportunities brought</span></div>
<div style="position:absolute;left:28.33px;top:651.65px" class="cls_002"><span class="cls_002">by the healthcare reform, further consolidated its competitive advantages and enhanced its market</span></div>
<div style="position:absolute;left:28.33px;top:668.66px" class="cls_002"><span class="cls_002">position.</span></div>
<div style="position:absolute;left:28.55px;top:702.65px" class="cls_007"><span class="cls_007">BUSINESS REVIEW</span></div>
<div style="position:absolute;left:28.33px;top:736.65px" class="cls_002"><span class="cls_002">In</span></div>
<div style="position:absolute;left:45.06px;top:736.65px" class="cls_002"><span class="cls_002">2019, the Group’s innovative drug products continued to maintain rapid growth. Key products</span></div>
<div style="position:absolute;left:28.33px;top:753.65px" class="cls_002"><span class="cls_002">such as NBP, Duomeisu, Jinyouli and Keaili recorded remarkable sales results once again. The new</span></div>
<div style="position:absolute;left:28.33px;top:770.66px" class="cls_002"><span class="cls_002">inclusion into 4 guidelines and conducting of more than 100 medical research projects cumulatively</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 2 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:1702px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background03.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_002"><span class="cls_002">provided NBP with strong support for market penetration and continuous growth. The oncology</span></div>
<div style="position:absolute;left:28.35px;top:56.61px" class="cls_002"><span class="cls_002">drugs further enhanced their market coverage over target hospitals with the continuous increase in</span></div>
<div style="position:absolute;left:28.35px;top:73.61px" class="cls_002"><span class="cls_002">investment in academic-based promotion and expansion of professional sales force. Keaili has taken</span></div>
<div style="position:absolute;left:28.35px;top:90.62px" class="cls_002"><span class="cls_002">less than 2 years to build its sales team to nearly 1,000 people covering nearly 1,500 hospitals, and</span></div>
<div style="position:absolute;left:28.35px;top:107.62px" class="cls_002"><span class="cls_002">achieved a breakthrough in sales growth. For common generic drug products, Encun (clopidogrel</span></div>
<div style="position:absolute;left:28.35px;top:124.62px" class="cls_002"><span class="cls_002">bisulfate tablets) won the first place at the nationwide expansion tender of the</span></div>
<div style="position:absolute;left:472.62px;top:124.62px" class="cls_002"><span class="cls_002">“4+7” centralised</span></div>
<div style="position:absolute;left:28.35px;top:141.63px" class="cls_002"><span class="cls_002">procurement and rapidly entered the hospital market, demonstrating the development advantages of</span></div>
<div style="position:absolute;left:28.35px;top:158.63px" class="cls_002"><span class="cls_002">the Group’s common generic drug products under the policy of nationwide centralised procurement</span></div>
<div style="position:absolute;left:28.35px;top:175.64px" class="cls_002"><span class="cls_002">of medicines. During the year, the Group’s Qixiao (arbidol hydrochloride tablets) was relaunched.</span></div>
<div style="position:absolute;left:28.35px;top:192.64px" class="cls_002"><span class="cls_002">Its efficacy was quickly confirmed during the novel coronavirus epidemic, and was included into the</span></div>
<div style="position:absolute;left:28.35px;top:209.64px" class="cls_002"><span class="cls_002">national “Guidelines for Diagnosis and Treatment of Influenza” and “Guidelines for Diagnosis and</span></div>
<div style="position:absolute;left:28.35px;top:226.65px" class="cls_002"><span class="cls_002">Treatment of Novel Coronavirus Pneumonia”.</span></div>
<div style="position:absolute;left:28.35px;top:260.64px" class="cls_002"><span class="cls_002">Since the beginning of 2019, a total of 10 products have been granted drug registration approval</span></div>
<div style="position:absolute;left:28.35px;top:277.65px" class="cls_002"><span class="cls_002">in China, 16 products granted clinical trial approval and 17 products have passed the consistency</span></div>
<div style="position:absolute;left:28.35px;top:294.65px" class="cls_002"><span class="cls_002">evaluation of generic drugs. In addition, Xuanning was granted marketing approval by the U.S.</span></div>
<div style="position:absolute;left:28.35px;top:311.66px" class="cls_002"><span class="cls_002">Food and Drug Administration (FDA) during the year, making it the first Chinese innovative drug</span></div>
<div style="position:absolute;left:28.35px;top:328.66px" class="cls_002"><span class="cls_002">granted full approval by U.S. FDA. Key product Amphotericin B Cholesteryl Sulfate Complex has</span></div>
<div style="position:absolute;left:28.35px;top:345.66px" class="cls_002"><span class="cls_002">been qualified for priority review and is expected to be approved for launch in 2020; Mitoxantrone</span></div>
<div style="position:absolute;left:28.35px;top:362.67px" class="cls_002"><span class="cls_002">Liposome has completed enrolment for pivotal clinical trial and submitted the application for pre-</span></div>
<div style="position:absolute;left:28.35px;top:379.67px" class="cls_002"><span class="cls_002">NDA meeting; Duvelisib Capsules and JMT103 (RANKL target) have entered the pivotal clinical</span></div>
<div style="position:absolute;left:28.35px;top:396.68px" class="cls_002"><span class="cls_002">trial stage, being the fastest in China; ALMB-0166 and ALMB-0168 have been granted approval to</span></div>
<div style="position:absolute;left:28.35px;top:413.68px" class="cls_002"><span class="cls_002">commence clinical trials in Australia. The clinical development of products and indications has made</span></div>
<div style="position:absolute;left:28.35px;top:430.68px" class="cls_002"><span class="cls_002">good progress during 2019.</span></div>
<div style="position:absolute;left:28.56px;top:464.68px" class="cls_007"><span class="cls_007">OUTLOOK</span></div>
<div style="position:absolute;left:28.35px;top:498.68px" class="cls_002"><span class="cls_002">In addition to maintaining stable growth of its existing products, the Group will enhance its R&D</span></div>
<div style="position:absolute;left:28.35px;top:515.68px" class="cls_002"><span class="cls_002">efficiency and expedite the launch of new drugs with high potentials. The Group will also formulate</span></div>
<div style="position:absolute;left:28.35px;top:532.68px" class="cls_002"><span class="cls_002">effective sales strategies in response to the market environment and product advantages, so as to</span></div>
<div style="position:absolute;left:28.35px;top:549.69px" class="cls_002"><span class="cls_002">improve product mix and enhance its comprehensive competitiveness. The existing key products</span></div>
<div style="position:absolute;left:28.35px;top:566.69px" class="cls_002"><span class="cls_002">such as NBP, Duomeisu, Jinyouli, Keaili and Xuanning have their own competitive edges in terms of</span></div>
<div style="position:absolute;left:28.35px;top:583.70px" class="cls_002"><span class="cls_002">market and brand. The Group will continue to adopt the sales strategy of academic-based promotion</span></div>
<div style="position:absolute;left:28.35px;top:600.70px" class="cls_002"><span class="cls_002">and market penetration or development to achieve sustained rapid growth of these products. Newly</span></div>
<div style="position:absolute;left:28.35px;top:617.70px" class="cls_002"><span class="cls_002">launched products will become new growth drivers. Most of these products, including Daxinning</span></div>
<div style="position:absolute;left:28.35px;top:634.71px" class="cls_002"><span class="cls_002">(dronedarone hydrochloride tablets), Shuanling</span></div>
<div style="position:absolute;left:309.88px;top:634.71px" class="cls_002"><span class="cls_002">(pentoxifylline injections/tablets), Meiluolin</span></div>
<div style="position:absolute;left:28.35px;top:651.71px" class="cls_002"><span class="cls_002">(ticagrelor tablets), Gubangjia</span></div>
<div style="position:absolute;left:197.93px;top:651.71px" class="cls_002"><span class="cls_002">(alendronate sodium-vitamin D3 tablets), Gaoshunsong (acemetacin</span></div>
<div style="position:absolute;left:28.35px;top:668.72px" class="cls_002"><span class="cls_002">extended-release capsules), Qixiao (arbidol hydrochloride tablets), Luoruite (erlotinib hydrochloride</span></div>
<div style="position:absolute;left:28.35px;top:685.72px" class="cls_002"><span class="cls_002">tablets), Enxi</span></div>
<div style="position:absolute;left:109.33px;top:685.72px" class="cls_002"><span class="cls_002">(pramipexole hydrochloride tablets), montelukast sodium tablets/chewable tablets,</span></div>
<div style="position:absolute;left:28.35px;top:702.72px" class="cls_002"><span class="cls_002">sitagliptin phosphate tablets and nintedanib esilate soft capsules, are exclusive or first-to-market</span></div>
<div style="position:absolute;left:28.35px;top:719.73px" class="cls_002"><span class="cls_002">products in China. With strong clinical demands, the market potential is expected to reach between</span></div>
<div style="position:absolute;left:28.35px;top:736.73px" class="cls_002"><span class="cls_002">RMB1 billion and RMB3 billion for a single product. The Group will also actively participate in the</span></div>
<div style="position:absolute;left:28.35px;top:753.74px" class="cls_002"><span class="cls_002">nationwide centralised procurement of medicines to leverage the opportunity provided by the policy,</span></div>
<div style="position:absolute;left:28.35px;top:770.74px" class="cls_002"><span class="cls_002">in order to facilitate generic drugs to rapidly occupy the hospital market.</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 3 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:2553px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background04.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_002"><span class="cls_002">The Group has a leading R&D team in China with R&D centres located in Shijiazhuang, Shanghai</span></div>
<div style="position:absolute;left:28.35px;top:56.61px" class="cls_002"><span class="cls_002">and Suzhou, as well as California and New Jersey in the U.S.. It has a comprehensive layout for</span></div>
<div style="position:absolute;left:28.35px;top:73.61px" class="cls_002"><span class="cls_002">small molecule and macromolecule innovative drugs and new preparations covering major therapeutic</span></div>
<div style="position:absolute;left:28.35px;top:90.62px" class="cls_002"><span class="cls_002">areas, with more than 300 products under development. The Group will adhere to innovative R&D</span></div>
<div style="position:absolute;left:28.35px;top:107.62px" class="cls_002"><span class="cls_002">strategies and continue to increase R&D investment to ensure a stable growth.</span></div>
<div style="position:absolute;left:28.56px;top:141.62px" class="cls_007"><span class="cls_007">appreciation</span></div>
<div style="position:absolute;left:28.35px;top:175.61px" class="cls_002"><span class="cls_002">I would like to take this opportunity to express my gratitude to all staff for their dedication and hard</span></div>
<div style="position:absolute;left:28.35px;top:192.62px" class="cls_002"><span class="cls_002">work, and to all our shareholders and customers for their continued support.</span></div>
<div style="position:absolute;left:469.29px;top:260.62px" class="cls_007"><span class="cls_007">CAI Dongchen</span></div>
<div style="position:absolute;left:484.32px;top:277.62px" class="cls_003"><span class="cls_003">Chairman</span></div>
<div style="position:absolute;left:28.35px;top:311.62px" class="cls_002"><span class="cls_002">Hong Kong, 30 March 2020</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 4 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:3404px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background05.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">RESULTS</span></div>
<div style="position:absolute;left:28.35px;top:71.61px" class="cls_002"><span class="cls_002">The Board of Directors of CSPC Pharmaceutical Group Limited (the “Company”) is pleased to</span></div>
<div style="position:absolute;left:28.35px;top:87.60px" class="cls_002"><span class="cls_002">announce the audited consolidated results of the Company and its subsidiaries (the “Group”) for the</span></div>
<div style="position:absolute;left:28.35px;top:103.60px" class="cls_002"><span class="cls_002">year ended 31 December 2019 as follows:</span></div>
<div style="position:absolute;left:28.56px;top:135.60px" class="cls_007"><span class="cls_007">CONSOLIDATED STATEMENT OF PROFIT OR LOSS</span></div>
<div style="position:absolute;left:28.35px;top:151.60px" class="cls_003"><span class="cls_003">For the year ended 31 December 2019</span></div>
<div style="position:absolute;left:456.54px;top:185.44px" class="cls_007"><span class="cls_007">2019</span></div>
<div style="position:absolute;left:541.59px;top:185.44px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:369.53px;top:200.44px" class="cls_003"><span class="cls_003">Notes</span></div>
<div style="position:absolute;left:430.51px;top:200.44px" class="cls_013"><span class="cls_013">RMB’000</span></div>
<div style="position:absolute;left:517.57px;top:200.44px" class="cls_003"><span class="cls_003">RMB’000</span></div>
<div style="position:absolute;left:517.56px;top:215.44px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:28.35px;top:245.44px" class="cls_002"><span class="cls_002">Revenue</span></div>
<div style="position:absolute;left:381.10px;top:245.44px" class="cls_003"><span class="cls_003">3</span></div>
<div style="position:absolute;left:423.84px;top:245.44px" class="cls_007"><span class="cls_007">22,103,192</span></div>
<div style="position:absolute;left:508.89px;top:245.44px" class="cls_002"><span class="cls_002">17,716,540</span></div>
<div style="position:absolute;left:28.36px;top:260.44px" class="cls_002"><span class="cls_002">Cost of sales</span></div>
<div style="position:absolute;left:425.40px;top:260.44px" class="cls_007"><span class="cls_007">(6,192,211)</span></div>
<div style="position:absolute;left:510.45px;top:260.44px" class="cls_002"><span class="cls_002">(5,979,187)</span></div>
<div style="position:absolute;left:28.35px;top:293.44px" class="cls_002"><span class="cls_002">Gross profit</span></div>
<div style="position:absolute;left:423.84px;top:293.44px" class="cls_007"><span class="cls_007">15,910,981</span></div>
<div style="position:absolute;left:508.89px;top:293.44px" class="cls_002"><span class="cls_002">11,737,353</span></div>
<div style="position:absolute;left:28.36px;top:308.44px" class="cls_002"><span class="cls_002">Other income</span></div>
<div style="position:absolute;left:440.20px;top:308.44px" class="cls_007"><span class="cls_007">243,783</span></div>
<div style="position:absolute;left:525.24px;top:308.44px" class="cls_002"><span class="cls_002">139,742</span></div>
<div style="position:absolute;left:28.36px;top:323.44px" class="cls_002"><span class="cls_002">Other gains or losses</span></div>
<div style="position:absolute;left:446.65px;top:323.44px" class="cls_007"><span class="cls_007">48,450</span></div>
<div style="position:absolute;left:525.24px;top:323.44px" class="cls_002"><span class="cls_002">155,195</span></div>
<div style="position:absolute;left:28.36px;top:338.44px" class="cls_002"><span class="cls_002">Selling and distribution expenses</span></div>
<div style="position:absolute;left:425.40px;top:338.44px" class="cls_007"><span class="cls_007">(8,712,083)</span></div>
<div style="position:absolute;left:510.45px;top:338.44px" class="cls_002"><span class="cls_002">(6,184,505)</span></div>
<div style="position:absolute;left:28.36px;top:353.44px" class="cls_002"><span class="cls_002">Administrative expenses</span></div>
<div style="position:absolute;left:435.30px;top:353.44px" class="cls_007"><span class="cls_007">(748,509)</span></div>
<div style="position:absolute;left:520.35px;top:353.44px" class="cls_002"><span class="cls_002">(656,597)</span></div>
<div style="position:absolute;left:28.36px;top:368.44px" class="cls_002"><span class="cls_002">Research and development expenses</span></div>
<div style="position:absolute;left:425.40px;top:368.44px" class="cls_007"><span class="cls_007">(2,000,426)</span></div>
<div style="position:absolute;left:510.45px;top:368.44px" class="cls_002"><span class="cls_002">(1,342,101)</span></div>
<div style="position:absolute;left:28.36px;top:383.44px" class="cls_002"><span class="cls_002">Other expenses</span></div>
<div style="position:absolute;left:435.30px;top:383.44px" class="cls_007"><span class="cls_007">(142,015)</span></div>
<div style="position:absolute;left:526.79px;top:383.44px" class="cls_002"><span class="cls_002">(26,125)</span></div>
<div style="position:absolute;left:28.35px;top:416.44px" class="cls_002"><span class="cls_002">Operating profit</span></div>
<div style="position:absolute;left:430.29px;top:416.44px" class="cls_007"><span class="cls_007">4,600,181</span></div>
<div style="position:absolute;left:515.33px;top:416.44px" class="cls_002"><span class="cls_002">3,822,962</span></div>
<div style="position:absolute;left:28.35px;top:431.44px" class="cls_002"><span class="cls_002">Finance costs</span></div>
<div style="position:absolute;left:441.75px;top:431.44px" class="cls_007"><span class="cls_007">(32,426)</span></div>
<div style="position:absolute;left:526.79px;top:431.44px" class="cls_002"><span class="cls_002">(74,337)</span></div>
<div style="position:absolute;left:28.36px;top:446.44px" class="cls_002"><span class="cls_002">Share of results of joint ventures</span></div>
<div style="position:absolute;left:446.65px;top:446.44px" class="cls_007"><span class="cls_007">58,407</span></div>
<div style="position:absolute;left:531.70px;top:446.44px" class="cls_002"><span class="cls_002">43,554</span></div>
<div style="position:absolute;left:28.35px;top:479.44px" class="cls_002"><span class="cls_002">Profit before tax</span></div>
<div style="position:absolute;left:430.29px;top:479.44px" class="cls_007"><span class="cls_007">4,626,162</span></div>
<div style="position:absolute;left:515.33px;top:479.44px" class="cls_002"><span class="cls_002">3,792,179</span></div>
<div style="position:absolute;left:28.35px;top:494.44px" class="cls_002"><span class="cls_002">Income tax expense</span></div>
<div style="position:absolute;left:381.10px;top:494.44px" class="cls_003"><span class="cls_003">5</span></div>
<div style="position:absolute;left:435.30px;top:494.44px" class="cls_007"><span class="cls_007">(892,810)</span></div>
<div style="position:absolute;left:520.35px;top:494.44px" class="cls_002"><span class="cls_002">(733,760)</span></div>
<div style="position:absolute;left:28.35px;top:527.44px" class="cls_002"><span class="cls_002">Profit for the year</span></div>
<div style="position:absolute;left:381.10px;top:527.44px" class="cls_003"><span class="cls_003">4</span></div>
<div style="position:absolute;left:430.30px;top:527.44px" class="cls_007"><span class="cls_007">3,733,352</span></div>
<div style="position:absolute;left:515.34px;top:527.44px" class="cls_002"><span class="cls_002">3,058,419</span></div>
<div style="position:absolute;left:28.35px;top:564.69px" class="cls_002"><span class="cls_002">Profit (loss) for the year attributable to:</span></div>
<div style="position:absolute;left:36.85px;top:579.69px" class="cls_002"><span class="cls_002">Owners of the Company</span></div>
<div style="position:absolute;left:430.30px;top:579.69px" class="cls_007"><span class="cls_007">3,714,106</span></div>
<div style="position:absolute;left:515.34px;top:579.69px" class="cls_002"><span class="cls_002">3,080,802</span></div>
<div style="position:absolute;left:36.87px;top:594.69px" class="cls_002"><span class="cls_002">Non-controlling interests</span></div>
<div style="position:absolute;left:446.65px;top:594.69px" class="cls_007"><span class="cls_007">19,246</span></div>
<div style="position:absolute;left:526.80px;top:594.69px" class="cls_002"><span class="cls_002">(22,383)</span></div>
<div style="position:absolute;left:430.29px;top:627.69px" class="cls_007"><span class="cls_007">3,733,352</span></div>
<div style="position:absolute;left:515.33px;top:627.69px" class="cls_002"><span class="cls_002">3,058,419</span></div>
<div style="position:absolute;left:422.68px;top:664.94px" class="cls_013"><span class="cls_013">RMB cents</span></div>
<div style="position:absolute;left:510.41px;top:664.94px" class="cls_003"><span class="cls_003">RMB cents</span></div>
<div style="position:absolute;left:517.55px;top:679.94px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:28.33px;top:709.94px" class="cls_002"><span class="cls_002">Earnings per share</span></div>
<div style="position:absolute;left:36.84px;top:724.94px" class="cls_002"><span class="cls_002">Basic</span></div>
<div style="position:absolute;left:381.09px;top:724.94px" class="cls_003"><span class="cls_003">6</span></div>
<div style="position:absolute;left:453.09px;top:724.94px" class="cls_007"><span class="cls_007">59.65</span></div>
<div style="position:absolute;left:538.13px;top:724.94px" class="cls_002"><span class="cls_002">49.36</span></div>
<div style="position:absolute;left:36.85px;top:762.19px" class="cls_002"><span class="cls_002">Diluted</span></div>
<div style="position:absolute;left:381.10px;top:762.19px" class="cls_003"><span class="cls_003">6</span></div>
<div style="position:absolute;left:453.10px;top:762.19px" class="cls_007"><span class="cls_007">59.64</span></div>
<div style="position:absolute;left:545.37px;top:762.19px" class="cls_002"><span class="cls_002">N/A</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 5 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:4255px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background06.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE</span></div>
<div style="position:absolute;left:28.56px;top:56.61px" class="cls_007"><span class="cls_007">INCOME</span></div>
<div style="position:absolute;left:28.35px;top:73.61px" class="cls_003"><span class="cls_003">For the year ended 31 December 2019</span></div>
<div style="position:absolute;left:456.54px;top:110.45px" class="cls_007"><span class="cls_007">2019</span></div>
<div style="position:absolute;left:541.59px;top:110.45px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:430.53px;top:127.46px" class="cls_013"><span class="cls_013">RMB’000</span></div>
<div style="position:absolute;left:517.59px;top:127.46px" class="cls_003"><span class="cls_003">RMB’000</span></div>
<div style="position:absolute;left:517.57px;top:144.46px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:28.36px;top:178.46px" class="cls_002"><span class="cls_002">Profit for the year</span></div>
<div style="position:absolute;left:430.30px;top:178.46px" class="cls_007"><span class="cls_007">3,733,352</span></div>
<div style="position:absolute;left:515.34px;top:178.46px" class="cls_002"><span class="cls_002">3,058,419</span></div>
<div style="position:absolute;left:28.35px;top:215.43px" class="cls_007"><span class="cls_007">Other comprehensive income (expense):</span></div>
<div style="position:absolute;left:28.35px;top:232.44px" class="cls_013"><span class="cls_013">Item that will not be reclassified to profit or loss:</span></div>
<div style="position:absolute;left:28.35px;top:249.44px" class="cls_002"><span class="cls_002">Fair value gain on investments in financial assets measured at fair</span></div>
<div style="position:absolute;left:36.85px;top:266.45px" class="cls_002"><span class="cls_002">value through other comprehensive income</span></div>
<div style="position:absolute;left:440.20px;top:266.45px" class="cls_007"><span class="cls_007">184,227</span></div>
<div style="position:absolute;left:531.69px;top:266.45px" class="cls_002"><span class="cls_002">51,765</span></div>
<div style="position:absolute;left:28.36px;top:300.44px" class="cls_013"><span class="cls_013">Item that may be reclassified subsequently to profit or loss:</span></div>
<div style="position:absolute;left:28.36px;top:317.45px" class="cls_002"><span class="cls_002">Exchange differences on translation of foreign operations</span></div>
<div style="position:absolute;left:441.76px;top:317.45px" class="cls_007"><span class="cls_007">(24,503)</span></div>
<div style="position:absolute;left:533.25px;top:317.45px" class="cls_002"><span class="cls_002">(2,463)</span></div>
<div style="position:absolute;left:28.35px;top:354.43px" class="cls_002"><span class="cls_002">Other comprehensive income for the year, net of income tax</span></div>
<div style="position:absolute;left:440.19px;top:354.43px" class="cls_007"><span class="cls_007">159,724</span></div>
<div style="position:absolute;left:531.67px;top:354.43px" class="cls_002"><span class="cls_002">49,302</span></div>
<div style="position:absolute;left:28.35px;top:391.43px" class="cls_002"><span class="cls_002">Total comprehensive income for the year</span></div>
<div style="position:absolute;left:430.29px;top:391.43px" class="cls_007"><span class="cls_007">3,893,076</span></div>
<div style="position:absolute;left:515.33px;top:391.43px" class="cls_002"><span class="cls_002">3,107,721</span></div>
<div style="position:absolute;left:28.35px;top:432.68px" class="cls_002"><span class="cls_002">Total comprehensive income for the year attributable to:</span></div>
<div style="position:absolute;left:36.85px;top:449.69px" class="cls_002"><span class="cls_002">Owners of the Company</span></div>
<div style="position:absolute;left:430.30px;top:449.69px" class="cls_007"><span class="cls_007">3,873,830</span></div>
<div style="position:absolute;left:515.34px;top:449.69px" class="cls_002"><span class="cls_002">3,130,104</span></div>
<div style="position:absolute;left:36.87px;top:466.69px" class="cls_002"><span class="cls_002">Non-controlling interests</span></div>
<div style="position:absolute;left:446.65px;top:466.69px" class="cls_007"><span class="cls_007">19,246</span></div>
<div style="position:absolute;left:526.80px;top:466.69px" class="cls_002"><span class="cls_002">(22,383)</span></div>
<div style="position:absolute;left:430.29px;top:503.68px" class="cls_007"><span class="cls_007">3,893,076</span></div>
<div style="position:absolute;left:515.33px;top:503.68px" class="cls_002"><span class="cls_002">3,107,721</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 6 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:5106px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background07.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">CONSOLIDATED STATEMENT OF FINANCIAL POSITION</span></div>
<div style="position:absolute;left:28.35px;top:56.61px" class="cls_003"><span class="cls_003">At 31 December 2019</span></div>
<div style="position:absolute;left:368.11px;top:93.45px" class="cls_007"><span class="cls_007">As at</span></div>
<div style="position:absolute;left:454.49px;top:93.45px" class="cls_002"><span class="cls_002">As at</span></div>
<div style="position:absolute;left:539.53px;top:93.45px" class="cls_002"><span class="cls_002">As at</span></div>
<div style="position:absolute;left:324.78px;top:110.45px" class="cls_007"><span class="cls_007">31 December</span></div>
<div style="position:absolute;left:412.49px;top:110.45px" class="cls_002"><span class="cls_002">31 December</span></div>
<div style="position:absolute;left:516.41px;top:110.45px" class="cls_002"><span class="cls_002">1 January</span></div>
<div style="position:absolute;left:371.50px;top:127.46px" class="cls_007"><span class="cls_007">2019</span></div>
<div style="position:absolute;left:456.54px;top:127.46px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:541.59px;top:127.46px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:284.50px;top:144.46px" class="cls_003"><span class="cls_003">Notes</span></div>
<div style="position:absolute;left:345.48px;top:144.46px" class="cls_013"><span class="cls_013">RMB’000</span></div>
<div style="position:absolute;left:432.54px;top:144.46px" class="cls_003"><span class="cls_003">RMB’000</span></div>
<div style="position:absolute;left:517.59px;top:144.46px" class="cls_003"><span class="cls_003">RMB’000</span></div>
<div style="position:absolute;left:432.53px;top:161.46px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:517.57px;top:161.46px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:28.36px;top:195.46px" class="cls_007"><span class="cls_007">Non-current assets</span></div>
<div style="position:absolute;left:28.36px;top:212.46px" class="cls_002"><span class="cls_002">Property, plant and equipment</span></div>
<div style="position:absolute;left:345.27px;top:212.46px" class="cls_007"><span class="cls_007">8,459,176</span></div>
<div style="position:absolute;left:430.31px;top:212.46px" class="cls_002"><span class="cls_002">6,692,220</span></div>
<div style="position:absolute;left:515.35px;top:212.46px" class="cls_002"><span class="cls_002">5,548,993</span></div>
<div style="position:absolute;left:28.37px;top:229.47px" class="cls_002"><span class="cls_002">Right-of-use assets</span></div>
<div style="position:absolute;left:355.18px;top:229.47px" class="cls_007"><span class="cls_007">823,202</span></div>
<div style="position:absolute;left:469.92px;top:229.47px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:554.97px;top:229.47px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.38px;top:246.47px" class="cls_002"><span class="cls_002">Prepaid lease payments</span></div>
<div style="position:absolute;left:384.89px;top:246.47px" class="cls_007"><span class="cls_007">—</span></div>
<div style="position:absolute;left:440.23px;top:246.47px" class="cls_002"><span class="cls_002">526,903</span></div>
<div style="position:absolute;left:525.28px;top:246.47px" class="cls_002"><span class="cls_002">479,095</span></div>
<div style="position:absolute;left:28.39px;top:263.48px" class="cls_002"><span class="cls_002">Goodwill</span></div>
<div style="position:absolute;left:355.20px;top:263.48px" class="cls_007"><span class="cls_007">188,964</span></div>
<div style="position:absolute;left:440.25px;top:263.48px" class="cls_002"><span class="cls_002">140,752</span></div>
<div style="position:absolute;left:525.29px;top:263.48px" class="cls_002"><span class="cls_002">101,771</span></div>
<div style="position:absolute;left:28.41px;top:280.48px" class="cls_002"><span class="cls_002">Other intangible assets</span></div>
<div style="position:absolute;left:345.31px;top:280.48px" class="cls_007"><span class="cls_007">1,135,662</span></div>
<div style="position:absolute;left:440.26px;top:280.48px" class="cls_002"><span class="cls_002">806,986</span></div>
<div style="position:absolute;left:531.75px;top:280.48px" class="cls_002"><span class="cls_002">86,254</span></div>
<div style="position:absolute;left:28.42px;top:297.48px" class="cls_002"><span class="cls_002">Interest in an associate</span></div>
<div style="position:absolute;left:355.23px;top:297.48px" class="cls_007"><span class="cls_007">231,135</span></div>
<div style="position:absolute;left:469.97px;top:297.48px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:555.01px;top:297.48px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.43px;top:314.49px" class="cls_002"><span class="cls_002">Interests in joint ventures</span></div>
<div style="position:absolute;left:355.24px;top:314.49px" class="cls_007"><span class="cls_007">176,639</span></div>
<div style="position:absolute;left:440.28px;top:314.49px" class="cls_002"><span class="cls_002">126,279</span></div>
<div style="position:absolute;left:531.77px;top:314.49px" class="cls_002"><span class="cls_002">91,942</span></div>
<div style="position:absolute;left:28.44px;top:331.49px" class="cls_002"><span class="cls_002">Financial assets measured at fair value</span></div>
<div style="position:absolute;left:36.95px;top:348.50px" class="cls_002"><span class="cls_002">through other comprehensive income</span></div>
<div style="position:absolute;left:345.35px;top:348.50px" class="cls_007"><span class="cls_007">1,077,932</span></div>
<div style="position:absolute;left:440.29px;top:348.50px" class="cls_002"><span class="cls_002">672,263</span></div>
<div style="position:absolute;left:525.34px;top:348.50px" class="cls_002"><span class="cls_002">264,796</span></div>
<div style="position:absolute;left:28.45px;top:365.50px" class="cls_002"><span class="cls_002">Amount due from a joint venture</span></div>
<div style="position:absolute;left:355.26px;top:365.50px" class="cls_007"><span class="cls_007">150,432</span></div>
<div style="position:absolute;left:470.01px;top:365.50px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:555.05px;top:365.50px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.47px;top:382.50px" class="cls_002"><span class="cls_002">Deferred tax assets</span></div>
<div style="position:absolute;left:361.72px;top:382.50px" class="cls_007"><span class="cls_007">34,843</span></div>
<div style="position:absolute;left:446.76px;top:382.50px" class="cls_002"><span class="cls_002">18,946</span></div>
<div style="position:absolute;left:531.81px;top:382.50px" class="cls_002"><span class="cls_002">17,323</span></div>
<div style="position:absolute;left:28.48px;top:399.51px" class="cls_002"><span class="cls_002">Deposits and prepayments</span></div>
<div style="position:absolute;left:296.19px;top:399.51px" class="cls_003"><span class="cls_003">9</span></div>
<div style="position:absolute;left:355.29px;top:399.51px" class="cls_007"><span class="cls_007">343,380</span></div>
<div style="position:absolute;left:440.33px;top:399.51px" class="cls_002"><span class="cls_002">329,000</span></div>
<div style="position:absolute;left:555.07px;top:399.51px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.49px;top:416.51px" class="cls_002"><span class="cls_002">Bank deposits</span></div>
<div style="position:absolute;left:385.00px;top:416.51px" class="cls_007"><span class="cls_007">—</span></div>
<div style="position:absolute;left:440.34px;top:416.51px" class="cls_002"><span class="cls_002">100,000</span></div>
<div style="position:absolute;left:555.09px;top:416.51px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:338.80px;top:453.43px" class="cls_007"><span class="cls_007">12,621,365</span></div>
<div style="position:absolute;left:430.29px;top:453.43px" class="cls_002"><span class="cls_002">9,413,349</span></div>
<div style="position:absolute;left:515.33px;top:453.43px" class="cls_002"><span class="cls_002">6,590,174</span></div>
<div style="position:absolute;left:28.35px;top:490.43px" class="cls_007"><span class="cls_007">Current assets</span></div>
<div style="position:absolute;left:28.35px;top:507.44px" class="cls_002"><span class="cls_002">Inventories</span></div>
<div style="position:absolute;left:345.25px;top:507.44px" class="cls_007"><span class="cls_007">2,535,743</span></div>
<div style="position:absolute;left:430.30px;top:507.44px" class="cls_002"><span class="cls_002">3,045,318</span></div>
<div style="position:absolute;left:515.34px;top:507.44px" class="cls_002"><span class="cls_002">2,425,053</span></div>
<div style="position:absolute;left:28.36px;top:524.44px" class="cls_002"><span class="cls_002">Trade receivables</span></div>
<div style="position:absolute;left:296.07px;top:524.44px" class="cls_003"><span class="cls_003">8</span></div>
<div style="position:absolute;left:345.27px;top:524.44px" class="cls_007"><span class="cls_007">2,258,844</span></div>
<div style="position:absolute;left:430.31px;top:524.44px" class="cls_002"><span class="cls_002">2,064,925</span></div>
<div style="position:absolute;left:515.35px;top:524.44px" class="cls_002"><span class="cls_002">1,546,942</span></div>
<div style="position:absolute;left:28.37px;top:541.45px" class="cls_002"><span class="cls_002">Deposits, prepayments</span></div>
<div style="position:absolute;left:36.87px;top:558.45px" class="cls_002"><span class="cls_002">and other receivables</span></div>
<div style="position:absolute;left:296.07px;top:558.45px" class="cls_003"><span class="cls_003">9</span></div>
<div style="position:absolute;left:355.17px;top:558.45px" class="cls_007"><span class="cls_007">567,252</span></div>
<div style="position:absolute;left:440.21px;top:558.45px" class="cls_002"><span class="cls_002">481,087</span></div>
<div style="position:absolute;left:525.25px;top:558.45px" class="cls_002"><span class="cls_002">404,516</span></div>
<div style="position:absolute;left:28.37px;top:575.45px" class="cls_002"><span class="cls_002">Bills receivables</span></div>
<div style="position:absolute;left:292.85px;top:575.45px" class="cls_003"><span class="cls_003">10</span></div>
<div style="position:absolute;left:345.27px;top:575.45px" class="cls_007"><span class="cls_007">1,993,083</span></div>
<div style="position:absolute;left:430.31px;top:575.45px" class="cls_002"><span class="cls_002">1,296,364</span></div>
<div style="position:absolute;left:515.35px;top:575.45px" class="cls_002"><span class="cls_002">1,234,773</span></div>
<div style="position:absolute;left:28.37px;top:592.46px" class="cls_002"><span class="cls_002">Trade receivables due from related</span></div>
<div style="position:absolute;left:36.88px;top:609.46px" class="cls_002"><span class="cls_002">companies</span></div>
<div style="position:absolute;left:292.86px;top:609.46px" class="cls_003"><span class="cls_003">11</span></div>
<div style="position:absolute;left:355.18px;top:609.46px" class="cls_007"><span class="cls_007">140,183</span></div>
<div style="position:absolute;left:446.67px;top:609.46px" class="cls_002"><span class="cls_002">63,443</span></div>
<div style="position:absolute;left:531.71px;top:609.46px" class="cls_002"><span class="cls_002">58,132</span></div>
<div style="position:absolute;left:28.38px;top:626.47px" class="cls_002"><span class="cls_002">Amounts due from joint ventures</span></div>
<div style="position:absolute;left:361.63px;top:626.47px" class="cls_007"><span class="cls_007">58,628</span></div>
<div style="position:absolute;left:440.22px;top:626.47px" class="cls_002"><span class="cls_002">204,450</span></div>
<div style="position:absolute;left:525.27px;top:626.47px" class="cls_002"><span class="cls_002">231,430</span></div>
<div style="position:absolute;left:28.38px;top:643.47px" class="cls_002"><span class="cls_002">Prepaid lease payments</span></div>
<div style="position:absolute;left:384.89px;top:643.47px" class="cls_007"><span class="cls_007">—</span></div>
<div style="position:absolute;left:446.68px;top:643.47px" class="cls_002"><span class="cls_002">16,570</span></div>
<div style="position:absolute;left:531.72px;top:643.47px" class="cls_002"><span class="cls_002">15,268</span></div>
<div style="position:absolute;left:28.39px;top:660.47px" class="cls_002"><span class="cls_002">Other financial assets</span></div>
<div style="position:absolute;left:378.00px;top:660.47px" class="cls_007"><span class="cls_007">536</span></div>
<div style="position:absolute;left:463.05px;top:660.47px" class="cls_002"><span class="cls_002">443</span></div>
<div style="position:absolute;left:548.09px;top:660.47px" class="cls_002"><span class="cls_002">612</span></div>
<div style="position:absolute;left:28.41px;top:677.48px" class="cls_002"><span class="cls_002">Structured bank deposits</span></div>
<div style="position:absolute;left:345.31px;top:677.48px" class="cls_007"><span class="cls_007">1,838,159</span></div>
<div style="position:absolute;left:430.36px;top:677.48px" class="cls_002"><span class="cls_002">2,292,366</span></div>
<div style="position:absolute;left:515.40px;top:677.48px" class="cls_002"><span class="cls_002">1,100,000</span></div>
<div style="position:absolute;left:28.42px;top:694.48px" class="cls_002"><span class="cls_002">Restricted bank deposits</span></div>
<div style="position:absolute;left:355.23px;top:694.48px" class="cls_007"><span class="cls_007">186,293</span></div>
<div style="position:absolute;left:453.17px;top:694.48px" class="cls_002"><span class="cls_002">2,909</span></div>
<div style="position:absolute;left:538.21px;top:694.48px" class="cls_002"><span class="cls_002">2,909</span></div>
<div style="position:absolute;left:28.43px;top:711.49px" class="cls_002"><span class="cls_002">Bank balances and cash</span></div>
<div style="position:absolute;left:345.34px;top:711.49px" class="cls_007"><span class="cls_007">4,118,236</span></div>
<div style="position:absolute;left:430.38px;top:711.49px" class="cls_002"><span class="cls_002">4,335,613</span></div>
<div style="position:absolute;left:515.43px;top:711.49px" class="cls_002"><span class="cls_002">4,378,996</span></div>
<div style="position:absolute;left:338.80px;top:748.43px" class="cls_007"><span class="cls_007">13,696,957</span></div>
<div style="position:absolute;left:423.84px;top:748.43px" class="cls_002"><span class="cls_002">13,803,488</span></div>
<div style="position:absolute;left:508.89px;top:748.43px" class="cls_002"><span class="cls_002">11,398,631</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 7 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:5957px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background08.jpg" width=595 height=841></div>
<div style="position:absolute;left:368.11px;top:44.60px" class="cls_007"><span class="cls_007">As at</span></div>
<div style="position:absolute;left:454.49px;top:44.60px" class="cls_002"><span class="cls_002">As at</span></div>
<div style="position:absolute;left:539.53px;top:44.60px" class="cls_002"><span class="cls_002">As at</span></div>
<div style="position:absolute;left:324.78px;top:61.60px" class="cls_007"><span class="cls_007">31 December</span></div>
<div style="position:absolute;left:412.49px;top:61.60px" class="cls_002"><span class="cls_002">31 December</span></div>
<div style="position:absolute;left:516.41px;top:61.60px" class="cls_002"><span class="cls_002">1 January</span></div>
<div style="position:absolute;left:371.50px;top:78.60px" class="cls_007"><span class="cls_007">2019</span></div>
<div style="position:absolute;left:456.54px;top:78.60px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:541.59px;top:78.60px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:284.50px;top:95.61px" class="cls_003"><span class="cls_003">Notes</span></div>
<div style="position:absolute;left:345.48px;top:95.61px" class="cls_013"><span class="cls_013">RMB’000</span></div>
<div style="position:absolute;left:432.54px;top:95.61px" class="cls_003"><span class="cls_003">RMB’000</span></div>
<div style="position:absolute;left:517.59px;top:95.61px" class="cls_003"><span class="cls_003">RMB’000</span></div>
<div style="position:absolute;left:432.53px;top:112.61px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:517.57px;top:112.61px" class="cls_002"><span class="cls_002">(Restated)</span></div>
<div style="position:absolute;left:28.36px;top:145.61px" class="cls_007"><span class="cls_007">Current liabilities</span></div>
<div style="position:absolute;left:28.36px;top:161.61px" class="cls_002"><span class="cls_002">Trade payables</span></div>
<div style="position:absolute;left:292.84px;top:161.61px" class="cls_003"><span class="cls_003">12</span></div>
<div style="position:absolute;left:345.25px;top:161.61px" class="cls_007"><span class="cls_007">1,110,883</span></div>
<div style="position:absolute;left:430.30px;top:161.61px" class="cls_002"><span class="cls_002">1,619,356</span></div>
<div style="position:absolute;left:515.34px;top:161.61px" class="cls_002"><span class="cls_002">1,241,765</span></div>
<div style="position:absolute;left:28.36px;top:177.60px" class="cls_002"><span class="cls_002">Other payables</span></div>
<div style="position:absolute;left:292.84px;top:177.60px" class="cls_003"><span class="cls_003">13</span></div>
<div style="position:absolute;left:345.25px;top:177.60px" class="cls_007"><span class="cls_007">3,691,652</span></div>
<div style="position:absolute;left:430.30px;top:177.60px" class="cls_002"><span class="cls_002">2,920,262</span></div>
<div style="position:absolute;left:515.34px;top:177.60px" class="cls_002"><span class="cls_002">2,531,423</span></div>
<div style="position:absolute;left:28.36px;top:193.60px" class="cls_002"><span class="cls_002">Contract liabilities</span></div>
<div style="position:absolute;left:355.17px;top:193.60px" class="cls_007"><span class="cls_007">503,755</span></div>
<div style="position:absolute;left:440.21px;top:193.60px" class="cls_002"><span class="cls_002">700,075</span></div>
<div style="position:absolute;left:554.95px;top:193.60px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.37px;top:209.60px" class="cls_002"><span class="cls_002">Bills payables</span></div>
<div style="position:absolute;left:292.85px;top:209.60px" class="cls_003"><span class="cls_003">14</span></div>
<div style="position:absolute;left:355.17px;top:209.60px" class="cls_007"><span class="cls_007">316,137</span></div>
<div style="position:absolute;left:430.31px;top:209.60px" class="cls_002"><span class="cls_002">1,654,470</span></div>
<div style="position:absolute;left:531.70px;top:209.60px" class="cls_002"><span class="cls_002">50,000</span></div>
<div style="position:absolute;left:28.37px;top:225.59px" class="cls_002"><span class="cls_002">Contingent consideration payable</span></div>
<div style="position:absolute;left:361.62px;top:225.59px" class="cls_007"><span class="cls_007">18,130</span></div>
<div style="position:absolute;left:446.67px;top:225.59px" class="cls_002"><span class="cls_002">12,375</span></div>
<div style="position:absolute;left:554.95px;top:225.59px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.37px;top:242.60px" class="cls_002"><span class="cls_002">Amount due to a joint venture</span></div>
<div style="position:absolute;left:355.17px;top:242.60px" class="cls_007"><span class="cls_007">104,678</span></div>
<div style="position:absolute;left:469.91px;top:242.60px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:538.15px;top:242.60px" class="cls_002"><span class="cls_002">7,791</span></div>
<div style="position:absolute;left:28.37px;top:258.59px" class="cls_002"><span class="cls_002">Amounts due to related companies</span></div>
<div style="position:absolute;left:361.62px;top:258.59px" class="cls_007"><span class="cls_007">10,854</span></div>
<div style="position:absolute;left:446.67px;top:258.59px" class="cls_002"><span class="cls_002">28,425</span></div>
<div style="position:absolute;left:531.71px;top:258.59px" class="cls_002"><span class="cls_002">36,298</span></div>
<div style="position:absolute;left:28.38px;top:274.59px" class="cls_002"><span class="cls_002">Amount due to an associate</span></div>
<div style="position:absolute;left:355.19px;top:274.59px" class="cls_007"><span class="cls_007">124,627</span></div>
<div style="position:absolute;left:469.93px;top:274.59px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:554.98px;top:274.59px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.39px;top:290.58px" class="cls_002"><span class="cls_002">Lease liabilities</span></div>
<div style="position:absolute;left:361.65px;top:290.58px" class="cls_007"><span class="cls_007">74,235</span></div>
<div style="position:absolute;left:469.93px;top:290.58px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:554.98px;top:290.58px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.39px;top:306.58px" class="cls_002"><span class="cls_002">Tax liabilities</span></div>
<div style="position:absolute;left:355.20px;top:306.58px" class="cls_007"><span class="cls_007">258,823</span></div>
<div style="position:absolute;left:440.25px;top:306.58px" class="cls_002"><span class="cls_002">241,465</span></div>
<div style="position:absolute;left:525.29px;top:306.58px" class="cls_002"><span class="cls_002">172,789</span></div>
<div style="position:absolute;left:28.41px;top:322.58px" class="cls_002"><span class="cls_002">Borrowings</span></div>
<div style="position:absolute;left:361.66px;top:322.58px" class="cls_007"><span class="cls_007">23,000</span></div>
<div style="position:absolute;left:446.70px;top:322.58px" class="cls_002"><span class="cls_002">70,589</span></div>
<div style="position:absolute;left:525.29px;top:322.58px" class="cls_002"><span class="cls_002">775,208</span></div>
<div style="position:absolute;left:345.25px;top:357.61px" class="cls_007"><span class="cls_007">6,236,774</span></div>
<div style="position:absolute;left:430.30px;top:357.61px" class="cls_002"><span class="cls_002">7,247,017</span></div>
<div style="position:absolute;left:515.34px;top:357.61px" class="cls_002"><span class="cls_002">4,815,274</span></div>
<div style="position:absolute;left:28.35px;top:392.61px" class="cls_007"><span class="cls_007">Net current assets</span></div>
<div style="position:absolute;left:345.25px;top:392.61px" class="cls_007"><span class="cls_007">7,460,183</span></div>
<div style="position:absolute;left:430.30px;top:392.61px" class="cls_002"><span class="cls_002">6,556,471</span></div>
<div style="position:absolute;left:515.34px;top:392.61px" class="cls_002"><span class="cls_002">6,583,357</span></div>
<div style="position:absolute;left:28.35px;top:427.61px" class="cls_007"><span class="cls_007">Total assets less current liabilities</span></div>
<div style="position:absolute;left:338.80px;top:427.61px" class="cls_007"><span class="cls_007">20,081,548</span></div>
<div style="position:absolute;left:423.84px;top:427.61px" class="cls_002"><span class="cls_002">15,969,820</span></div>
<div style="position:absolute;left:508.89px;top:427.61px" class="cls_002"><span class="cls_002">13,173,531</span></div>
<div style="position:absolute;left:28.35px;top:462.61px" class="cls_007"><span class="cls_007">Non-current liabilities</span></div>
<div style="position:absolute;left:28.35px;top:478.60px" class="cls_002"><span class="cls_002">Other payables</span></div>
<div style="position:absolute;left:292.83px;top:478.60px" class="cls_003"><span class="cls_003">13</span></div>
<div style="position:absolute;left:355.14px;top:478.60px" class="cls_007"><span class="cls_007">154,733</span></div>
<div style="position:absolute;left:440.19px;top:478.60px" class="cls_002"><span class="cls_002">182,404</span></div>
<div style="position:absolute;left:525.23px;top:478.60px" class="cls_002"><span class="cls_002">153,804</span></div>
<div style="position:absolute;left:28.35px;top:494.60px" class="cls_002"><span class="cls_002">Contingent consideration payable</span></div>
<div style="position:absolute;left:361.60px;top:494.60px" class="cls_007"><span class="cls_007">13,923</span></div>
<div style="position:absolute;left:446.64px;top:494.60px" class="cls_002"><span class="cls_002">19,899</span></div>
<div style="position:absolute;left:554.93px;top:494.60px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.35px;top:510.59px" class="cls_002"><span class="cls_002">Lease liabilities</span></div>
<div style="position:absolute;left:361.60px;top:510.59px" class="cls_007"><span class="cls_007">90,300</span></div>
<div style="position:absolute;left:469.89px;top:510.59px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:554.93px;top:510.59px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:28.35px;top:526.59px" class="cls_002"><span class="cls_002">Deferred tax liabilities</span></div>
<div style="position:absolute;left:355.15px;top:526.59px" class="cls_007"><span class="cls_007">304,427</span></div>
<div style="position:absolute;left:440.20px;top:526.59px" class="cls_002"><span class="cls_002">237,917</span></div>
<div style="position:absolute;left:525.24px;top:526.59px" class="cls_002"><span class="cls_002">110,019</span></div>
<div style="position:absolute;left:28.36px;top:542.59px" class="cls_002"><span class="cls_002">Borrowings</span></div>
<div style="position:absolute;left:384.87px;top:542.59px" class="cls_007"><span class="cls_007">—</span></div>
<div style="position:absolute;left:469.91px;top:542.59px" class="cls_002"><span class="cls_002">—</span></div>
<div style="position:absolute;left:531.70px;top:542.59px" class="cls_002"><span class="cls_002">50,000</span></div>
<div style="position:absolute;left:355.15px;top:577.61px" class="cls_007"><span class="cls_007">563,383</span></div>
<div style="position:absolute;left:440.20px;top:577.61px" class="cls_002"><span class="cls_002">440,220</span></div>
<div style="position:absolute;left:525.24px;top:577.61px" class="cls_002"><span class="cls_002">313,823</span></div>
<div style="position:absolute;left:28.35px;top:612.61px" class="cls_007"><span class="cls_007">Net assets</span></div>
<div style="position:absolute;left:338.80px;top:612.61px" class="cls_007"><span class="cls_007">19,518,165</span></div>
<div style="position:absolute;left:423.84px;top:612.61px" class="cls_002"><span class="cls_002">15,529,600</span></div>
<div style="position:absolute;left:508.89px;top:612.61px" class="cls_002"><span class="cls_002">12,859,708</span></div>
<div style="position:absolute;left:28.35px;top:651.86px" class="cls_007"><span class="cls_007">Capital and reserves</span></div>
<div style="position:absolute;left:28.35px;top:667.85px" class="cls_002"><span class="cls_002">Share capital</span></div>
<div style="position:absolute;left:338.80px;top:667.85px" class="cls_007"><span class="cls_007">10,899,412</span></div>
<div style="position:absolute;left:423.84px;top:667.85px" class="cls_002"><span class="cls_002">10,899,412</span></div>
<div style="position:absolute;left:508.89px;top:667.85px" class="cls_002"><span class="cls_002">10,899,412</span></div>
<div style="position:absolute;left:28.36px;top:683.85px" class="cls_002"><span class="cls_002">Reserves</span></div>
<div style="position:absolute;left:345.27px;top:683.85px" class="cls_007"><span class="cls_007">7,562,311</span></div>
<div style="position:absolute;left:430.31px;top:683.85px" class="cls_002"><span class="cls_002">4,152,848</span></div>
<div style="position:absolute;left:515.35px;top:683.85px" class="cls_002"><span class="cls_002">1,889,243</span></div>
<div style="position:absolute;left:28.35px;top:718.86px" class="cls_002"><span class="cls_002">Equity attributable to owners of the Company</span></div>
<div style="position:absolute;left:338.80px;top:718.86px" class="cls_007"><span class="cls_007">18,461,723</span></div>
<div style="position:absolute;left:423.84px;top:718.86px" class="cls_002"><span class="cls_002">15,052,260</span></div>
<div style="position:absolute;left:508.89px;top:718.86px" class="cls_002"><span class="cls_002">12,788,655</span></div>
<div style="position:absolute;left:28.36px;top:734.85px" class="cls_002"><span class="cls_002">Non-controlling interests</span></div>
<div style="position:absolute;left:345.27px;top:734.85px" class="cls_007"><span class="cls_007">1,056,442</span></div>
<div style="position:absolute;left:440.21px;top:734.85px" class="cls_002"><span class="cls_002">477,340</span></div>
<div style="position:absolute;left:531.70px;top:734.85px" class="cls_002"><span class="cls_002">71,053</span></div>
<div style="position:absolute;left:28.35px;top:769.86px" class="cls_007"><span class="cls_007">Total equity</span></div>
<div style="position:absolute;left:338.80px;top:769.86px" class="cls_007"><span class="cls_007">19,518,165</span></div>
<div style="position:absolute;left:423.84px;top:769.86px" class="cls_002"><span class="cls_002">15,529,600</span></div>
<div style="position:absolute;left:508.89px;top:769.86px" class="cls_002"><span class="cls_002">12,859,708</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 8 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:6808px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background09.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.77px" class="cls_014"><span class="cls_014">NOTES TO consolidated FINANCIAL STATEMENTS</span></div>
<div style="position:absolute;left:28.35px;top:69.77px" class="cls_014"><span class="cls_014">1.</span></div>
<div style="position:absolute;left:56.69px;top:69.77px" class="cls_014"><span class="cls_014">Basis of Preparation</span></div>
<div style="position:absolute;left:56.69px;top:99.77px" class="cls_015"><span class="cls_015">The consolidated financial statements have been prepared in accordance with Hong Kong Financial</span></div>
<div style="position:absolute;left:56.69px;top:114.77px" class="cls_015"><span class="cls_015">Reporting Standards (“HKFRSs”) issued by the Hong Kong Institute of Certified Public Accountants (the</span></div>
<div style="position:absolute;left:56.69px;top:129.77px" class="cls_015"><span class="cls_015">“HKICPA”) and on the historical cost basis except for certain financial instruments that are measured at</span></div>
<div style="position:absolute;left:56.69px;top:144.78px" class="cls_015"><span class="cls_015">fair value at the end of the reporting period.</span></div>
<div style="position:absolute;left:56.69px;top:174.77px" class="cls_015"><span class="cls_015">The financial information relating to the years ended</span></div>
<div style="position:absolute;left:334.09px;top:174.77px" class="cls_015"><span class="cls_015">31 December 2019 and 2018 included in this</span></div>
<div style="position:absolute;left:56.69px;top:189.78px" class="cls_015"><span class="cls_015">preliminary announcement of annual results 2019 does not constitute the Company’s statutory annual</span></div>
<div style="position:absolute;left:56.69px;top:204.78px" class="cls_015"><span class="cls_015">consolidated financial statements for those years but is derived from those financial statements. Further</span></div>
<div style="position:absolute;left:56.69px;top:219.79px" class="cls_015"><span class="cls_015">information relating to these statutory financial statements required to be disclosed in accordance with</span></div>
<div style="position:absolute;left:56.69px;top:234.79px" class="cls_015"><span class="cls_015">section 436 of the Hong Kong Companies Ordinance is as follows:</span></div>
<div style="position:absolute;left:56.69px;top:264.79px" class="cls_015"><span class="cls_015">•</span></div>
<div style="position:absolute;left:85.04px;top:264.79px" class="cls_015"><span class="cls_015">The Company has delivered the financial statements for the year ended 31 December 2018 to</span></div>
<div style="position:absolute;left:85.01px;top:279.79px" class="cls_015"><span class="cls_015">the Registrar of Companies as required by section 662(3) of, and Part 3 of Schedule 6 to, the</span></div>
<div style="position:absolute;left:85.01px;top:294.80px" class="cls_015"><span class="cls_015">Hong Kong Companies Ordinance and will deliver the financial statements for the year ended 31</span></div>
<div style="position:absolute;left:85.01px;top:309.80px" class="cls_015"><span class="cls_015">December 2019 in due course.</span></div>
<div style="position:absolute;left:56.66px;top:339.80px" class="cls_015"><span class="cls_015">•</span></div>
<div style="position:absolute;left:85.01px;top:339.80px" class="cls_015"><span class="cls_015">The Company’s auditor has reported on the financial statements of the Group for the years ended</span></div>
<div style="position:absolute;left:85.00px;top:354.80px" class="cls_015"><span class="cls_015">31 December 2019 and 2018. The auditor’s reports for both years were unqualified; did not</span></div>
<div style="position:absolute;left:85.00px;top:369.80px" class="cls_015"><span class="cls_015">include a reference to any matters to which the auditor drew attention by way of emphasis without</span></div>
<div style="position:absolute;left:85.00px;top:384.81px" class="cls_015"><span class="cls_015">qualifying its reports; and did not contain a statement under sections 406(2), 407(2) or (3) of the</span></div>
<div style="position:absolute;left:85.00px;top:399.81px" class="cls_015"><span class="cls_015">Hong Kong Companies Ordinance.</span></div>
<div style="position:absolute;left:56.65px;top:429.81px" class="cls_015"><span class="cls_015">The functional currency of the Company is Renminbi</span></div>
<div style="position:absolute;left:342.57px;top:429.81px" class="cls_015"><span class="cls_015">(“RMB”). The presentation currency of the</span></div>
<div style="position:absolute;left:56.65px;top:444.81px" class="cls_015"><span class="cls_015">consolidated financial statements in prior financial years was Hong Kong dollars (“HK$”). In view of</span></div>
<div style="position:absolute;left:56.65px;top:459.82px" class="cls_015"><span class="cls_015">the fact that the Group’s operation is mainly located in the PRC with transactions mainly denominated</span></div>
<div style="position:absolute;left:56.65px;top:474.82px" class="cls_015"><span class="cls_015">in RMB, the directors of the Company (the “Directors”) consider that it is more appropriate to use RMB</span></div>
<div style="position:absolute;left:56.65px;top:489.83px" class="cls_015"><span class="cls_015">as the presentation currency in presenting the financial performance and financial positions of the Group</span></div>
<div style="position:absolute;left:56.65px;top:504.83px" class="cls_015"><span class="cls_015">effective from 1 January 2019, and the comparative information has been restated to reflect the change</span></div>
<div style="position:absolute;left:56.65px;top:519.83px" class="cls_015"><span class="cls_015">in presentation currency to RMB accordingly.</span></div>
<div style="position:absolute;left:28.30px;top:549.83px" class="cls_014"><span class="cls_014">2.</span></div>
<div style="position:absolute;left:56.65px;top:549.83px" class="cls_014"><span class="cls_014">Application of New and Amendments to HKFRSs</span></div>
<div style="position:absolute;left:56.65px;top:579.83px" class="cls_016"><span class="cls_016">New and amendments to HKFRSs that are mandatorily effective for the current year</span></div>
<div style="position:absolute;left:56.65px;top:609.82px" class="cls_015"><span class="cls_015">The Group has applied the following new and amendments to HKFRSs issued by the HKICPA for the</span></div>
<div style="position:absolute;left:56.65px;top:624.83px" class="cls_015"><span class="cls_015">first time in the current year:</span></div>
<div style="position:absolute;left:56.65px;top:657.66px" class="cls_015"><span class="cls_015">HKFRS 16</span></div>
<div style="position:absolute;left:243.74px;top:657.66px" class="cls_015"><span class="cls_015">Leases</span></div>
<div style="position:absolute;left:56.65px;top:672.67px" class="cls_015"><span class="cls_015">HK(IFRIC) — Int 23</span></div>
<div style="position:absolute;left:243.74px;top:672.67px" class="cls_015"><span class="cls_015">Uncertainty over Income Tax Treatments</span></div>
<div style="position:absolute;left:56.65px;top:687.67px" class="cls_015"><span class="cls_015">Amendments to HKFRS 9</span></div>
<div style="position:absolute;left:243.74px;top:687.67px" class="cls_015"><span class="cls_015">Prepayment Features with Negative Compensation</span></div>
<div style="position:absolute;left:56.65px;top:702.68px" class="cls_015"><span class="cls_015">Amendments to HKAS 19</span></div>
<div style="position:absolute;left:243.74px;top:702.68px" class="cls_015"><span class="cls_015">Plan Amendment, Curtailment or Settlement</span></div>
<div style="position:absolute;left:56.65px;top:717.68px" class="cls_015"><span class="cls_015">Amendments to HKAS 28</span></div>
<div style="position:absolute;left:243.74px;top:717.68px" class="cls_015"><span class="cls_015">Long-term Interests in Associates and Joint Ventures</span></div>
<div style="position:absolute;left:56.65px;top:732.68px" class="cls_015"><span class="cls_015">Amendments to HKFRSs</span></div>
<div style="position:absolute;left:243.74px;top:732.68px" class="cls_015"><span class="cls_015">Annual Improvements to HKFRSs 2015 - 2017 Cycle</span></div>
<div style="position:absolute;left:278.74px;top:800.70px" class="cls_002"><span class="cls_002">— 9 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:7659px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background10.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_015"><span class="cls_015">Except as described below, the application of the new and amendments to HKFRSs in the current year</span></div>
<div style="position:absolute;left:56.69px;top:54.78px" class="cls_015"><span class="cls_015">has had no material impact on the Group’s financial positions and performance for the current and prior</span></div>
<div style="position:absolute;left:56.69px;top:69.78px" class="cls_015"><span class="cls_015">years and/or on the disclosures set out in these consolidated financial statements.</span></div>
<div style="position:absolute;left:56.69px;top:99.78px" class="cls_016"><span class="cls_016">HKFRS 16 Leases</span></div>
<div style="position:absolute;left:56.69px;top:129.77px" class="cls_015"><span class="cls_015">The Group has applied HKFRS 16 for the first time in the current year. HKFRS 16 superseded HKAS</span></div>
<div style="position:absolute;left:56.69px;top:144.78px" class="cls_015"><span class="cls_015">17 </span><span class="cls_006">Leases</span><span class="cls_015"> (“HKAS 17”), and the related interpretations.</span></div>
<div style="position:absolute;left:56.69px;top:174.77px" class="cls_016"><span class="cls_016">Definition of a lease</span></div>
<div style="position:absolute;left:56.69px;top:204.77px" class="cls_015"><span class="cls_015">The Group has elected the practical expedient to apply HKFRS 16 to contracts that were previously</span></div>
<div style="position:absolute;left:56.69px;top:219.78px" class="cls_015"><span class="cls_015">identified as leases applying HKAS 17 and HK(IFRIC) — Int 4 </span><span class="cls_006">Determining whether an Arrangement</span></div>
<div style="position:absolute;left:56.69px;top:234.78px" class="cls_006"><span class="cls_006">contains a Lease</span><span class="cls_015"> and not apply this standard to contracts that were not previously identified as</span></div>
<div style="position:absolute;left:56.69px;top:249.78px" class="cls_015"><span class="cls_015">containing a lease. Therefore, the Group has not reassessed contracts which already existed prior to the</span></div>
<div style="position:absolute;left:56.69px;top:264.79px" class="cls_015"><span class="cls_015">date of initial application.</span></div>
<div style="position:absolute;left:56.69px;top:294.78px" class="cls_015"><span class="cls_015">For contracts entered into or modified on or after 1 January 2019, the Group applies the definition of a</span></div>
<div style="position:absolute;left:56.69px;top:309.79px" class="cls_015"><span class="cls_015">lease in accordance with the requirements set out in HKFRS 16 in assessing whether a contract contains</span></div>
<div style="position:absolute;left:56.69px;top:324.79px" class="cls_015"><span class="cls_015">a lease.</span></div>
<div style="position:absolute;left:56.69px;top:354.79px" class="cls_016"><span class="cls_016">As a lessee</span></div>
<div style="position:absolute;left:56.69px;top:384.79px" class="cls_015"><span class="cls_015">The Group has applied HKFRS 16 retrospectively with the cumulative effect recognised at the date of</span></div>
<div style="position:absolute;left:56.69px;top:399.79px" class="cls_015"><span class="cls_015">initial application, 1 January 2019.</span></div>
<div style="position:absolute;left:56.69px;top:429.79px" class="cls_015"><span class="cls_015">As at 1 January 2019, the Group recognised additional lease liabilities and right-of-use assets at amounts</span></div>
<div style="position:absolute;left:56.69px;top:444.79px" class="cls_015"><span class="cls_015">equal to the related lease liabilities adjusted by any prepaid or accrued lease payments by applying</span></div>
<div style="position:absolute;left:56.69px;top:459.80px" class="cls_015"><span class="cls_015">HKFRS 16.C8(b)(ii) transition and comparative information has not be restated.</span></div>
<div style="position:absolute;left:56.69px;top:489.79px" class="cls_015"><span class="cls_015">When applying the modified retrospective approach under HKFRS 16 at transition, the Group applied</span></div>
<div style="position:absolute;left:56.69px;top:504.80px" class="cls_015"><span class="cls_015">the following practical expedients to leases previously classified as operating leases under HKAS 17, on</span></div>
<div style="position:absolute;left:56.69px;top:519.80px" class="cls_015"><span class="cls_015">lease-by-lease basis, to the extent relevant to the respective lease contracts:</span></div>
<div style="position:absolute;left:56.69px;top:549.80px" class="cls_015"><span class="cls_015">i.</span></div>
<div style="position:absolute;left:85.04px;top:549.80px" class="cls_015"><span class="cls_015">relied on the assessment of whether leases are onerous by applying HKAS</span></div>
<div style="position:absolute;left:492.29px;top:549.80px" class="cls_015"><span class="cls_015">37 </span><span class="cls_006">Provisions,</span></div>
<div style="position:absolute;left:85.04px;top:564.80px" class="cls_006"><span class="cls_006">Contingent Liabilities and Contingent Assets</span><span class="cls_015"> as an alternative of impairment review;</span></div>
<div style="position:absolute;left:56.69px;top:594.80px" class="cls_015"><span class="cls_015">ii.</span></div>
<div style="position:absolute;left:85.04px;top:594.80px" class="cls_015"><span class="cls_015">elected not to recognise right-of-use assets and lease liabilities for leases with lease term ends</span></div>
<div style="position:absolute;left:85.04px;top:609.80px" class="cls_015"><span class="cls_015">within 12 months of the date of initial application;</span></div>
<div style="position:absolute;left:56.69px;top:639.80px" class="cls_015"><span class="cls_015">iii.</span></div>
<div style="position:absolute;left:85.03px;top:639.80px" class="cls_015"><span class="cls_015">excluded initial direct costs from measuring the right-of-use assets at the date of initial</span></div>
<div style="position:absolute;left:85.03px;top:654.80px" class="cls_015"><span class="cls_015">application; and</span></div>
<div style="position:absolute;left:56.68px;top:684.80px" class="cls_015"><span class="cls_015">iv.</span></div>
<div style="position:absolute;left:85.03px;top:684.80px" class="cls_015"><span class="cls_015">applied a single discount rate to a portfolio of leases with similar remaining terms for similar class</span></div>
<div style="position:absolute;left:85.03px;top:699.80px" class="cls_015"><span class="cls_015">of underlying assets in similar economic environment.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 10 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:8510px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background11.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_015"><span class="cls_015">When recognising the lease liabilities for leases previously classified as operating leases, the Group has</span></div>
<div style="position:absolute;left:56.69px;top:54.78px" class="cls_015"><span class="cls_015">applied incremental borrowing rates of the relevant group entities at the date of initial application. The</span></div>
<div style="position:absolute;left:56.69px;top:69.78px" class="cls_015"><span class="cls_015">weighted average incremental borrowing rate applied is 4.35%.</span></div>
<div style="position:absolute;left:555.52px;top:102.61px" class="cls_015"><span class="cls_015">At</span></div>
<div style="position:absolute;left:520.63px;top:117.62px" class="cls_015"><span class="cls_015">1 January</span></div>
<div style="position:absolute;left:543.70px;top:132.62px" class="cls_015"><span class="cls_015">2019</span></div>
<div style="position:absolute;left:521.70px;top:147.63px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:56.70px;top:177.62px" class="cls_015"><span class="cls_015">Operating lease commitments disclosed as at 31 December 2018 (Restated)</span></div>
<div style="position:absolute;left:528.71px;top:177.62px" class="cls_015"><span class="cls_015">213,907</span></div>
<div style="position:absolute;left:56.70px;top:192.63px" class="cls_006"><span class="cls_006">Less:</span><span class="cls_015"> Commitment of lease which commenced after 1 January 2019</span></div>
<div style="position:absolute;left:536.05px;top:192.63px" class="cls_015"><span class="cls_015">(9,584)</span></div>
<div style="position:absolute;left:528.70px;top:225.61px" class="cls_015"><span class="cls_015">204,323</span></div>
<div style="position:absolute;left:56.69px;top:262.86px" class="cls_015"><span class="cls_015">Lease liabilities discounted at relevant incremental borrowing rates</span></div>
<div style="position:absolute;left:528.70px;top:262.86px" class="cls_015"><span class="cls_015">189,659</span></div>
<div style="position:absolute;left:56.69px;top:277.86px" class="cls_006"><span class="cls_006">Less:</span><span class="cls_015"> Recognition exemption — short-term leases</span></div>
<div style="position:absolute;left:536.04px;top:277.86px" class="cls_015"><span class="cls_015">(9,155)</span></div>
<div style="position:absolute;left:56.69px;top:310.86px" class="cls_015"><span class="cls_015">Lease liabilities as at 1 January 2019</span></div>
<div style="position:absolute;left:528.70px;top:310.86px" class="cls_015"><span class="cls_015">180,504</span></div>
<div style="position:absolute;left:56.69px;top:348.11px" class="cls_015"><span class="cls_015">Analysed as</span></div>
<div style="position:absolute;left:65.20px;top:363.11px" class="cls_015"><span class="cls_015">Current</span></div>
<div style="position:absolute;left:534.62px;top:363.11px" class="cls_015"><span class="cls_015">55,850</span></div>
<div style="position:absolute;left:65.20px;top:378.12px" class="cls_015"><span class="cls_015">Non-current</span></div>
<div style="position:absolute;left:528.70px;top:378.12px" class="cls_015"><span class="cls_015">124,654</span></div>
<div style="position:absolute;left:528.70px;top:411.11px" class="cls_015"><span class="cls_015">180,504</span></div>
<div style="position:absolute;left:56.69px;top:449.34px" class="cls_015"><span class="cls_015">The carrying amount of right-of-use assets as at 1 January 2019 comprises the following:</span></div>
<div style="position:absolute;left:506.79px;top:482.17px" class="cls_015"><span class="cls_015">Right-of-use</span></div>
<div style="position:absolute;left:539.21px;top:497.17px" class="cls_015"><span class="cls_015">assets</span></div>
<div style="position:absolute;left:458.13px;top:512.18px" class="cls_006"><span class="cls_006">Note</span></div>
<div style="position:absolute;left:521.68px;top:512.18px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:56.69px;top:542.18px" class="cls_015"><span class="cls_015">Right-of-use assets relating to operating leases recognised upon</span></div>
<div style="position:absolute;left:65.20px;top:557.18px" class="cls_015"><span class="cls_015">application of HKFRS 16</span></div>
<div style="position:absolute;left:528.70px;top:557.18px" class="cls_015"><span class="cls_015">180,504</span></div>
<div style="position:absolute;left:56.69px;top:572.18px" class="cls_015"><span class="cls_015">Reclassified from prepaid lease payments</span></div>
<div style="position:absolute;left:462.31px;top:572.18px" class="cls_006"><span class="cls_006">(a)</span></div>
<div style="position:absolute;left:528.70px;top:572.18px" class="cls_015"><span class="cls_015">543,473</span></div>
<div style="position:absolute;left:528.70px;top:605.17px" class="cls_015"><span class="cls_015">723,977</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 11 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:9361px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background12.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_015"><span class="cls_015">The following adjustments were made to the amounts recognised in the consolidated statement of</span></div>
<div style="position:absolute;left:56.69px;top:54.78px" class="cls_015"><span class="cls_015">financial position at 1 January 2019. Line items that were not affected by the changes have not been</span></div>
<div style="position:absolute;left:56.69px;top:69.78px" class="cls_015"><span class="cls_015">included.</span></div>
<div style="position:absolute;left:354.86px;top:102.61px" class="cls_015"><span class="cls_015">Carrying</span></div>
<div style="position:absolute;left:524.95px;top:102.64px" class="cls_015"><span class="cls_015">Carrying</span></div>
<div style="position:absolute;left:357.10px;top:117.62px" class="cls_015"><span class="cls_015">amounts</span></div>
<div style="position:absolute;left:527.20px;top:117.64px" class="cls_015"><span class="cls_015">amounts</span></div>
<div style="position:absolute;left:346.71px;top:132.62px" class="cls_015"><span class="cls_015">previously</span></div>
<div style="position:absolute;left:540.25px;top:132.64px" class="cls_015"><span class="cls_015">under</span></div>
<div style="position:absolute;left:344.85px;top:147.63px" class="cls_015"><span class="cls_015">reported at</span></div>
<div style="position:absolute;left:514.30px;top:147.65px" class="cls_015"><span class="cls_015">HKFRS 16</span></div>
<div style="position:absolute;left:333.24px;top:162.63px" class="cls_015"><span class="cls_015">31 December</span></div>
<div style="position:absolute;left:508.17px;top:162.65px" class="cls_015"><span class="cls_015">at 1 January</span></div>
<div style="position:absolute;left:288.04px;top:177.61px" class="cls_006"><span class="cls_006">Note</span></div>
<div style="position:absolute;left:373.62px;top:177.63px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:422.17px;top:177.63px" class="cls_015"><span class="cls_015">Adjustments</span></div>
<div style="position:absolute;left:543.72px;top:177.66px" class="cls_015"><span class="cls_015">2019</span></div>
<div style="position:absolute;left:351.64px;top:192.66px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:436.68px;top:192.66px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.72px;top:192.66px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:351.62px;top:207.66px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.71px;top:237.66px" class="cls_014"><span class="cls_014">Non-current Assets</span></div>
<div style="position:absolute;left:56.71px;top:252.67px" class="cls_015"><span class="cls_015">Prepaid lease payments</span></div>
<div style="position:absolute;left:292.25px;top:252.67px" class="cls_006"><span class="cls_006">(a)</span></div>
<div style="position:absolute;left:358.64px;top:252.67px" class="cls_015"><span class="cls_015">526,903</span></div>
<div style="position:absolute;left:439.20px;top:252.67px" class="cls_015"><span class="cls_015">(526,903)</span></div>
<div style="position:absolute;left:555.95px;top:252.67px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.71px;top:267.67px" class="cls_015"><span class="cls_015">Right-of-use assets</span></div>
<div style="position:absolute;left:385.87px;top:267.67px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:443.68px;top:267.67px" class="cls_015"><span class="cls_015">723,977</span></div>
<div style="position:absolute;left:528.72px;top:267.67px" class="cls_015"><span class="cls_015">723,977</span></div>
<div style="position:absolute;left:56.71px;top:297.67px" class="cls_014"><span class="cls_014">Current Assets</span></div>
<div style="position:absolute;left:56.71px;top:312.67px" class="cls_015"><span class="cls_015">Prepaid lease payments</span></div>
<div style="position:absolute;left:292.25px;top:312.67px" class="cls_006"><span class="cls_006">(a)</span></div>
<div style="position:absolute;left:364.55px;top:312.67px" class="cls_015"><span class="cls_015">16,570</span></div>
<div style="position:absolute;left:445.10px;top:312.67px" class="cls_015"><span class="cls_015">(16,570)</span></div>
<div style="position:absolute;left:555.94px;top:312.67px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.70px;top:342.67px" class="cls_014"><span class="cls_014">Current Liabilities</span></div>
<div style="position:absolute;left:56.70px;top:357.67px" class="cls_015"><span class="cls_015">Lease liabilities</span></div>
<div style="position:absolute;left:385.86px;top:357.67px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:445.09px;top:357.67px" class="cls_015"><span class="cls_015">(55,850)</span></div>
<div style="position:absolute;left:530.13px;top:357.67px" class="cls_015"><span class="cls_015">(55,850)</span></div>
<div style="position:absolute;left:56.69px;top:387.67px" class="cls_014"><span class="cls_014">Non-current liabilities</span></div>
<div style="position:absolute;left:56.69px;top:402.67px" class="cls_015"><span class="cls_015">Lease liabilities</span></div>
<div style="position:absolute;left:385.85px;top:402.67px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:439.17px;top:402.67px" class="cls_015"><span class="cls_015">(124,654)</span></div>
<div style="position:absolute;left:524.21px;top:402.67px" class="cls_015"><span class="cls_015">(124,654)</span></div>
<div style="position:absolute;left:56.69px;top:433.65px" class="cls_006"><span class="cls_006">Notes:</span></div>
<div style="position:absolute;left:56.69px;top:463.65px" class="cls_015"><span class="cls_015">(a)</span></div>
<div style="position:absolute;left:85.04px;top:463.65px" class="cls_015"><span class="cls_015">Upfront payments for</span></div>
<div style="position:absolute;left:198.14px;top:463.65px" class="cls_015"><span class="cls_015">leasehold lands</span></div>
<div style="position:absolute;left:279.26px;top:463.65px" class="cls_015"><span class="cls_015">in the PRC were classified as prepaid lease payments as</span></div>
<div style="position:absolute;left:85.04px;top:478.65px" class="cls_015"><span class="cls_015">at</span></div>
<div style="position:absolute;left:99.37px;top:478.65px" class="cls_015"><span class="cls_015">31 December 2018. Upon application of HKFRS 16, the current and non-current portion of</span></div>
<div style="position:absolute;left:85.04px;top:493.65px" class="cls_015"><span class="cls_015">prepaid lease payments, amounting to RMB16,570,000 and RMB526,903,000 respectively, were</span></div>
<div style="position:absolute;left:85.04px;top:508.66px" class="cls_015"><span class="cls_015">reclassified to right-of-use assets.</span></div>
<div style="position:absolute;left:56.69px;top:538.65px" class="cls_015"><span class="cls_015">(b)   For the purpose of reporting cash flows from operating activities under indirect method for the</span></div>
<div style="position:absolute;left:85.04px;top:553.66px" class="cls_015"><span class="cls_015">year ended</span></div>
<div style="position:absolute;left:146.18px;top:553.66px" class="cls_015"><span class="cls_015">31 December 2019, movements in working capital have been computed based on</span></div>
<div style="position:absolute;left:85.04px;top:568.66px" class="cls_015"><span class="cls_015">opening consolidated statement of financial position as at 1 January 2019 as disclosed above.</span></div>
<div style="position:absolute;left:28.35px;top:598.66px" class="cls_014"><span class="cls_014">3.</span></div>
<div style="position:absolute;left:56.69px;top:598.66px" class="cls_014"><span class="cls_014">Revenue and Segment Information</span></div>
<div style="position:absolute;left:458.65px;top:631.49px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:631.49px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:646.50px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:646.50px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:661.50px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:691.50px" class="cls_015"><span class="cls_015">Sale of goods</span></div>
<div style="position:absolute;left:428.68px;top:691.50px" class="cls_014"><span class="cls_014">22,103,192</span></div>
<div style="position:absolute;left:513.72px;top:691.50px" class="cls_015"><span class="cls_015">17,716,540</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 12 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:10212px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background13.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_015"><span class="cls_015">Information reported to executive directors, being collectively the chief operating decision maker</span></div>
<div style="position:absolute;left:56.69px;top:54.78px" class="cls_015"><span class="cls_015">(“CODM”), for the purposes of resource allocation and assessment of segment performance focuses on</span></div>
<div style="position:absolute;left:56.69px;top:69.78px" class="cls_015"><span class="cls_015">types of goods delivered.</span></div>
<div style="position:absolute;left:56.69px;top:99.78px" class="cls_015"><span class="cls_015">The Group’s reportable segments under HKFRS 8 </span><span class="cls_006">Operating Segments</span><span class="cls_015"> are as follows:</span></div>
<div style="position:absolute;left:56.69px;top:129.77px" class="cls_015"><span class="cls_015">(a)</span></div>
<div style="position:absolute;left:85.04px;top:129.77px" class="cls_015"><span class="cls_015">Finished drugs — research and development, manufacture and sale of pharmaceutical products;</span></div>
<div style="position:absolute;left:56.69px;top:159.77px" class="cls_015"><span class="cls_015">(b)   Vitamin C — manufacture and sale of vitamin C products in bulk form;</span></div>
<div style="position:absolute;left:56.69px;top:189.77px" class="cls_015"><span class="cls_015">(c)</span></div>
<div style="position:absolute;left:85.04px;top:189.77px" class="cls_015"><span class="cls_015">Antibiotics — manufacture and sale of antibiotic products in bulk form; and</span></div>
<div style="position:absolute;left:56.69px;top:219.76px" class="cls_015"><span class="cls_015">(d)   Others</span></div>
<div style="position:absolute;left:122.95px;top:219.76px" class="cls_015"><span class="cls_015">— manufacture and sale of functional food products (including caffeine additives and</span></div>
<div style="position:absolute;left:85.04px;top:234.77px" class="cls_015"><span class="cls_015">vitamin supplements), glucose products and provision of healthcare services</span></div>
<div style="position:absolute;left:56.69px;top:264.77px" class="cls_015"><span class="cls_015">Vitamin supplements are included as functional food products in the segment of others for the current</span></div>
<div style="position:absolute;left:56.69px;top:279.77px" class="cls_015"><span class="cls_015">year, while they were included in the segment of finished drugs in prior years. The comparative</span></div>
<div style="position:absolute;left:56.69px;top:294.77px" class="cls_015"><span class="cls_015">information has been restated to conform with current year presentation.</span></div>
<div style="position:absolute;left:56.69px;top:324.77px" class="cls_015"><span class="cls_015">Revenue is recognised at a point of time upon control of the goods has transferred, being when the</span></div>
<div style="position:absolute;left:56.69px;top:339.77px" class="cls_015"><span class="cls_015">goods have been delivered to the customer’s specific location. Following delivery, the customer bears</span></div>
<div style="position:absolute;left:56.69px;top:354.78px" class="cls_015"><span class="cls_015">the risks of obsolescence and loss in relation to the goods. The normal credit term is 90 days upon</span></div>
<div style="position:absolute;left:56.69px;top:369.78px" class="cls_015"><span class="cls_015">delivery.</span></div>
<div style="position:absolute;left:56.69px;top:399.78px" class="cls_015"><span class="cls_015">The transaction price received by the Group is recognised as a contract liability until the goods have</span></div>
<div style="position:absolute;left:56.69px;top:414.78px" class="cls_015"><span class="cls_015">been delivered to the customer.</span></div>
<div style="position:absolute;left:56.69px;top:444.78px" class="cls_015"><span class="cls_015">As at 31 December 2019, all outstanding sales contracts are expected to be fulfilled within one year.</span></div>
<div style="position:absolute;left:56.69px;top:459.78px" class="cls_015"><span class="cls_015">As permitted under HKFRS 15, the transaction price allocated to these unsatisfied contracts is not</span></div>
<div style="position:absolute;left:56.69px;top:474.79px" class="cls_015"><span class="cls_015">disclosed.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 13 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:11063px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background14.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_023"><span class="cls_023">Segment revenues and results</span></div>
<div style="position:absolute;left:56.69px;top:69.77px" class="cls_015"><span class="cls_015">The following is an analysis of the Group’s revenue and results by operating and reportable segments.</span></div>
<div style="position:absolute;left:56.69px;top:99.77px" class="cls_016"><span class="cls_016">For the year ended 31 December 2019:</span></div>
<div style="position:absolute;left:196.51px;top:134.40px" class="cls_017"><span class="cls_017">Finished</span></div>
<div style="position:absolute;left:423.58px;top:134.40px" class="cls_017"><span class="cls_017">Segment</span></div>
<div style="position:absolute;left:206.79px;top:149.41px" class="cls_017"><span class="cls_017">drugs</span></div>
<div style="position:absolute;left:246.33px;top:149.41px" class="cls_017"><span class="cls_017">Vitamin C    Antibiotics</span></div>
<div style="position:absolute;left:372.74px;top:149.41px" class="cls_017"><span class="cls_017">Others</span></div>
<div style="position:absolute;left:437.42px;top:149.41px" class="cls_017"><span class="cls_017">total   Eliminations   Consolidated</span></div>
<div style="position:absolute;left:193.80px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:250.49px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:307.19px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:363.88px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:420.58px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:477.27px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:533.97px;top:164.41px" class="cls_018"><span class="cls_018">RMB’000</span></div>
<div style="position:absolute;left:56.70px;top:194.41px" class="cls_017"><span class="cls_017">SEGMENT REVENUE</span></div>
<div style="position:absolute;left:56.70px;top:209.41px" class="cls_019"><span class="cls_019">External sales</span></div>
<div style="position:absolute;left:189.53px;top:209.41px" class="cls_017"><span class="cls_017">17,937,001</span></div>
<div style="position:absolute;left:250.36px;top:209.41px" class="cls_017"><span class="cls_017">1,921,704</span></div>
<div style="position:absolute;left:313.41px;top:209.41px" class="cls_017"><span class="cls_017">878,921</span></div>
<div style="position:absolute;left:363.75px;top:209.41px" class="cls_017"><span class="cls_017">1,365,566</span></div>
<div style="position:absolute;left:416.30px;top:209.41px" class="cls_017"><span class="cls_017">22,103,192</span></div>
<div style="position:absolute;left:502.54px;top:209.41px" class="cls_017"><span class="cls_017">—</span></div>
<div style="position:absolute;left:529.69px;top:209.41px" class="cls_017"><span class="cls_017">22,103,192</span></div>
<div style="position:absolute;left:56.70px;top:224.42px" class="cls_019"><span class="cls_019">Inter-segment sales</span></div>
<div style="position:absolute;left:219.08px;top:224.42px" class="cls_017"><span class="cls_017">—</span></div>
<div style="position:absolute;left:264.99px;top:224.42px" class="cls_017"><span class="cls_017">5,446</span></div>
<div style="position:absolute;left:313.41px;top:224.42px" class="cls_017"><span class="cls_017">119,483</span></div>
<div style="position:absolute;left:378.38px;top:224.42px" class="cls_017"><span class="cls_017">7,051</span></div>
<div style="position:absolute;left:426.80px;top:224.42px" class="cls_017"><span class="cls_017">131,980</span></div>
<div style="position:absolute;left:480.35px;top:224.42px" class="cls_017"><span class="cls_017">(131,980)</span></div>
<div style="position:absolute;left:559.25px;top:224.42px" class="cls_017"><span class="cls_017">—</span></div>
<div style="position:absolute;left:56.69px;top:257.40px" class="cls_017"><span class="cls_017">TOTAL REVENUE</span></div>
<div style="position:absolute;left:189.53px;top:257.40px" class="cls_017"><span class="cls_017">17,937,001</span></div>
<div style="position:absolute;left:250.36px;top:257.40px" class="cls_017"><span class="cls_017">1,927,150</span></div>
<div style="position:absolute;left:313.40px;top:257.40px" class="cls_017"><span class="cls_017">998,404</span></div>
<div style="position:absolute;left:363.75px;top:257.40px" class="cls_017"><span class="cls_017">1,372,617</span></div>
<div style="position:absolute;left:416.30px;top:257.40px" class="cls_017"><span class="cls_017">22,235,172</span></div>
<div style="position:absolute;left:480.34px;top:257.40px" class="cls_017"><span class="cls_017">(131,980)</span></div>
<div style="position:absolute;left:529.68px;top:257.40px" class="cls_017"><span class="cls_017">22,103,192</span></div>
<div style="position:absolute;left:56.69px;top:294.65px" class="cls_017"><span class="cls_017">SEGMENT PROFIT</span></div>
<div style="position:absolute;left:193.66px;top:294.65px" class="cls_017"><span class="cls_017">3,943,808</span></div>
<div style="position:absolute;left:256.71px;top:294.65px" class="cls_017"><span class="cls_017">391,271</span></div>
<div style="position:absolute;left:321.68px;top:294.65px" class="cls_017"><span class="cls_017">4,103</span></div>
<div style="position:absolute;left:370.10px;top:294.65px" class="cls_017"><span class="cls_017">263,991</span></div>
<div style="position:absolute;left:420.44px;top:294.65px" class="cls_017"><span class="cls_017">4,603,173</span></div>
<div style="position:absolute;left:533.82px;top:294.65px" class="cls_017"><span class="cls_017">4,603,173</span></div>
<div style="position:absolute;left:56.69px;top:331.90px" class="cls_019"><span class="cls_019">Unallocated income</span></div>
<div style="position:absolute;left:540.17px;top:331.90px" class="cls_017"><span class="cls_017">150,723</span></div>
<div style="position:absolute;left:56.69px;top:346.91px" class="cls_019"><span class="cls_019">Unallocated expenses</span></div>
<div style="position:absolute;left:537.03px;top:346.91px" class="cls_017"><span class="cls_017">(153,715)</span></div>
<div style="position:absolute;left:56.69px;top:379.90px" class="cls_019"><span class="cls_019">Operating profit</span></div>
<div style="position:absolute;left:533.82px;top:379.90px" class="cls_017"><span class="cls_017">4,600,181</span></div>
<div style="position:absolute;left:56.69px;top:394.91px" class="cls_019"><span class="cls_019">Finance costs</span></div>
<div style="position:absolute;left:541.17px;top:394.91px" class="cls_017"><span class="cls_017">(32,426)</span></div>
<div style="position:absolute;left:56.69px;top:409.91px" class="cls_019"><span class="cls_019">Share of results of joint ventures</span></div>
<div style="position:absolute;left:544.31px;top:409.91px" class="cls_017"><span class="cls_017">58,407</span></div>
<div style="position:absolute;left:56.69px;top:442.90px" class="cls_019"><span class="cls_019">Profit before tax</span></div>
<div style="position:absolute;left:533.82px;top:442.90px" class="cls_017"><span class="cls_017">4,626,162</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 14 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:11914px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background15.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_006"><span class="cls_006">For the year ended 31 December 2018 (Restated):</span></div>
<div style="position:absolute;left:198.23px;top:73.90px" class="cls_019"><span class="cls_019">Finished</span></div>
<div style="position:absolute;left:424.87px;top:73.90px" class="cls_019"><span class="cls_019">Segment</span></div>
<div style="position:absolute;left:208.50px;top:88.40px" class="cls_019"><span class="cls_019">drugs</span></div>
<div style="position:absolute;left:248.48px;top:88.40px" class="cls_019"><span class="cls_019">Vitamin C</span></div>
<div style="position:absolute;left:303.05px;top:88.40px" class="cls_019"><span class="cls_019">Antibiotics</span></div>
<div style="position:absolute;left:374.89px;top:88.40px" class="cls_019"><span class="cls_019">Others</span></div>
<div style="position:absolute;left:438.71px;top:88.40px" class="cls_019"><span class="cls_019">total</span></div>
<div style="position:absolute;left:467.72px;top:88.40px" class="cls_019"><span class="cls_019">Eliminations   Consolidated</span></div>
<div style="position:absolute;left:195.11px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:251.81px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:308.50px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:365.20px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:421.89px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:478.59px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:535.29px;top:102.90px" class="cls_020"><span class="cls_020">RMB’000</span></div>
<div style="position:absolute;left:56.71px;top:131.89px" class="cls_019"><span class="cls_019">SEGMENT REVENUE</span></div>
<div style="position:absolute;left:56.71px;top:146.39px" class="cls_019"><span class="cls_019">External sales</span></div>
<div style="position:absolute;left:189.55px;top:146.39px" class="cls_019"><span class="cls_019">13,503,386</span></div>
<div style="position:absolute;left:250.38px;top:146.39px" class="cls_019"><span class="cls_019">1,783,510</span></div>
<div style="position:absolute;left:307.07px;top:146.39px" class="cls_019"><span class="cls_019">1,086,725</span></div>
<div style="position:absolute;left:363.77px;top:146.39px" class="cls_019"><span class="cls_019">1,342,919</span></div>
<div style="position:absolute;left:416.32px;top:146.39px" class="cls_019"><span class="cls_019">17,716,540</span></div>
<div style="position:absolute;left:502.56px;top:146.39px" class="cls_019"><span class="cls_019">—</span></div>
<div style="position:absolute;left:529.70px;top:146.39px" class="cls_019"><span class="cls_019">17,716,540</span></div>
<div style="position:absolute;left:56.71px;top:160.89px" class="cls_019"><span class="cls_019">Inter-segment sales</span></div>
<div style="position:absolute;left:219.09px;top:160.89px" class="cls_019"><span class="cls_019">—</span></div>
<div style="position:absolute;left:260.86px;top:160.89px" class="cls_019"><span class="cls_019">11,775</span></div>
<div style="position:absolute;left:317.56px;top:160.89px" class="cls_019"><span class="cls_019">90,574</span></div>
<div style="position:absolute;left:378.39px;top:160.89px" class="cls_019"><span class="cls_019">6,486</span></div>
<div style="position:absolute;left:426.81px;top:160.89px" class="cls_019"><span class="cls_019">108,835</span></div>
<div style="position:absolute;left:480.36px;top:160.89px" class="cls_019"><span class="cls_019">(108,835)</span></div>
<div style="position:absolute;left:559.26px;top:160.89px" class="cls_019"><span class="cls_019">—</span></div>
<div style="position:absolute;left:56.69px;top:192.90px" class="cls_019"><span class="cls_019">TOTAL REVENUE</span></div>
<div style="position:absolute;left:189.53px;top:192.90px" class="cls_019"><span class="cls_019">13,503,386</span></div>
<div style="position:absolute;left:250.36px;top:192.90px" class="cls_019"><span class="cls_019">1,795,285</span></div>
<div style="position:absolute;left:307.05px;top:192.90px" class="cls_019"><span class="cls_019">1,177,299</span></div>
<div style="position:absolute;left:363.75px;top:192.90px" class="cls_019"><span class="cls_019">1,349,405</span></div>
<div style="position:absolute;left:416.30px;top:192.90px" class="cls_019"><span class="cls_019">17,825,375</span></div>
<div style="position:absolute;left:480.34px;top:192.90px" class="cls_019"><span class="cls_019">(108,835)</span></div>
<div style="position:absolute;left:529.68px;top:192.90px" class="cls_019"><span class="cls_019">17,716,540</span></div>
<div style="position:absolute;left:56.69px;top:229.15px" class="cls_019"><span class="cls_019">SEGMENT PROFIT</span></div>
<div style="position:absolute;left:193.66px;top:229.15px" class="cls_019"><span class="cls_019">2,815,148</span></div>
<div style="position:absolute;left:256.71px;top:229.15px" class="cls_019"><span class="cls_019">679,928</span></div>
<div style="position:absolute;left:317.54px;top:229.15px" class="cls_019"><span class="cls_019">32,593</span></div>
<div style="position:absolute;left:370.09px;top:229.15px" class="cls_019"><span class="cls_019">267,791</span></div>
<div style="position:absolute;left:420.43px;top:229.15px" class="cls_019"><span class="cls_019">3,795,460</span></div>
<div style="position:absolute;left:533.82px;top:229.15px" class="cls_019"><span class="cls_019">3,795,460</span></div>
<div style="position:absolute;left:56.69px;top:265.40px" class="cls_019"><span class="cls_019">Unallocated income</span></div>
<div style="position:absolute;left:540.17px;top:265.40px" class="cls_019"><span class="cls_019">198,122</span></div>
<div style="position:absolute;left:56.69px;top:279.90px" class="cls_019"><span class="cls_019">Unallocated expenses</span></div>
<div style="position:absolute;left:537.03px;top:279.90px" class="cls_019"><span class="cls_019">(170,620)</span></div>
<div style="position:absolute;left:56.69px;top:311.90px" class="cls_019"><span class="cls_019">Operating profit</span></div>
<div style="position:absolute;left:533.82px;top:311.90px" class="cls_019"><span class="cls_019">3,822,962</span></div>
<div style="position:absolute;left:56.69px;top:326.40px" class="cls_019"><span class="cls_019">Finance costs</span></div>
<div style="position:absolute;left:541.17px;top:326.40px" class="cls_019"><span class="cls_019">(74,337)</span></div>
<div style="position:absolute;left:56.69px;top:340.90px" class="cls_019"><span class="cls_019">Share of results of joint ventures</span></div>
<div style="position:absolute;left:544.31px;top:340.90px" class="cls_019"><span class="cls_019">43,554</span></div>
<div style="position:absolute;left:56.69px;top:372.90px" class="cls_019"><span class="cls_019">Profit before tax</span></div>
<div style="position:absolute;left:533.82px;top:372.90px" class="cls_019"><span class="cls_019">3,792,179</span></div>
<div style="position:absolute;left:56.69px;top:409.34px" class="cls_015"><span class="cls_015">Segment profit represents the profit earned by each segment without allocation of interest income, fair</span></div>
<div style="position:absolute;left:56.69px;top:424.34px" class="cls_015"><span class="cls_015">value changes on structured bank deposits, finance costs, central administrative expenses and share</span></div>
<div style="position:absolute;left:56.69px;top:439.34px" class="cls_015"><span class="cls_015">of results of joint ventures. This is the measure reported to the CODM for the purposes of resource</span></div>
<div style="position:absolute;left:56.69px;top:454.35px" class="cls_015"><span class="cls_015">allocation and performance assessment.</span></div>
<div style="position:absolute;left:56.69px;top:484.34px" class="cls_015"><span class="cls_015">Inter-segment sales are charged at prevailing market rates.</span></div>
<div style="position:absolute;left:56.69px;top:514.34px" class="cls_015"><span class="cls_015">Segment assets and liabilities are not regularly provided to the CODM for review.</span></div>
<div style="position:absolute;left:56.69px;top:544.34px" class="cls_023"><span class="cls_023">Geographical information</span></div>
<div style="position:absolute;left:56.69px;top:574.34px" class="cls_015"><span class="cls_015">Information about the Group’s revenue from external customers is presented based on the geographical</span></div>
<div style="position:absolute;left:56.69px;top:589.34px" class="cls_015"><span class="cls_015">location of customers:</span></div>
<div style="position:absolute;left:458.65px;top:621.68px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:621.68px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:636.18px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:636.18px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:650.68px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:679.67px" class="cls_015"><span class="cls_015">The People’s Republic of China (the “PRC”) (country of domicile)</span></div>
<div style="position:absolute;left:428.68px;top:679.67px" class="cls_014"><span class="cls_014">18,897,453</span></div>
<div style="position:absolute;left:513.72px;top:679.67px" class="cls_015"><span class="cls_015">14,682,452</span></div>
<div style="position:absolute;left:56.69px;top:694.17px" class="cls_015"><span class="cls_015">Other Asian regions</span></div>
<div style="position:absolute;left:434.59px;top:694.17px" class="cls_014"><span class="cls_014">1,045,038</span></div>
<div style="position:absolute;left:519.63px;top:694.17px" class="cls_015"><span class="cls_015">1,264,785</span></div>
<div style="position:absolute;left:56.69px;top:708.67px" class="cls_015"><span class="cls_015">Americas</span></div>
<div style="position:absolute;left:443.66px;top:708.67px" class="cls_014"><span class="cls_014">974,937</span></div>
<div style="position:absolute;left:528.70px;top:708.67px" class="cls_015"><span class="cls_015">783,175</span></div>
<div style="position:absolute;left:56.69px;top:723.17px" class="cls_015"><span class="cls_015">Europe</span></div>
<div style="position:absolute;left:434.59px;top:723.17px" class="cls_014"><span class="cls_014">1,093,405</span></div>
<div style="position:absolute;left:528.70px;top:723.17px" class="cls_015"><span class="cls_015">817,993</span></div>
<div style="position:absolute;left:56.69px;top:737.66px" class="cls_015"><span class="cls_015">Others</span></div>
<div style="position:absolute;left:449.58px;top:737.66px" class="cls_014"><span class="cls_014">92,359</span></div>
<div style="position:absolute;left:528.70px;top:737.66px" class="cls_015"><span class="cls_015">168,135</span></div>
<div style="position:absolute;left:428.68px;top:769.67px" class="cls_014"><span class="cls_014">22,103,192</span></div>
<div style="position:absolute;left:513.72px;top:769.67px" class="cls_015"><span class="cls_015">17,716,540</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 15 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:12765px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background16.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_015"><span class="cls_015">The Group’s operations are substantially based in the PRC and substantially all non-current assets of the</span></div>
<div style="position:absolute;left:56.69px;top:54.78px" class="cls_015"><span class="cls_015">Group are located in the PRC. Therefore, no further analysis of geographical information is presented.</span></div>
<div style="position:absolute;left:56.69px;top:84.77px" class="cls_015"><span class="cls_015">None of the Group’s customers contributed over 10% of the total revenue of the Group for both years.</span></div>
<div style="position:absolute;left:28.35px;top:114.77px" class="cls_014"><span class="cls_014">4.</span></div>
<div style="position:absolute;left:56.69px;top:114.77px" class="cls_014"><span class="cls_014">Profit For The Year</span></div>
<div style="position:absolute;left:458.65px;top:147.60px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:147.60px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:162.61px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:162.61px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:177.61px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:207.61px" class="cls_015"><span class="cls_015">Profit for the year has been arrived at after charging (crediting):</span></div>
<div style="position:absolute;left:56.69px;top:237.61px" class="cls_015"><span class="cls_015">Staff costs, including directors’ and chief executive’s remuneration</span></div>
<div style="position:absolute;left:65.20px;top:252.61px" class="cls_015"><span class="cls_015">— salaries, wages and other benefits</span></div>
<div style="position:absolute;left:434.59px;top:252.61px" class="cls_014"><span class="cls_014">1,912,253</span></div>
<div style="position:absolute;left:519.63px;top:252.61px" class="cls_015"><span class="cls_015">1,305,860</span></div>
<div style="position:absolute;left:65.20px;top:267.61px" class="cls_015"><span class="cls_015">— contribution to retirement benefit schemes</span></div>
<div style="position:absolute;left:443.66px;top:267.61px" class="cls_014"><span class="cls_014">142,693</span></div>
<div style="position:absolute;left:528.70px;top:267.61px" class="cls_015"><span class="cls_015">127,416</span></div>
<div style="position:absolute;left:65.20px;top:282.62px" class="cls_015"><span class="cls_015">— shared-based payment expense</span></div>
<div style="position:absolute;left:455.49px;top:282.62px" class="cls_014"><span class="cls_014">6,721</span></div>
<div style="position:absolute;left:555.93px;top:282.62px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.69px;top:315.61px" class="cls_015"><span class="cls_015">Total staff costs</span></div>
<div style="position:absolute;left:434.59px;top:315.61px" class="cls_014"><span class="cls_014">2,061,667</span></div>
<div style="position:absolute;left:519.63px;top:315.61px" class="cls_015"><span class="cls_015">1,433,276</span></div>
<div style="position:absolute;left:56.69px;top:348.61px" class="cls_015"><span class="cls_015">Amortisation of other intangible assets</span></div>
<div style="position:absolute;left:449.58px;top:348.61px" class="cls_014"><span class="cls_014">17,954</span></div>
<div style="position:absolute;left:534.62px;top:348.61px" class="cls_015"><span class="cls_015">20,142</span></div>
<div style="position:absolute;left:56.69px;top:363.61px" class="cls_015"><span class="cls_015">Depreciation of right-of-use assets</span></div>
<div style="position:absolute;left:449.58px;top:363.61px" class="cls_014"><span class="cls_014">85,749</span></div>
<div style="position:absolute;left:555.93px;top:363.61px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.69px;top:378.61px" class="cls_015"><span class="cls_015">Depreciation of property, plant and equipment</span></div>
<div style="position:absolute;left:443.66px;top:378.61px" class="cls_014"><span class="cls_014">587,892</span></div>
<div style="position:absolute;left:528.70px;top:378.61px" class="cls_015"><span class="cls_015">594,006</span></div>
<div style="position:absolute;left:56.69px;top:411.61px" class="cls_015"><span class="cls_015">Total depreciation and amortisation</span></div>
<div style="position:absolute;left:443.66px;top:411.61px" class="cls_014"><span class="cls_014">691,595</span></div>
<div style="position:absolute;left:528.70px;top:411.61px" class="cls_015"><span class="cls_015">614,148</span></div>
<div style="position:absolute;left:56.69px;top:444.61px" class="cls_015"><span class="cls_015">Release of prepaid lease payments</span></div>
<div style="position:absolute;left:470.89px;top:444.61px" class="cls_014"><span class="cls_014">—</span></div>
<div style="position:absolute;left:534.61px;top:444.61px" class="cls_015"><span class="cls_015">15,700</span></div>
<div style="position:absolute;left:56.68px;top:459.61px" class="cls_015"><span class="cls_015">Auditor’s remuneration</span></div>
<div style="position:absolute;left:455.48px;top:459.61px" class="cls_014"><span class="cls_014">3,872</span></div>
<div style="position:absolute;left:540.52px;top:459.61px" class="cls_015"><span class="cls_015">3,427</span></div>
<div style="position:absolute;left:56.68px;top:474.61px" class="cls_015"><span class="cls_015">Fair value changes on structured bank deposits</span></div>
<div style="position:absolute;left:65.18px;top:489.62px" class="cls_015"><span class="cls_015">(included in other gains or losses)</span></div>
<div style="position:absolute;left:445.08px;top:489.62px" class="cls_014"><span class="cls_014">(84,371)</span></div>
<div style="position:absolute;left:524.20px;top:489.62px" class="cls_015"><span class="cls_015">(112,440)</span></div>
<div style="position:absolute;left:56.68px;top:504.62px" class="cls_015"><span class="cls_015">Government grant income (included in other income)</span></div>
<div style="position:absolute;left:439.16px;top:504.62px" class="cls_014"><span class="cls_014">(135,748)</span></div>
<div style="position:absolute;left:530.11px;top:504.62px" class="cls_015"><span class="cls_015">(29,107)</span></div>
<div style="position:absolute;left:56.67px;top:519.63px" class="cls_015"><span class="cls_015">Interest income on bank balances (included in other income)</span></div>
<div style="position:absolute;left:445.07px;top:519.63px" class="cls_014"><span class="cls_014">(64,740)</span></div>
<div style="position:absolute;left:530.11px;top:519.63px" class="cls_015"><span class="cls_015">(53,070)</span></div>
<div style="position:absolute;left:56.67px;top:534.63px" class="cls_015"><span class="cls_015">Loss on disposal of property, plant and equipment</span></div>
<div style="position:absolute;left:65.17px;top:549.63px" class="cls_015"><span class="cls_015">(included in other gains or losses)</span></div>
<div style="position:absolute;left:449.56px;top:549.63px" class="cls_014"><span class="cls_014">15,161</span></div>
<div style="position:absolute;left:534.60px;top:549.63px" class="cls_015"><span class="cls_015">16,020</span></div>
<div style="position:absolute;left:56.67px;top:564.64px" class="cls_015"><span class="cls_015">Net foreign exchange gain (included in other gains or losses)</span></div>
<div style="position:absolute;left:445.07px;top:564.64px" class="cls_014"><span class="cls_014">(18,563)</span></div>
<div style="position:absolute;left:530.11px;top:564.64px" class="cls_015"><span class="cls_015">(59,752)</span></div>
<div style="position:absolute;left:56.67px;top:579.64px" class="cls_015"><span class="cls_015">Impairment of prepayment for acquisition of intangible assets</span></div>
<div style="position:absolute;left:65.17px;top:594.65px" class="cls_015"><span class="cls_015">(included in other expenses)</span></div>
<div style="position:absolute;left:443.64px;top:594.65px" class="cls_014"><span class="cls_014">100,000</span></div>
<div style="position:absolute;left:555.91px;top:594.65px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.67px;top:609.65px" class="cls_015"><span class="cls_015">Loss on deemed disposal of partial interest in a joint venture</span></div>
<div style="position:absolute;left:65.17px;top:624.65px" class="cls_015"><span class="cls_015">(included in other gains or losses)</span></div>
<div style="position:absolute;left:449.56px;top:624.65px" class="cls_014"><span class="cls_014">17,235</span></div>
<div style="position:absolute;left:555.91px;top:624.65px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.67px;top:639.66px" class="cls_015"><span class="cls_015">Fair value change on contingent consideration payables</span></div>
<div style="position:absolute;left:65.17px;top:654.66px" class="cls_015"><span class="cls_015">(included in other gains or losses)</span></div>
<div style="position:absolute;left:449.56px;top:654.66px" class="cls_014"><span class="cls_014">12,728</span></div>
<div style="position:absolute;left:555.91px;top:654.66px" class="cls_015"><span class="cls_015">—</span></div>
<div style="position:absolute;left:56.69px;top:692.83px" class="cls_006"><span class="cls_006">Note:</span><span class="cls_015"> Cost of inventories recognised as an expense approximated cost</span></div>
<div style="position:absolute;left:434.48px;top:692.83px" class="cls_015"><span class="cls_015">of sales as</span></div>
<div style="position:absolute;left:498.10px;top:692.83px" class="cls_015"><span class="cls_015">shown in the</span></div>
<div style="position:absolute;left:85.04px;top:707.84px" class="cls_015"><span class="cls_015">consolidated statement of profit or loss for the years ended 31 December 2019 and 2018.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 16 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:13616px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background17.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.77px" class="cls_014"><span class="cls_014">5.</span></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_014"><span class="cls_014">Income Tax Expense</span></div>
<div style="position:absolute;left:458.66px;top:72.61px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:72.61px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:87.61px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.69px;top:87.61px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:102.61px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:132.61px" class="cls_015"><span class="cls_015">Current taxation:</span></div>
<div style="position:absolute;left:65.20px;top:147.62px" class="cls_015"><span class="cls_015">— PRC Enterprise Income Tax</span></div>
<div style="position:absolute;left:443.66px;top:147.62px" class="cls_014"><span class="cls_014">786,220</span></div>
<div style="position:absolute;left:528.70px;top:147.62px" class="cls_015"><span class="cls_015">628,345</span></div>
<div style="position:absolute;left:65.20px;top:162.62px" class="cls_015"><span class="cls_015">— PRC withholding tax on dividends distributed by subsidiaries</span></div>
<div style="position:absolute;left:449.58px;top:162.62px" class="cls_014"><span class="cls_014">94,815</span></div>
<div style="position:absolute;left:534.62px;top:162.62px" class="cls_015"><span class="cls_015">67,535</span></div>
<div style="position:absolute;left:65.20px;top:177.62px" class="cls_015"><span class="cls_015">— United States of America (“USA”) Federal and State Income tax</span></div>
<div style="position:absolute;left:455.49px;top:177.62px" class="cls_014"><span class="cls_014">3,148</span></div>
<div style="position:absolute;left:540.53px;top:177.62px" class="cls_015"><span class="cls_015">8,870</span></div>
<div style="position:absolute;left:443.66px;top:210.61px" class="cls_014"><span class="cls_014">884,183</span></div>
<div style="position:absolute;left:528.71px;top:210.61px" class="cls_015"><span class="cls_015">704,750</span></div>
<div style="position:absolute;left:56.70px;top:225.61px" class="cls_015"><span class="cls_015">Deferred taxation</span></div>
<div style="position:absolute;left:455.49px;top:225.61px" class="cls_014"><span class="cls_014">8,627</span></div>
<div style="position:absolute;left:534.61px;top:225.61px" class="cls_015"><span class="cls_015">29,010</span></div>
<div style="position:absolute;left:443.66px;top:258.61px" class="cls_014"><span class="cls_014">892,810</span></div>
<div style="position:absolute;left:528.71px;top:258.61px" class="cls_015"><span class="cls_015">733,760</span></div>
<div style="position:absolute;left:56.69px;top:296.83px" class="cls_015"><span class="cls_015">The calculation of Hong Kong Profits Tax for the Company and its subsidiaries incorporated in Hong</span></div>
<div style="position:absolute;left:56.69px;top:311.84px" class="cls_015"><span class="cls_015">Kong is based on the prevailing tax rates in Hong Kong. No Hong Kong Profits Tax has been recognised</span></div>
<div style="position:absolute;left:56.69px;top:326.84px" class="cls_015"><span class="cls_015">as the Company and its subsidiaries incorporated in Hong Kong had no assessable profits for both years.</span></div>
<div style="position:absolute;left:56.69px;top:356.84px" class="cls_015"><span class="cls_015">The basic tax rate of the Company’s PRC subsidiaries is 25% under the law of the PRC on Enterprise</span></div>
<div style="position:absolute;left:56.69px;top:371.84px" class="cls_015"><span class="cls_015">Income Tax (the “EIT Law”) and implementation regulations of the EIT Law. Certain subsidiaries of</span></div>
<div style="position:absolute;left:56.69px;top:386.85px" class="cls_015"><span class="cls_015">the Company are qualified as advanced technology enterprises and have obtained approvals from the</span></div>
<div style="position:absolute;left:56.69px;top:401.85px" class="cls_015"><span class="cls_015">relevant tax authorities for the applicable tax rate reduced to 15% for a period of 3 years up to 2020.</span></div>
<div style="position:absolute;left:56.69px;top:431.85px" class="cls_015"><span class="cls_015">The calculation of USA Federal and State Income Tax is based on the prevailing tax rates in</span></div>
<div style="position:absolute;left:56.69px;top:446.85px" class="cls_015"><span class="cls_015">the USA.</span></div>
<div style="position:absolute;left:28.35px;top:476.85px" class="cls_014"><span class="cls_014">6.</span></div>
<div style="position:absolute;left:56.69px;top:476.85px" class="cls_014"><span class="cls_014">Earnings Per Share</span></div>
<div style="position:absolute;left:56.69px;top:506.85px" class="cls_015"><span class="cls_015">The calculation of the basic and diluted earnings per share attributable to the owners of the Company is</span></div>
<div style="position:absolute;left:56.69px;top:521.85px" class="cls_015"><span class="cls_015">based on the following data:</span></div>
<div style="position:absolute;left:458.65px;top:554.68px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:554.68px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:569.69px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:569.69px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:584.69px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:614.69px" class="cls_014"><span class="cls_014">Earnings</span></div>
<div style="position:absolute;left:56.69px;top:629.69px" class="cls_015"><span class="cls_015">Earnings for the purpose of basic and diluted earnings per share</span></div>
<div style="position:absolute;left:434.59px;top:629.69px" class="cls_014"><span class="cls_014">3,714,106</span></div>
<div style="position:absolute;left:519.63px;top:629.69px" class="cls_015"><span class="cls_015">3,080,802</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 17 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:14467px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background18.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:43.77px" class="cls_014"><span class="cls_014">Number of shares</span></div>
<div style="position:absolute;left:458.65px;top:43.77px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:43.77px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:460.49px;top:58.78px" class="cls_016"><span class="cls_016">’000</span></div>
<div style="position:absolute;left:545.53px;top:58.78px" class="cls_006"><span class="cls_006">’000</span></div>
<div style="position:absolute;left:56.69px;top:88.77px" class="cls_015"><span class="cls_015">Weighted average number of ordinary shares for the purpose</span></div>
<div style="position:absolute;left:65.20px;top:103.78px" class="cls_015"><span class="cls_015">of basic earnings per share</span></div>
<div style="position:absolute;left:434.59px;top:103.78px" class="cls_014"><span class="cls_014">6,226,545</span></div>
<div style="position:absolute;left:519.63px;top:103.78px" class="cls_015"><span class="cls_015">6,242,083</span></div>
<div style="position:absolute;left:56.69px;top:133.77px" class="cls_015"><span class="cls_015">Effect of dilutive potential ordinary shares:</span></div>
<div style="position:absolute;left:65.20px;top:148.78px" class="cls_015"><span class="cls_015">Unvested shares under share award scheme</span></div>
<div style="position:absolute;left:464.56px;top:148.78px" class="cls_014"><span class="cls_014">917</span></div>
<div style="position:absolute;left:547.16px;top:148.78px" class="cls_015"><span class="cls_015">N/A</span></div>
<div style="position:absolute;left:56.69px;top:181.77px" class="cls_015"><span class="cls_015">Weighted average number of ordinary shares for the purpose</span></div>
<div style="position:absolute;left:65.20px;top:196.78px" class="cls_015"><span class="cls_015">of diluted earnings per share</span></div>
<div style="position:absolute;left:434.59px;top:196.78px" class="cls_014"><span class="cls_014">6,227,462</span></div>
<div style="position:absolute;left:547.16px;top:196.78px" class="cls_015"><span class="cls_015">N/A</span></div>
<div style="position:absolute;left:56.69px;top:235.00px" class="cls_015"><span class="cls_015">For the year ended 31 December 2019, the weighted average number of ordinary shares for the purpose</span></div>
<div style="position:absolute;left:56.69px;top:250.00px" class="cls_015"><span class="cls_015">of calculation of basic earnings per share has been adjusted for the effect of shares held by the Trustee</span></div>
<div style="position:absolute;left:56.69px;top:265.01px" class="cls_015"><span class="cls_015">pursuant to the share award scheme.</span></div>
<div style="position:absolute;left:56.69px;top:295.00px" class="cls_015"><span class="cls_015">No diluted earnings per share is presented for the year ended</span></div>
<div style="position:absolute;left:383.29px;top:295.00px" class="cls_015"><span class="cls_015">31 December 2018 as there was no</span></div>
<div style="position:absolute;left:56.69px;top:310.01px" class="cls_015"><span class="cls_015">potential ordinary shares in issue during the year.</span></div>
<div style="position:absolute;left:28.35px;top:340.00px" class="cls_014"><span class="cls_014">7.</span></div>
<div style="position:absolute;left:56.69px;top:340.00px" class="cls_014"><span class="cls_014">Dividends</span></div>
<div style="position:absolute;left:458.65px;top:372.84px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:372.84px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:387.84px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:387.84px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:402.85px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:432.84px" class="cls_015"><span class="cls_015">Dividends for ordinary shareholders of the Company</span></div>
<div style="position:absolute;left:65.20px;top:447.85px" class="cls_015"><span class="cls_015">recognised as distribution during the year:</span></div>
<div style="position:absolute;left:56.69px;top:477.85px" class="cls_015"><span class="cls_015">2018 Final, paid — HK18 cents</span></div>
<div style="position:absolute;left:65.20px;top:492.85px" class="cls_015"><span class="cls_015">(equivalent to approximately RMB15.5 cents)</span></div>
<div style="position:absolute;left:65.20px;top:507.85px" class="cls_015"><span class="cls_015">(2018: 2017 Final, paid — HK15 cents</span></div>
<div style="position:absolute;left:65.20px;top:522.86px" class="cls_015"><span class="cls_015">(equivalent to approximately RMB12.5 cents)) per share</span></div>
<div style="position:absolute;left:443.66px;top:522.86px" class="cls_014"><span class="cls_014">965,385</span></div>
<div style="position:absolute;left:528.70px;top:522.86px" class="cls_015"><span class="cls_015">782,875</span></div>
<div style="position:absolute;left:28.35px;top:561.06px" class="cls_014"><span class="cls_014">8.</span></div>
<div style="position:absolute;left:56.69px;top:561.06px" class="cls_014"><span class="cls_014">Trade Receivables</span></div>
<div style="position:absolute;left:458.66px;top:593.90px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:593.90px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:608.90px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.69px;top:608.90px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:623.90px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:653.90px" class="cls_015"><span class="cls_015">Trade receivables</span></div>
<div style="position:absolute;left:434.59px;top:653.90px" class="cls_014"><span class="cls_014">2,273,530</span></div>
<div style="position:absolute;left:519.63px;top:653.90px" class="cls_015"><span class="cls_015">2,076,986</span></div>
<div style="position:absolute;left:56.69px;top:668.90px" class="cls_006"><span class="cls_006">Less:</span><span class="cls_015"> allowance for impairment</span></div>
<div style="position:absolute;left:445.09px;top:668.90px" class="cls_014"><span class="cls_014">(14,686)</span></div>
<div style="position:absolute;left:530.13px;top:668.90px" class="cls_015"><span class="cls_015">(12,061)</span></div>
<div style="position:absolute;left:434.59px;top:701.90px" class="cls_014"><span class="cls_014">2,258,844</span></div>
<div style="position:absolute;left:519.63px;top:701.90px" class="cls_015"><span class="cls_015">2,064,925</span></div>
<div style="position:absolute;left:56.69px;top:740.12px" class="cls_015"><span class="cls_015">As at 1 January 2018, trade receivables from contracts with customers amounted to RMB1,546,942,000.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 18 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:15318px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background19.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.69px;top:39.77px" class="cls_015"><span class="cls_015">The Group allows a general credit period of 90 days to its trade customers. The following is an aged</span></div>
<div style="position:absolute;left:56.69px;top:54.27px" class="cls_015"><span class="cls_015">analysis of trade receivables</span></div>
<div style="position:absolute;left:208.92px;top:54.27px" class="cls_015"><span class="cls_015">(net of allowance for impairment) at the end of the reporting period</span></div>
<div style="position:absolute;left:56.69px;top:68.77px" class="cls_015"><span class="cls_015">presented based on the invoice dates which approximated the respective revenue recognition dates:</span></div>
<div style="position:absolute;left:458.65px;top:101.11px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:101.11px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:116.11px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:116.11px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:131.12px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:161.11px" class="cls_015"><span class="cls_015">0 to 90 days</span></div>
<div style="position:absolute;left:434.59px;top:161.11px" class="cls_014"><span class="cls_014">2,124,588</span></div>
<div style="position:absolute;left:519.63px;top:161.11px" class="cls_015"><span class="cls_015">1,861,714</span></div>
<div style="position:absolute;left:56.69px;top:176.12px" class="cls_015"><span class="cls_015">91 to 180 days</span></div>
<div style="position:absolute;left:443.66px;top:176.12px" class="cls_014"><span class="cls_014">125,010</span></div>
<div style="position:absolute;left:528.70px;top:176.12px" class="cls_015"><span class="cls_015">188,303</span></div>
<div style="position:absolute;left:56.69px;top:191.12px" class="cls_015"><span class="cls_015">181 to 365 days</span></div>
<div style="position:absolute;left:455.49px;top:191.12px" class="cls_014"><span class="cls_014">2,830</span></div>
<div style="position:absolute;left:540.53px;top:191.12px" class="cls_015"><span class="cls_015">7,880</span></div>
<div style="position:absolute;left:56.69px;top:206.12px" class="cls_015"><span class="cls_015">More than 365 days</span></div>
<div style="position:absolute;left:455.49px;top:206.12px" class="cls_014"><span class="cls_014">6,416</span></div>
<div style="position:absolute;left:540.53px;top:206.12px" class="cls_015"><span class="cls_015">7,028</span></div>
<div style="position:absolute;left:434.59px;top:239.11px" class="cls_014"><span class="cls_014">2,258,844</span></div>
<div style="position:absolute;left:519.63px;top:239.11px" class="cls_015"><span class="cls_015">2,064,925</span></div>
<div style="position:absolute;left:56.69px;top:276.33px" class="cls_015"><span class="cls_015">Trade receivables with aggregate carrying amount of RMB134,256,000 (2018: RMB203,211,000) are</span></div>
<div style="position:absolute;left:56.69px;top:290.83px" class="cls_015"><span class="cls_015">past due as at the reporting date. The amounts are not considered as in default because there had not</span></div>
<div style="position:absolute;left:56.69px;top:305.33px" class="cls_015"><span class="cls_015">been significant change in credit quality and the amounts are still considered recoverable. The Group</span></div>
<div style="position:absolute;left:56.69px;top:319.83px" class="cls_015"><span class="cls_015">does not hold any collateral or other credit enhancements over these balances nor does it has a legal</span></div>
<div style="position:absolute;left:56.69px;top:334.33px" class="cls_015"><span class="cls_015">right of offset against any amounts owed by the Group to the counterparty.</span></div>
<div style="position:absolute;left:28.35px;top:363.32px" class="cls_014"><span class="cls_014">9.</span></div>
<div style="position:absolute;left:56.69px;top:363.32px" class="cls_014"><span class="cls_014">Deposits, Prepayments and Other Receivables</span></div>
<div style="position:absolute;left:458.65px;top:395.66px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.70px;top:395.66px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.80px;top:410.67px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:410.67px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:425.67px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:455.67px" class="cls_015"><span class="cls_015">Prepayments for purchase of raw materials</span></div>
<div style="position:absolute;left:443.66px;top:455.67px" class="cls_014"><span class="cls_014">176,471</span></div>
<div style="position:absolute;left:528.70px;top:455.67px" class="cls_015"><span class="cls_015">143,067</span></div>
<div style="position:absolute;left:56.69px;top:470.67px" class="cls_015"><span class="cls_015">Prepaid research and development expenses</span></div>
<div style="position:absolute;left:455.49px;top:470.67px" class="cls_014"><span class="cls_014">4,459</span></div>
<div style="position:absolute;left:534.61px;top:470.67px" class="cls_015"><span class="cls_015">44,464</span></div>
<div style="position:absolute;left:56.68px;top:485.67px" class="cls_015"><span class="cls_015">Prepayment for acquisition of intangible assets </span><span class="cls_006">(Note)</span></div>
<div style="position:absolute;left:470.89px;top:485.67px" class="cls_014"><span class="cls_014">—</span></div>
<div style="position:absolute;left:528.70px;top:485.67px" class="cls_015"><span class="cls_015">100,000</span></div>
<div style="position:absolute;left:56.69px;top:500.68px" class="cls_015"><span class="cls_015">Deposits paid for right-of-use assets/prepaid lease payments</span></div>
<div style="position:absolute;left:443.66px;top:500.68px" class="cls_014"><span class="cls_014">333,380</span></div>
<div style="position:absolute;left:528.70px;top:500.68px" class="cls_015"><span class="cls_015">229,000</span></div>
<div style="position:absolute;left:56.69px;top:515.68px" class="cls_015"><span class="cls_015">Deposits and prepayments for utilities</span></div>
<div style="position:absolute;left:449.58px;top:515.68px" class="cls_014"><span class="cls_014">51,646</span></div>
<div style="position:absolute;left:534.62px;top:515.68px" class="cls_015"><span class="cls_015">35,400</span></div>
<div style="position:absolute;left:56.69px;top:530.69px" class="cls_015"><span class="cls_015">Other taxes recoverable</span></div>
<div style="position:absolute;left:443.66px;top:530.69px" class="cls_014"><span class="cls_014">114,453</span></div>
<div style="position:absolute;left:534.61px;top:530.69px" class="cls_015"><span class="cls_015">70,756</span></div>
<div style="position:absolute;left:56.68px;top:545.69px" class="cls_015"><span class="cls_015">Others</span></div>
<div style="position:absolute;left:443.65px;top:545.69px" class="cls_014"><span class="cls_014">230,223</span></div>
<div style="position:absolute;left:528.69px;top:545.69px" class="cls_015"><span class="cls_015">187,400</span></div>
<div style="position:absolute;left:443.66px;top:578.67px" class="cls_014"><span class="cls_014">910,632</span></div>
<div style="position:absolute;left:528.71px;top:578.67px" class="cls_015"><span class="cls_015">810,087</span></div>
<div style="position:absolute;left:56.69px;top:615.92px" class="cls_015"><span class="cls_015">Analysed as:</span></div>
<div style="position:absolute;left:65.20px;top:630.92px" class="cls_015"><span class="cls_015">Current</span></div>
<div style="position:absolute;left:443.66px;top:630.92px" class="cls_014"><span class="cls_014">567,252</span></div>
<div style="position:absolute;left:528.70px;top:630.92px" class="cls_015"><span class="cls_015">481,087</span></div>
<div style="position:absolute;left:65.20px;top:645.93px" class="cls_015"><span class="cls_015">Non-current</span></div>
<div style="position:absolute;left:443.66px;top:645.93px" class="cls_014"><span class="cls_014">343,380</span></div>
<div style="position:absolute;left:528.70px;top:645.93px" class="cls_015"><span class="cls_015">329,000</span></div>
<div style="position:absolute;left:443.66px;top:678.92px" class="cls_014"><span class="cls_014">910,632</span></div>
<div style="position:absolute;left:528.71px;top:678.92px" class="cls_015"><span class="cls_015">810,087</span></div>
<div style="position:absolute;left:56.69px;top:716.15px" class="cls_006"><span class="cls_006">Note:</span><span class="cls_015"> During the year ended</span></div>
<div style="position:absolute;left:206.73px;top:716.15px" class="cls_015"><span class="cls_015">31 December 2018, the Group</span></div>
<div style="position:absolute;left:369.34px;top:716.15px" class="cls_015"><span class="cls_015">entered into a collaboration agreement</span></div>
<div style="position:absolute;left:85.04px;top:730.64px" class="cls_015"><span class="cls_015">with a third party and paid upfront payment of RMB100 million for acquiring the exclusive</span></div>
<div style="position:absolute;left:85.04px;top:745.14px" class="cls_015"><span class="cls_015">commercialisation right of a pharmaceutical product undergoing clinical trials in the PRC. During</span></div>
<div style="position:absolute;left:85.04px;top:759.64px" class="cls_015"><span class="cls_015">the year, the collaboration was terminated and an impairment provision of RMB100,000,000 in</span></div>
<div style="position:absolute;left:85.04px;top:774.14px" class="cls_015"><span class="cls_015">respect of upfront payment was recognised.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 19 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:16169px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background20.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.77px" class="cls_014"><span class="cls_014">10.</span></div>
<div style="position:absolute;left:56.68px;top:39.77px" class="cls_014"><span class="cls_014">Bills Receivables</span></div>
<div style="position:absolute;left:56.68px;top:69.77px" class="cls_015"><span class="cls_015">Bills receivables represent bills on hand. All bills receivables of the Group are with a maturity period</span></div>
<div style="position:absolute;left:56.68px;top:84.77px" class="cls_015"><span class="cls_015">of less than 365 days (2018: less than 365 days) and not yet due at the end of the reporting period. The</span></div>
<div style="position:absolute;left:56.68px;top:99.78px" class="cls_015"><span class="cls_015">management considers the default rate is low based on historical information and experience.</span></div>
<div style="position:absolute;left:56.68px;top:129.77px" class="cls_015"><span class="cls_015">During the year ended 31 December 2018, bills receivables issued by group companies for settlement of</span></div>
<div style="position:absolute;left:56.68px;top:144.78px" class="cls_015"><span class="cls_015">intragroup transactions were discounted to bank without recourse for proceeds of RMB1,504,583,000,</span></div>
<div style="position:absolute;left:56.68px;top:159.78px" class="cls_015"><span class="cls_015">and the related liabilities were included in bills payables as at 31 December 2018.</span></div>
<div style="position:absolute;left:28.34px;top:189.78px" class="cls_014"><span class="cls_014">11.</span></div>
<div style="position:absolute;left:56.67px;top:189.78px" class="cls_014"><span class="cls_014">Trade Receivables Due from Related Companies</span></div>
<div style="position:absolute;left:56.67px;top:219.78px" class="cls_015"><span class="cls_015">The Group generally allows a trade credit period of 90 days (2018: 90 days) to its related companies.</span></div>
<div style="position:absolute;left:56.67px;top:234.78px" class="cls_015"><span class="cls_015">The following is an aged analysis of trade receivables due from related companies at the end of</span></div>
<div style="position:absolute;left:56.67px;top:249.78px" class="cls_015"><span class="cls_015">the reporting period presented based on invoice dates which approximated the respective revenue</span></div>
<div style="position:absolute;left:56.67px;top:264.79px" class="cls_015"><span class="cls_015">recognition dates:</span></div>
<div style="position:absolute;left:458.63px;top:294.78px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.67px;top:294.78px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.77px;top:309.79px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.66px;top:309.79px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.65px;top:324.79px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.67px;top:354.79px" class="cls_015"><span class="cls_015">0 to 90 days</span></div>
<div style="position:absolute;left:443.64px;top:354.79px" class="cls_014"><span class="cls_014">140,183</span></div>
<div style="position:absolute;left:534.59px;top:354.79px" class="cls_015"><span class="cls_015">63,443</span></div>
<div style="position:absolute;left:28.35px;top:388.16px" class="cls_014"><span class="cls_014">12.</span></div>
<div style="position:absolute;left:56.68px;top:388.16px" class="cls_014"><span class="cls_014">Trade Payables</span></div>
<div style="position:absolute;left:56.68px;top:418.16px" class="cls_015"><span class="cls_015">The following is an aged analysis of trade payables at the end of the reporting period presented based</span></div>
<div style="position:absolute;left:56.68px;top:433.17px" class="cls_015"><span class="cls_015">on the invoice dates:</span></div>
<div style="position:absolute;left:458.64px;top:466.00px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.69px;top:466.00px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.79px;top:481.00px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:481.00px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.66px;top:496.01px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.68px;top:526.01px" class="cls_015"><span class="cls_015">0 to 90 days</span></div>
<div style="position:absolute;left:443.65px;top:526.01px" class="cls_014"><span class="cls_014">941,700</span></div>
<div style="position:absolute;left:519.62px;top:526.01px" class="cls_015"><span class="cls_015">1,455,498</span></div>
<div style="position:absolute;left:56.68px;top:541.01px" class="cls_015"><span class="cls_015">91 to 180 days</span></div>
<div style="position:absolute;left:449.57px;top:541.01px" class="cls_014"><span class="cls_014">34,626</span></div>
<div style="position:absolute;left:534.61px;top:541.01px" class="cls_015"><span class="cls_015">60,093</span></div>
<div style="position:absolute;left:56.68px;top:556.01px" class="cls_015"><span class="cls_015">More than 180 days</span></div>
<div style="position:absolute;left:443.65px;top:556.01px" class="cls_014"><span class="cls_014">134,557</span></div>
<div style="position:absolute;left:528.69px;top:556.01px" class="cls_015"><span class="cls_015">103,765</span></div>
<div style="position:absolute;left:434.59px;top:589.00px" class="cls_014"><span class="cls_014">1,110,883</span></div>
<div style="position:absolute;left:519.63px;top:589.00px" class="cls_015"><span class="cls_015">1,619,356</span></div>
<div style="position:absolute;left:56.69px;top:627.23px" class="cls_015"><span class="cls_015">The general credit period on purchases of goods is up to</span></div>
<div style="position:absolute;left:357.25px;top:627.23px" class="cls_015"><span class="cls_015">90 days (2018: 90 days). The Group has</span></div>
<div style="position:absolute;left:56.69px;top:642.23px" class="cls_015"><span class="cls_015">financial risk management policies in place to ensure that all payables are settled within the credit</span></div>
<div style="position:absolute;left:56.69px;top:657.23px" class="cls_015"><span class="cls_015">timeframe.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 20 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:17020px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background21.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.77px" class="cls_014"><span class="cls_014">13.</span></div>
<div style="position:absolute;left:56.68px;top:39.77px" class="cls_014"><span class="cls_014">Other Payables</span></div>
<div style="position:absolute;left:458.64px;top:72.61px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.69px;top:72.61px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.79px;top:87.61px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:87.61px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.66px;top:102.61px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.68px;top:132.61px" class="cls_015"><span class="cls_015">Customers’ deposits</span></div>
<div style="position:absolute;left:443.65px;top:132.61px" class="cls_014"><span class="cls_014">238,748</span></div>
<div style="position:absolute;left:528.69px;top:132.61px" class="cls_015"><span class="cls_015">340,811</span></div>
<div style="position:absolute;left:56.68px;top:147.62px" class="cls_015"><span class="cls_015">Other taxes payable</span></div>
<div style="position:absolute;left:443.65px;top:147.62px" class="cls_014"><span class="cls_014">126,489</span></div>
<div style="position:absolute;left:528.69px;top:147.62px" class="cls_015"><span class="cls_015">206,275</span></div>
<div style="position:absolute;left:56.68px;top:162.62px" class="cls_015"><span class="cls_015">Selling expense payable and other accrual charges</span></div>
<div style="position:absolute;left:434.58px;top:162.62px" class="cls_014"><span class="cls_014">1,512,130</span></div>
<div style="position:absolute;left:528.69px;top:162.62px" class="cls_015"><span class="cls_015">950,798</span></div>
<div style="position:absolute;left:56.68px;top:177.62px" class="cls_015"><span class="cls_015">Payables arising from construction cost and</span></div>
<div style="position:absolute;left:65.19px;top:192.63px" class="cls_015"><span class="cls_015">acquisition of property, plant and equipment</span></div>
<div style="position:absolute;left:434.58px;top:192.63px" class="cls_014"><span class="cls_014">1,157,020</span></div>
<div style="position:absolute;left:528.69px;top:192.63px" class="cls_015"><span class="cls_015">845,308</span></div>
<div style="position:absolute;left:56.68px;top:207.63px" class="cls_015"><span class="cls_015">Government grants</span></div>
<div style="position:absolute;left:443.65px;top:207.63px" class="cls_014"><span class="cls_014">359,841</span></div>
<div style="position:absolute;left:528.69px;top:207.63px" class="cls_015"><span class="cls_015">360,375</span></div>
<div style="position:absolute;left:56.68px;top:222.64px" class="cls_015"><span class="cls_015">Staff welfare payable</span></div>
<div style="position:absolute;left:443.65px;top:222.64px" class="cls_014"><span class="cls_014">244,848</span></div>
<div style="position:absolute;left:528.69px;top:222.64px" class="cls_015"><span class="cls_015">239,559</span></div>
<div style="position:absolute;left:56.68px;top:237.64px" class="cls_015"><span class="cls_015">Others</span></div>
<div style="position:absolute;left:443.65px;top:237.64px" class="cls_014"><span class="cls_014">207,309</span></div>
<div style="position:absolute;left:528.69px;top:237.64px" class="cls_015"><span class="cls_015">159,540</span></div>
<div style="position:absolute;left:434.59px;top:270.61px" class="cls_014"><span class="cls_014">3,846,385</span></div>
<div style="position:absolute;left:519.63px;top:270.61px" class="cls_015"><span class="cls_015">3,102,666</span></div>
<div style="position:absolute;left:458.65px;top:311.67px" class="cls_014"><span class="cls_014">2019</span></div>
<div style="position:absolute;left:543.69px;top:311.67px" class="cls_015"><span class="cls_015">2018</span></div>
<div style="position:absolute;left:434.79px;top:326.67px" class="cls_016"><span class="cls_016">RMB’000</span></div>
<div style="position:absolute;left:521.68px;top:326.67px" class="cls_006"><span class="cls_006">RMB’000</span></div>
<div style="position:absolute;left:521.67px;top:341.68px" class="cls_015"><span class="cls_015">(Restated)</span></div>
<div style="position:absolute;left:56.69px;top:371.67px" class="cls_015"><span class="cls_015">Analysed as:</span></div>
<div style="position:absolute;left:56.69px;top:386.68px" class="cls_015"><span class="cls_015">Current</span></div>
<div style="position:absolute;left:434.58px;top:386.68px" class="cls_014"><span class="cls_014">3,691,652</span></div>
<div style="position:absolute;left:519.63px;top:386.68px" class="cls_015"><span class="cls_015">2,920,262</span></div>
<div style="position:absolute;left:56.69px;top:401.68px" class="cls_015"><span class="cls_015">Non-current</span></div>
<div style="position:absolute;left:443.66px;top:401.68px" class="cls_014"><span class="cls_014">154,733</span></div>
<div style="position:absolute;left:528.70px;top:401.68px" class="cls_015"><span class="cls_015">182,404</span></div>
<div style="position:absolute;left:434.59px;top:434.67px" class="cls_014"><span class="cls_014">3,846,385</span></div>
<div style="position:absolute;left:519.63px;top:434.67px" class="cls_015"><span class="cls_015">3,102,666</span></div>
<div style="position:absolute;left:28.35px;top:472.90px" class="cls_014"><span class="cls_014">14.</span></div>
<div style="position:absolute;left:56.68px;top:472.90px" class="cls_014"><span class="cls_014">Bills Payables</span></div>
<div style="position:absolute;left:56.68px;top:502.89px" class="cls_015"><span class="cls_015">All bills payables of the Group are aged within</span></div>
<div style="position:absolute;left:308.33px;top:502.89px" class="cls_015"><span class="cls_015">365 days (2018: 365 days) and not yet due at the</span></div>
<div style="position:absolute;left:56.68px;top:517.90px" class="cls_015"><span class="cls_015">end of the reporting period. As at</span></div>
<div style="position:absolute;left:242.84px;top:517.90px" class="cls_015"><span class="cls_015">31 December 2019, bills payables of RMB198,648,600 (2018:</span></div>
<div style="position:absolute;left:56.68px;top:532.90px" class="cls_015"><span class="cls_015">RMB1,504,583,000) are secured by certain bank deposits and structured bank deposits.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 21 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:17871px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background22.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">MANAGEMENT DISCUSSION AND ANALYSIS</span></div>
<div style="position:absolute;left:28.56px;top:73.60px" class="cls_007"><span class="cls_007">Finished Drug Business</span></div>
<div style="position:absolute;left:28.34px;top:107.60px" class="cls_002"><span class="cls_002">The finished drug business continued to achieve satisfactory growth in</span></div>
<div style="position:absolute;left:432.39px;top:107.60px" class="cls_002"><span class="cls_002">2019 with sales revenue</span></div>
<div style="position:absolute;left:28.34px;top:124.60px" class="cls_002"><span class="cls_002">reaching RMB17,937 million, 32.8% higher than the previous year.</span></div>
<div style="position:absolute;left:28.34px;top:158.60px" class="cls_007"><span class="cls_007">(i)</span></div>
<div style="position:absolute;left:56.68px;top:158.60px" class="cls_007"><span class="cls_007">Innovative Drug Products</span></div>
<div style="position:absolute;left:56.68px;top:192.59px" class="cls_002"><span class="cls_002">During the year, the Group continued to expand the dedicated sales force, accelerate market</span></div>
<div style="position:absolute;left:56.68px;top:209.60px" class="cls_002"><span class="cls_002">expansion in major cities and hospitals, and adopt different sales strategies based on the market</span></div>
<div style="position:absolute;left:56.68px;top:226.60px" class="cls_002"><span class="cls_002">positions and competitive landscape of the products, including i) stepping up market penetration</span></div>
<div style="position:absolute;left:56.68px;top:243.60px" class="cls_002"><span class="cls_002">into county-level hospitals and community medical institutions; ii) rapidly establishing strong</span></div>
<div style="position:absolute;left:56.68px;top:260.61px" class="cls_002"><span class="cls_002">sales teams for new products and actively developing the market of major hospitals; iii) striving</span></div>
<div style="position:absolute;left:56.68px;top:277.61px" class="cls_002"><span class="cls_002">for market share gain through emphasis on the competitive edge from product differentiation;</span></div>
<div style="position:absolute;left:56.68px;top:294.62px" class="cls_002"><span class="cls_002">and iv) strengthening market expansion in different indications through professional academic-</span></div>
<div style="position:absolute;left:56.68px;top:311.62px" class="cls_002"><span class="cls_002">based promotion. Leveraging the market competitiveness of the products and the effective sales</span></div>
<div style="position:absolute;left:56.68px;top:328.62px" class="cls_002"><span class="cls_002">strategies, innovative drug products maintained a strong growth momentum and achieved sales</span></div>
<div style="position:absolute;left:56.68px;top:345.63px" class="cls_002"><span class="cls_002">of RMB12,975 million in 2019, representing a 48.4% growth. In particular, the sales of NBP</span></div>
<div style="position:absolute;left:56.68px;top:362.63px" class="cls_002"><span class="cls_002">increased by 35.8% and the sales of oncology drugs increased by 148.8%, becoming the dual</span></div>
<div style="position:absolute;left:56.68px;top:379.64px" class="cls_002"><span class="cls_002">engines of the Group’s growth.</span></div>
<div style="position:absolute;left:56.68px;top:413.63px" class="cls_002"><span class="cls_002">The following are the Group’s major innovative drug products:</span></div>
<div style="position:absolute;left:56.68px;top:446.98px" class="cls_013"><span class="cls_013">NB</span><span class="cls_002">（</span><span class="cls_021">恩必普</span><span class="cls_002">）</span><span class="cls_013">(butylphthalide soft capsule and injection)</span></div>
<div style="position:absolute;left:56.69px;top:481.60px" class="cls_002"><span class="cls_002">NBP is a Class 1 new chemical drug in China and a patent-protected exclusive product</span></div>
<div style="position:absolute;left:56.69px;top:498.60px" class="cls_002"><span class="cls_002">mainly used for the treatment of acute ischemic stroke. NBP has been listed as one of the</span></div>
<div style="position:absolute;left:56.69px;top:515.61px" class="cls_002"><span class="cls_002">recommended drugs in previous editions of “Guidelines for Acute Ischemic Stroke Treatment</span></div>
<div style="position:absolute;left:56.69px;top:532.61px" class="cls_002"><span class="cls_002">in China”. It has also been listed on more than ten guidelines and consensuses, including the</span></div>
<div style="position:absolute;left:56.69px;top:549.62px" class="cls_002"><span class="cls_002">“Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke of China”, “Guidelines</span></div>
<div style="position:absolute;left:56.69px;top:566.62px" class="cls_002"><span class="cls_002">for the Assessment and Intervention of Cerebral Collateral Circulation in Ischemic Stroke</span></div>
<div style="position:absolute;left:56.69px;top:583.62px" class="cls_002"><span class="cls_002">in China</span></div>
<div style="position:absolute;left:110.68px;top:583.62px" class="cls_002"><span class="cls_002">(2017)”,</span></div>
<div style="position:absolute;left:160.98px;top:583.62px" class="cls_002"><span class="cls_002">“Guidelines for the Diagnosis and Treatment of Cerebral Infarction with</span></div>
<div style="position:absolute;left:56.69px;top:600.63px" class="cls_002"><span class="cls_002">Chinese and Western Medicines in China (2017)”, “Guidelines for the Reasonable Medication</span></div>
<div style="position:absolute;left:56.69px;top:617.63px" class="cls_002"><span class="cls_002">for Stroke in China</span></div>
<div style="position:absolute;left:174.36px;top:617.63px" class="cls_002"><span class="cls_002">(2019)” and</span></div>
<div style="position:absolute;left:247.30px;top:617.63px" class="cls_002"><span class="cls_002">“Guidelines for Clinical Management of Cerebrovascular</span></div>
<div style="position:absolute;left:56.69px;top:634.64px" class="cls_002"><span class="cls_002">Diseases in China (2019)”. These serve to recognise the clinical efficacy of NBP for treating</span></div>
<div style="position:absolute;left:56.69px;top:651.64px" class="cls_002"><span class="cls_002">acute ischemic stroke and provide strong academic evidence for its academic-based promotion.</span></div>
<div style="position:absolute;left:56.69px;top:668.64px" class="cls_002"><span class="cls_002">The inclusion of both formulations of NBP into the national reimbursement drug list is also</span></div>
<div style="position:absolute;left:56.69px;top:685.65px" class="cls_002"><span class="cls_002">favourable for the promotion of sequential treatment</span></div>
<div style="position:absolute;left:356.64px;top:685.65px" class="cls_002"><span class="cls_002">(injection for emergency use and soft</span></div>
<div style="position:absolute;left:56.69px;top:702.65px" class="cls_002"><span class="cls_002">capsule for recovery use).</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 22 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:18722px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background23.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.60px" class="cls_002"><span class="cls_002">For the exploration of new therapeutic areas, 134 research projects in respect of butylphthalide</span></div>
<div style="position:absolute;left:56.70px;top:56.61px" class="cls_002"><span class="cls_002">are in progress, including 69 fundamental and 65 clinical projects. In particular, butylphthalide</span></div>
<div style="position:absolute;left:56.70px;top:73.61px" class="cls_002"><span class="cls_002">soft capsule for the treatment of vascular dementia has been approved to commence phase</span></div>
<div style="position:absolute;left:56.70px;top:90.62px" class="cls_002"><span class="cls_002">III clinical trial directly, accelerating the expected launch for the new indication. In addition,</span></div>
<div style="position:absolute;left:56.70px;top:107.62px" class="cls_002"><span class="cls_002">NBP has also participated in seven national studies under the “13th Five Year Plan”, including</span></div>
<div style="position:absolute;left:56.70px;top:124.62px" class="cls_002"><span class="cls_002">efficacy and safety studies of butylphthalide for new treatment areas such as cerebral small</span></div>
<div style="position:absolute;left:56.70px;top:141.63px" class="cls_002"><span class="cls_002">vessel diseases, aortic atherosclerotic cerebral infarction and intravenous thrombolysis or</span></div>
<div style="position:absolute;left:56.70px;top:158.63px" class="cls_002"><span class="cls_002">endovascular treatment for acute ischemic stroke. Of which the research of butylphthalide for</span></div>
<div style="position:absolute;left:56.70px;top:175.64px" class="cls_002"><span class="cls_002">the treatment of hemorrhagic stroke led by Beijing Tiantan Hospital was a new study in 2019.</span></div>
<div style="position:absolute;left:56.70px;top:192.64px" class="cls_002"><span class="cls_002">The phase II clinical trial of butylphthalide soft capsule in the U.S. has enrolled 112 patients.</span></div>
<div style="position:absolute;left:56.70px;top:209.64px" class="cls_002"><span class="cls_002">The development of new indications and markets will be able to bring new growth opportunities</span></div>
<div style="position:absolute;left:56.70px;top:226.65px" class="cls_002"><span class="cls_002">to NBP.</span></div>
<div style="position:absolute;left:56.70px;top:260.64px" class="cls_002"><span class="cls_002">During the year, the Group further expanded its dedicated sales force of NBP and gradually</span></div>
<div style="position:absolute;left:56.70px;top:277.65px" class="cls_002"><span class="cls_002">developed the primary medical market of county level and community health centres. The</span></div>
<div style="position:absolute;left:56.70px;top:294.65px" class="cls_002"><span class="cls_002">number of hospitals with sales coverage increased rapidly with sales maintaining a high rate of</span></div>
<div style="position:absolute;left:56.70px;top:311.66px" class="cls_002"><span class="cls_002">growth. Currently, the coverage of NBP in the county-level market is still relatively low, and</span></div>
<div style="position:absolute;left:56.70px;top:328.66px" class="cls_002"><span class="cls_002">the growth potential for sequential treatment is promising. The Group believes that NBP will</span></div>
<div style="position:absolute;left:56.70px;top:345.66px" class="cls_002"><span class="cls_002">continue to enjoy a steady growth.</span></div>
<div style="position:absolute;left:56.70px;top:378.98px" class="cls_013"><span class="cls_013">Oulainin</span><span class="cls_002">（</span><span class="cls_021">歐來寧</span><span class="cls_002">）</span><span class="cls_013">(oxiracetam capsule and lyophilised powder injection)</span></div>
<div style="position:absolute;left:56.69px;top:413.60px" class="cls_002"><span class="cls_002">Oulaining is mainly used for the treatment of mild to moderate memory and mental impairment</span></div>
<div style="position:absolute;left:56.69px;top:430.60px" class="cls_002"><span class="cls_002">resulting from vascular dementia, senile dementia and brain trauma. During the year, policies</span></div>
<div style="position:absolute;left:56.69px;top:447.61px" class="cls_002"><span class="cls_002">such as the review and uniform implementation of the national reimbursement drug list</span></div>
<div style="position:absolute;left:56.69px;top:464.61px" class="cls_002"><span class="cls_002">throughout the country, and introduction of the National Key Drug List for Monitoring and</span></div>
<div style="position:absolute;left:56.69px;top:481.62px" class="cls_002"><span class="cls_002">Prescription Control had a significant impact on the sales of Oulaining, resulting in a sales</span></div>
<div style="position:absolute;left:56.69px;top:498.62px" class="cls_002"><span class="cls_002">decline. Nevertheless, Oulaining has been marketed in China for over 16 years and has also</span></div>
<div style="position:absolute;left:56.69px;top:515.62px" class="cls_002"><span class="cls_002">been included into various guidelines such as the “Guidelines for the Diagnosis and Treatment</span></div>
<div style="position:absolute;left:56.69px;top:532.63px" class="cls_002"><span class="cls_002">of Cognitive Impairment of Cerebral Small Vessel Diseases</span></div>
<div style="position:absolute;left:413.38px;top:532.63px" class="cls_002"><span class="cls_002">2019” and “Guidelines for</span></div>
<div style="position:absolute;left:56.69px;top:549.63px" class="cls_002"><span class="cls_002">Diagnosis and Treatment of Dementia and Cognitive Impairment in China</span></div>
<div style="position:absolute;left:482.56px;top:549.63px" class="cls_002"><span class="cls_002">2015”, and has</span></div>
<div style="position:absolute;left:56.69px;top:566.64px" class="cls_002"><span class="cls_002">become a basic drug commonly used in clinical practice with a relatively large user base of</span></div>
<div style="position:absolute;left:56.69px;top:583.64px" class="cls_002"><span class="cls_002">doctors and patients. In addition, a number of fundamental and clinical studies of oxiracetam</span></div>
<div style="position:absolute;left:56.69px;top:600.64px" class="cls_002"><span class="cls_002">led by authoritative neurology experts in China have been initiated, the results of which are</span></div>
<div style="position:absolute;left:56.69px;top:617.65px" class="cls_002"><span class="cls_002">believed to provide a strong support for the academic-based promotion of Oulaining.</span></div>
<div style="position:absolute;left:56.69px;top:651.64px" class="cls_002"><span class="cls_002">During the year, Oulaining has basically achieved a complete transformation of its sales</span></div>
<div style="position:absolute;left:56.69px;top:668.65px" class="cls_002"><span class="cls_002">model to direct sales. The strengthening of control over each level of end-user market and the</span></div>
<div style="position:absolute;left:56.69px;top:685.65px" class="cls_002"><span class="cls_002">increased efforts in academic-based promotion will bolster growth within its reasonable scope</span></div>
<div style="position:absolute;left:56.69px;top:702.66px" class="cls_002"><span class="cls_002">of use.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 23 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:19573px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background24.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.72px" class="cls_013"><span class="cls_013">Xuannin</span><span class="cls_002">（</span><span class="cls_021">玄寧</span><span class="cls_002">）</span><span class="cls_013">(maleate levamlodipine tablet and dispersible tablet)</span></div>
<div style="position:absolute;left:56.70px;top:74.34px" class="cls_002"><span class="cls_002">Xuanning is mainly used for the treatment of hypertension, chronic stable angina and variant</span></div>
<div style="position:absolute;left:56.70px;top:91.35px" class="cls_002"><span class="cls_002">angina. In December 2019, Xuanning received marketing approval from the U.S. Food and</span></div>
<div style="position:absolute;left:56.70px;top:108.35px" class="cls_002"><span class="cls_002">Drug Administration (FDA), becoming the first Chinese innovative drug granted full approval</span></div>
<div style="position:absolute;left:56.70px;top:125.35px" class="cls_002"><span class="cls_002">by the U.S. FDA. Levamlodipine is not the same chemical substance as amlodipine and has no</span></div>
<div style="position:absolute;left:56.70px;top:142.36px" class="cls_002"><span class="cls_002">reference drug. It is not expected to be included in the national centralised procurement in the</span></div>
<div style="position:absolute;left:56.70px;top:159.36px" class="cls_002"><span class="cls_002">near future. With the vigorous implementation of the national essential drugs policy, Xuanning</span></div>
<div style="position:absolute;left:56.70px;top:176.37px" class="cls_002"><span class="cls_002">will find better development opportunities.</span></div>
<div style="position:absolute;left:56.70px;top:210.36px" class="cls_002"><span class="cls_002">During the year, the Group has commenced to establish direct sales team for Xuanning and</span></div>
<div style="position:absolute;left:56.70px;top:227.37px" class="cls_002"><span class="cls_002">stepped up the efforts in building customer network and managing the primary market of</span></div>
<div style="position:absolute;left:56.70px;top:244.37px" class="cls_002"><span class="cls_002">county level and below, resulting in a stable increase of sales. The Group will strengthen its</span></div>
<div style="position:absolute;left:56.70px;top:261.37px" class="cls_002"><span class="cls_002">efforts in the establishment of the OTC team, participate in the differentiated competition with</span></div>
<div style="position:absolute;left:56.70px;top:278.38px" class="cls_002"><span class="cls_002">competing products based on product distinctiveness and effectively implement its strategies in</span></div>
<div style="position:absolute;left:56.70px;top:295.38px" class="cls_002"><span class="cls_002">prescription conversion and brand building.</span></div>
<div style="position:absolute;left:56.70px;top:328.72px" class="cls_013"><span class="cls_013">Jinyoul</span><span class="cls_002">（</span><span class="cls_021">津優力</span><span class="cls_002">）</span><span class="cls_013">(PEG-rhGCSF injection)</span></div>
<div style="position:absolute;left:56.69px;top:363.34px" class="cls_002"><span class="cls_002">Jinyouli is the first long-acting white blood cell booster drug in China. It is used to decrease the</span></div>
<div style="position:absolute;left:56.69px;top:380.35px" class="cls_002"><span class="cls_002">incidence of infection and pyrexia due to low neutrophil count in patients during chemotherapy,</span></div>
<div style="position:absolute;left:56.69px;top:397.35px" class="cls_002"><span class="cls_002">thus ensuring the administration of standardised dosage of chemotherapy. Jinyouli is well</span></div>
<div style="position:absolute;left:56.69px;top:414.35px" class="cls_002"><span class="cls_002">supported by clinical evidence with its phase IV clinical study having the largest sample size</span></div>
<div style="position:absolute;left:56.69px;top:431.36px" class="cls_002"><span class="cls_002">in respect of clinical study of long-acting granulocyte stimulating factor in China, covering</span></div>
<div style="position:absolute;left:56.69px;top:448.36px" class="cls_002"><span class="cls_002">lung cancer, breast cancer, lymphoma, ovarian cancer, colorectal cancer, gastric cancer and</span></div>
<div style="position:absolute;left:56.69px;top:465.37px" class="cls_002"><span class="cls_002">nasopharyngeal carcinoma, earning unanimous recommendations from domestic and foreign</span></div>
<div style="position:absolute;left:56.69px;top:482.37px" class="cls_002"><span class="cls_002">guidelines.</span></div>
<div style="position:absolute;left:56.69px;top:516.37px" class="cls_002"><span class="cls_002">During the year, the Group launched the prefilled syringe of Jinyouli, with an enhanced</span></div>
<div style="position:absolute;left:56.69px;top:533.37px" class="cls_002"><span class="cls_002">accuracy of drug administration and dosage utilization rate. The needs of different markets</span></div>
<div style="position:absolute;left:56.69px;top:550.37px" class="cls_002"><span class="cls_002">are also met more effectively with dual dosage forms. Meanwhile, the Group accelerated the</span></div>
<div style="position:absolute;left:56.69px;top:567.38px" class="cls_002"><span class="cls_002">development of Jinyouli in prefecture-level and county-level hospitals and pursued strategic</span></div>
<div style="position:absolute;left:56.69px;top:584.38px" class="cls_002"><span class="cls_002">cooperation with a number of key hospitals, achieving rapid sales growth during the year. The</span></div>
<div style="position:absolute;left:56.69px;top:601.39px" class="cls_002"><span class="cls_002">Group will explore the application opportunities in immunotherapy and target therapy, and</span></div>
<div style="position:absolute;left:56.69px;top:618.39px" class="cls_002"><span class="cls_002">further extend the therapeutic areas to haematological and bone cancers, expanding the market</span></div>
<div style="position:absolute;left:56.69px;top:635.39px" class="cls_002"><span class="cls_002">potential for Jinyouli.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 24 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:20424px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background25.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.72px" class="cls_013"><span class="cls_013">Duomeis</span><span class="cls_002">（</span><span class="cls_021">多美素</span><span class="cls_002">）</span><span class="cls_013">(doxorubicin hydrochloride liposome injection)</span></div>
<div style="position:absolute;left:56.69px;top:74.34px" class="cls_002"><span class="cls_002">Duomeisu was developed by the</span></div>
<div style="position:absolute;left:260.18px;top:74.34px" class="cls_002"><span class="cls_002">“National Key Laboratory for New Pharmaceutical</span></div>
<div style="position:absolute;left:56.69px;top:91.35px" class="cls_002"><span class="cls_002">Preparations and Excipients” of the Group and supported by the</span></div>
<div style="position:absolute;left:458.84px;top:91.35px" class="cls_002"><span class="cls_002">“Major New Drug</span></div>
<div style="position:absolute;left:56.69px;top:108.35px" class="cls_002"><span class="cls_002">Development” projects in China, and for the first-line treatment of lymphoma, ovarian cancer,</span></div>
<div style="position:absolute;left:56.69px;top:125.35px" class="cls_002"><span class="cls_002">relapsed or metastatic breast cancer, soft tissue sarcoma and AIDS-related Kaposi sarcoma.</span></div>
<div style="position:absolute;left:56.69px;top:142.36px" class="cls_002"><span class="cls_002">Duomeisu has considerable advantages in terms of efficacy and safety (especially cardiac safety</span></div>
<div style="position:absolute;left:56.69px;top:159.36px" class="cls_002"><span class="cls_002">of patients) as compared to traditional anthracyclines.</span></div>
<div style="position:absolute;left:56.69px;top:193.36px" class="cls_002"><span class="cls_002">After years of academic-based promotion, hospital development and marketing efforts,</span></div>
<div style="position:absolute;left:56.69px;top:210.36px" class="cls_002"><span class="cls_002">Duomeisu has become a leading brand in the domestic doxorubicin liposomal market. In</span></div>
<div style="position:absolute;left:56.69px;top:227.37px" class="cls_002"><span class="cls_002">addition, Duomeisu has started the consistency evaluation in 2019, which will further enhance</span></div>
<div style="position:absolute;left:56.69px;top:244.37px" class="cls_002"><span class="cls_002">its brand advantage and provide strong support for market share expansion.</span></div>
<div style="position:absolute;left:56.69px;top:278.37px" class="cls_002"><span class="cls_002">During the year, the sales of Duomeisu have maintained a rapid growth. The Group will</span></div>
<div style="position:absolute;left:56.69px;top:295.37px" class="cls_002"><span class="cls_002">continue to build on its competitive resources to strengthen academic-based promotion,</span></div>
<div style="position:absolute;left:56.69px;top:312.37px" class="cls_002"><span class="cls_002">cooperate with professional academies and experts, and carry out new clinical studies in order</span></div>
<div style="position:absolute;left:56.69px;top:329.38px" class="cls_002"><span class="cls_002">to enhance the market recognition and acceptance. Moreover, apart from strengthening the</span></div>
<div style="position:absolute;left:56.69px;top:346.38px" class="cls_002"><span class="cls_002">existing sales areas such as haematological cancer, breast cancer, gynecologic cancer and bone</span></div>
<div style="position:absolute;left:56.69px;top:363.39px" class="cls_002"><span class="cls_002">cancer, the Group will continue to explore new areas such as leukemia, liver cancer, bladder</span></div>
<div style="position:absolute;left:56.69px;top:380.39px" class="cls_002"><span class="cls_002">cancer, lung cancer and gastric cancer, with an aim of sustaining a steady sales growth of</span></div>
<div style="position:absolute;left:56.69px;top:397.39px" class="cls_002"><span class="cls_002">Duomeisu.</span></div>
<div style="position:absolute;left:56.69px;top:430.72px" class="cls_013"><span class="cls_013">Keail</span><span class="cls_002">（</span><span class="cls_021">克艾力</span><span class="cls_002">）</span><span class="cls_013">(paclitaxel for injection (albumin-bound))</span></div>
<div style="position:absolute;left:56.69px;top:465.34px" class="cls_002"><span class="cls_002">Keaili is the first-to-market generic of new generation of paclitaxel chemotherapy drug in</span></div>
<div style="position:absolute;left:56.69px;top:482.35px" class="cls_002"><span class="cls_002">China with the passing of consistency evaluation. It is made of stable nanoparticles formed</span></div>
<div style="position:absolute;left:56.69px;top:499.35px" class="cls_002"><span class="cls_002">by the integration of paclitaxel and human serum albumin (endogenous). The product has the</span></div>
<div style="position:absolute;left:56.69px;top:516.35px" class="cls_002"><span class="cls_002">distinctive features of convenience, high efficacy and safety. It can enhance the efficacy of</span></div>
<div style="position:absolute;left:56.69px;top:533.36px" class="cls_002"><span class="cls_002">paclitaxel drugs and is convenient to use. Toxic solvents and pre-treatment are not required and</span></div>
<div style="position:absolute;left:56.69px;top:550.36px" class="cls_002"><span class="cls_002">the administration only takes 30 minutes.</span></div>
<div style="position:absolute;left:56.69px;top:584.36px" class="cls_002"><span class="cls_002">Since the launch of Keaili, the Group has continuously increased investment in clinical trials</span></div>
<div style="position:absolute;left:56.69px;top:601.36px" class="cls_002"><span class="cls_002">and related medical projects, with 145 medical projects initiated to cover 13 areas of oncology</span></div>
<div style="position:absolute;left:56.69px;top:618.37px" class="cls_002"><span class="cls_002">including breast cancer, gynecologic cancer, gastric cancer, lung cancer and pancreatic cancer.</span></div>
<div style="position:absolute;left:56.69px;top:635.37px" class="cls_002"><span class="cls_002">Meanwhile, the Group has persevered with professional academic-based promotion and has</span></div>
<div style="position:absolute;left:56.69px;top:652.37px" class="cls_002"><span class="cls_002">organised more than 1,000 academic activities.</span></div>
<div style="position:absolute;left:56.69px;top:686.37px" class="cls_002"><span class="cls_002">During the year, Keaili has achieved a very remarkable growth in sales. The Group will grasp</span></div>
<div style="position:absolute;left:56.69px;top:703.37px" class="cls_002"><span class="cls_002">the opportunity of Keaili being included into the national centralised procurement list with the</span></div>
<div style="position:absolute;left:56.69px;top:720.38px" class="cls_002"><span class="cls_002">lowest price to accelerate hospital development and market penetration, and continue to adopt a</span></div>
<div style="position:absolute;left:56.69px;top:737.38px" class="cls_002"><span class="cls_002">professional academic-based promotion strategy in order to seize the market share of paclitaxel</span></div>
<div style="position:absolute;left:56.69px;top:754.39px" class="cls_002"><span class="cls_002">and achieve rapid sales growth of Keaili.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 25 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:21275px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background26.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.72px" class="cls_013"><span class="cls_013">Ailinen</span><span class="cls_002">（</span><span class="cls_021">艾利能</span><span class="cls_002">）</span><span class="cls_013">(elemene injection)</span></div>
<div style="position:absolute;left:56.69px;top:74.34px" class="cls_002"><span class="cls_002">Ailineng is an oncology drug developed in China and has been included into the national</span></div>
<div style="position:absolute;left:56.69px;top:91.35px" class="cls_002"><span class="cls_002">reimbursement drug list. The product is mainly used for the treatment of nerve glioma, brain</span></div>
<div style="position:absolute;left:56.69px;top:108.35px" class="cls_002"><span class="cls_002">metastases and malignant pleural and peritoneal effusion, and can be used in combination with</span></div>
<div style="position:absolute;left:56.69px;top:125.35px" class="cls_002"><span class="cls_002">radiotherapy and chemotherapy to boost treatment efficacy. After years of clinical verification,</span></div>
<div style="position:absolute;left:56.69px;top:142.36px" class="cls_002"><span class="cls_002">it has been widely recognised by the medical profession. The liquid formulation of the product</span></div>
<div style="position:absolute;left:56.69px;top:159.36px" class="cls_002"><span class="cls_002">has been granted patent in China. Compared with the traditional emulsion formulation, the</span></div>
<div style="position:absolute;left:56.69px;top:176.37px" class="cls_002"><span class="cls_002">purity and content of elemene are further improved with significant reduction of adverse</span></div>
<div style="position:absolute;left:56.69px;top:193.37px" class="cls_002"><span class="cls_002">clinical reaction.</span></div>
<div style="position:absolute;left:56.69px;top:227.37px" class="cls_002"><span class="cls_002">The current sales volume of Ailineng is still not significant. The Group will continue to</span></div>
<div style="position:absolute;left:56.69px;top:244.37px" class="cls_002"><span class="cls_002">strengthen academic-based promotion, initiate clinical medical research and constantly promote</span></div>
<div style="position:absolute;left:56.69px;top:261.37px" class="cls_002"><span class="cls_002">the transformation of regional sales model to further expand the market share of Ailineng.</span></div>
<div style="position:absolute;left:28.35px;top:295.37px" class="cls_007"><span class="cls_007">(ii)</span></div>
<div style="position:absolute;left:56.71px;top:295.37px" class="cls_007"><span class="cls_007">Common Generic Drug Products</span></div>
<div style="position:absolute;left:56.71px;top:329.37px" class="cls_002"><span class="cls_002">During the year, the Group continued with the strategy of enhancing sales mix by strengthening</span></div>
<div style="position:absolute;left:56.71px;top:346.37px" class="cls_002"><span class="cls_002">the promotion of non-antibiotic drugs and expanding the product line of oral formulation for</span></div>
<div style="position:absolute;left:56.71px;top:363.37px" class="cls_002"><span class="cls_002">chronic diseases. Products with higher sales growth included aspirin enteric-coated tablets,</span></div>
<div style="position:absolute;left:56.71px;top:380.38px" class="cls_002"><span class="cls_002">troxerutin tablets and compound aminophenazone barbital injection. The Group also actively</span></div>
<div style="position:absolute;left:56.71px;top:397.38px" class="cls_002"><span class="cls_002">pushed forward the consistency evaluation for key products, with 17 drugs passing during the</span></div>
<div style="position:absolute;left:56.71px;top:414.39px" class="cls_002"><span class="cls_002">year</span></div>
<div style="position:absolute;left:85.24px;top:414.39px" class="cls_002"><span class="cls_002">(cumulative</span></div>
<div style="position:absolute;left:153.56px;top:414.39px" class="cls_002"><span class="cls_002">23). Products passing the consistency evaluation can provide patients with</span></div>
<div style="position:absolute;left:56.71px;top:431.39px" class="cls_002"><span class="cls_002">medication options of high-quality and competitive price, and can relieve the burden of medical</span></div>
<div style="position:absolute;left:56.71px;top:448.39px" class="cls_002"><span class="cls_002">insurance expenditures. The Group will make full use of the opportunities brought about by the</span></div>
<div style="position:absolute;left:56.71px;top:465.40px" class="cls_002"><span class="cls_002">consistency evaluation to actively strive for a larger market share for the products. In addition,</span></div>
<div style="position:absolute;left:56.71px;top:482.40px" class="cls_002"><span class="cls_002">the Group will also make full use of the development opportunities brought about by the</span></div>
<div style="position:absolute;left:56.71px;top:499.41px" class="cls_002"><span class="cls_002">drug centralised procurement policy to develop the hospital market for common generic drug</span></div>
<div style="position:absolute;left:56.71px;top:516.41px" class="cls_002"><span class="cls_002">products.</span></div>
<div style="position:absolute;left:56.71px;top:550.41px" class="cls_002"><span class="cls_002">In</span></div>
<div style="position:absolute;left:74.07px;top:550.41px" class="cls_002"><span class="cls_002">2019, common generic drug products achieved sales of RMB4,962 million, representing</span></div>
<div style="position:absolute;left:56.71px;top:567.41px" class="cls_002"><span class="cls_002">a</span></div>
<div style="position:absolute;left:69.13px;top:567.41px" class="cls_002"><span class="cls_002">4.2% growth. In addition to the continuous implementation of the above development</span></div>
<div style="position:absolute;left:56.71px;top:584.41px" class="cls_002"><span class="cls_002">strategies, the Group will also promote the direct sales model through professional academic-</span></div>
<div style="position:absolute;left:56.71px;top:601.42px" class="cls_002"><span class="cls_002">based promotion to improve doctors’ recognition of the products, striving for better promotion</span></div>
<div style="position:absolute;left:56.71px;top:618.42px" class="cls_002"><span class="cls_002">results and higher sales growth.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 26 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:22126px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background27.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_007"><span class="cls_007">(iii)</span></div>
<div style="position:absolute;left:56.70px;top:39.60px" class="cls_007"><span class="cls_007">Newly Launched Products</span></div>
<div style="position:absolute;left:56.70px;top:73.60px" class="cls_002"><span class="cls_002">The strong R&D capability and rich pipeline of drugs under development enable the Group to</span></div>
<div style="position:absolute;left:56.70px;top:90.60px" class="cls_002"><span class="cls_002">have a continuous launch of new products. The Group believes that these new products will</span></div>
<div style="position:absolute;left:56.70px;top:107.61px" class="cls_002"><span class="cls_002">contribute considerable sales revenue in the next three years and become a new growth driver.</span></div>
<div style="position:absolute;left:56.70px;top:140.98px" class="cls_013"><span class="cls_013">Qixiao </span><span class="cls_007">(</span><span class="cls_021">琦效</span><span class="cls_007"> )</span><span class="cls_013"> (arbidol hydrochloride tablets)</span></div>
<div style="position:absolute;left:56.70px;top:175.60px" class="cls_002"><span class="cls_002">As a broad-spectrum antiviral drug, arbidol is mainly used for the treatment of viral infections</span></div>
<div style="position:absolute;left:56.70px;top:192.60px" class="cls_002"><span class="cls_002">represented by influenza. With its good clinical efficacy and outstanding performance in</span></div>
<div style="position:absolute;left:56.70px;top:209.61px" class="cls_002"><span class="cls_002">the treatment of novel coronavirus pneumonia, arbitol has been included into the national</span></div>
<div style="position:absolute;left:56.70px;top:226.61px" class="cls_002"><span class="cls_002">“Guidelines for Diagnosis and Treatment of Influenza” and</span></div>
<div style="position:absolute;left:397.93px;top:226.61px" class="cls_002"><span class="cls_002">“Guidelines for Diagnosis and</span></div>
<div style="position:absolute;left:56.70px;top:243.61px" class="cls_002"><span class="cls_002">Treatment of Novel Coronavirus Pneumonia”.</span></div>
<div style="position:absolute;left:56.70px;top:277.61px" class="cls_002"><span class="cls_002">The Group has established a dedicated sales team of more than 500 people, and will put full</span></div>
<div style="position:absolute;left:56.70px;top:294.61px" class="cls_002"><span class="cls_002">effort in the research of arbidol for the treatment of influenza, novel coronavirus and other</span></div>
<div style="position:absolute;left:56.70px;top:311.62px" class="cls_002"><span class="cls_002">viruses. Given the high incidence of influenza, Qixiao is expected to have a great market</span></div>
<div style="position:absolute;left:56.70px;top:328.62px" class="cls_002"><span class="cls_002">potential.</span></div>
<div style="position:absolute;left:56.70px;top:361.98px" class="cls_013"><span class="cls_013">Daxinning </span><span class="cls_007">(</span><span class="cls_021">達新寧</span><span class="cls_007"> )</span><span class="cls_013"> (dronedarone hydrochloride tablets)</span></div>
<div style="position:absolute;left:56.70px;top:396.60px" class="cls_002"><span class="cls_002">Dronedarone is indicated for sinus arrhythmia patients with a medical history of paroxysmal or</span></div>
<div style="position:absolute;left:56.70px;top:413.60px" class="cls_002"><span class="cls_002">persistent atrial fibrillation</span></div>
<div style="position:absolute;left:206.28px;top:413.60px" class="cls_002"><span class="cls_002">(AF) to reduce the risk of hospitalization due to atrial fibrillation,</span></div>
<div style="position:absolute;left:56.70px;top:430.61px" class="cls_002"><span class="cls_002">with high clinical demand and short supply in the market.</span></div>
<div style="position:absolute;left:56.70px;top:464.60px" class="cls_002"><span class="cls_002">The Group has established a dedicated sales team for Daxinning to vigorously explore the</span></div>
<div style="position:absolute;left:56.70px;top:481.61px" class="cls_002"><span class="cls_002">market of dronedarone in China. As an exclusive product in China, Daxinning has a huge</span></div>
<div style="position:absolute;left:56.70px;top:498.61px" class="cls_002"><span class="cls_002">market potential.</span></div>
<div style="position:absolute;left:56.70px;top:531.98px" class="cls_013"><span class="cls_013">Shuanling (</span><span class="cls_021">舒安靈</span><span class="cls_013"> ) (pentoxifylline injections/tablets)</span></div>
<div style="position:absolute;left:56.70px;top:566.60px" class="cls_002"><span class="cls_002">Pentoxifylline is a classic drug with clinical application for more than a century and can be</span></div>
<div style="position:absolute;left:56.70px;top:583.60px" class="cls_002"><span class="cls_002">used as an essential drug in Europe and the U.S.. It is indicated for treating dizziness caused by</span></div>
<div style="position:absolute;left:56.70px;top:600.61px" class="cls_002"><span class="cls_002">circulation cerebral ischemia, improving cognitive dysfunction caused by cerebral blood supply</span></div>
<div style="position:absolute;left:56.70px;top:617.61px" class="cls_002"><span class="cls_002">insufficiency and treating intermittent claudication caused by peripheral artery disease, and</span></div>
<div style="position:absolute;left:56.70px;top:634.62px" class="cls_002"><span class="cls_002">venous ulcers.</span></div>
<div style="position:absolute;left:56.70px;top:668.61px" class="cls_002"><span class="cls_002">The Group has established a dedicated sales team for Shuanling and will cultivate doctors’</span></div>
<div style="position:absolute;left:56.70px;top:685.62px" class="cls_002"><span class="cls_002">perception of using pentoxifylline through clinical trial projects. Since most of the competing</span></div>
<div style="position:absolute;left:56.70px;top:702.62px" class="cls_002"><span class="cls_002">products of pentoxifylline are subject to medical insurance restrictions, the current sales of</span></div>
<div style="position:absolute;left:56.70px;top:719.62px" class="cls_002"><span class="cls_002">pentoxifylline are increasing rapidly. Thus, Shuanling is expected to have a considerable market</span></div>
<div style="position:absolute;left:56.70px;top:736.63px" class="cls_002"><span class="cls_002">potential.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 27 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:22977px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background28.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.72px" class="cls_013"><span class="cls_013">Meiluolin (</span><span class="cls_021">美洛林</span><span class="cls_013"> ) (ticagrelor tablets)</span></div>
<div style="position:absolute;left:56.69px;top:74.34px" class="cls_002"><span class="cls_002">Ticagrelor is a first-line antiplatelet agent for the treatment of acute coronary syndrome and</span></div>
<div style="position:absolute;left:56.69px;top:91.35px" class="cls_002"><span class="cls_002">the top recommendation in the “Clinical Pathway of Acute ST-Segment Elevation Myocardial</span></div>
<div style="position:absolute;left:56.69px;top:108.35px" class="cls_002"><span class="cls_002">Infarction (2019)”. According to market data, total sales of the antiplatelet market amounts to</span></div>
<div style="position:absolute;left:56.69px;top:125.35px" class="cls_002"><span class="cls_002">RMB15.4 billion in 2019, of which P2Y12 receptor inhibitors accounted for 60%. Ticagrelor</span></div>
<div style="position:absolute;left:56.69px;top:142.36px" class="cls_002"><span class="cls_002">demonstrated the strongest growth among all with a CAGR of 103%, having a great market</span></div>
<div style="position:absolute;left:56.69px;top:159.36px" class="cls_002"><span class="cls_002">potential.</span></div>
<div style="position:absolute;left:56.69px;top:193.36px" class="cls_002"><span class="cls_002">Meiluolin is the second-to-market generic drug in China with an invention patent for its</span></div>
<div style="position:absolute;left:56.69px;top:210.36px" class="cls_002"><span class="cls_002">crystalline form. It is more stable than the originator drug and is the most value for money</span></div>
<div style="position:absolute;left:56.69px;top:227.37px" class="cls_002"><span class="cls_002">product currently available in the market. The Group will gradually establish a platform of</span></div>
<div style="position:absolute;left:56.69px;top:244.37px" class="cls_002"><span class="cls_002">experts in the cardiovascular field and develop a cardiovascular product portfolio. It will</span></div>
<div style="position:absolute;left:56.69px;top:261.37px" class="cls_002"><span class="cls_002">also build its brand influence through professional academic promotion and accelerate market</span></div>
<div style="position:absolute;left:56.69px;top:278.38px" class="cls_002"><span class="cls_002">development to seize market share.</span></div>
<div style="position:absolute;left:56.69px;top:311.72px" class="cls_013"><span class="cls_013">Gubangjia (</span><span class="cls_021">固邦佳</span><span class="cls_013"> ) (alendronate sodium-vitamin D3 tablets)</span></div>
<div style="position:absolute;left:56.69px;top:346.34px" class="cls_002"><span class="cls_002">Alendronate sodium-vitamin D3 is mainly used for the treatment of osteoporosis in</span></div>
<div style="position:absolute;left:56.69px;top:363.35px" class="cls_002"><span class="cls_002">postmenopausal women and osteoporosis in men to increase bone mass. The conservative</span></div>
<div style="position:absolute;left:56.69px;top:380.35px" class="cls_002"><span class="cls_002">estimate of osteoporosis patients in China is</span></div>
<div style="position:absolute;left:321.49px;top:380.35px" class="cls_002"><span class="cls_002">70 million. With the acceleration of aging</span></div>
<div style="position:absolute;left:56.69px;top:397.35px" class="cls_002"><span class="cls_002">population and changes in lifestyle, the incidence of osteoporosis is still increasing gradually.</span></div>
<div style="position:absolute;left:56.69px;top:414.36px" class="cls_002"><span class="cls_002">With the current treatment rate of only 11.5%, there is a promising market prospect.</span></div>
<div style="position:absolute;left:56.69px;top:448.35px" class="cls_002"><span class="cls_002">Gubangjia is the first and only compound preparation of alendronate sodium and vitamin D3 in</span></div>
<div style="position:absolute;left:56.69px;top:465.36px" class="cls_002"><span class="cls_002">China. The Group will expand the coverage of academic activities for doctors and patients, and</span></div>
<div style="position:absolute;left:56.69px;top:482.36px" class="cls_002"><span class="cls_002">establish its own sales force.</span></div>
<div style="position:absolute;left:56.69px;top:515.72px" class="cls_013"><span class="cls_013">Gaoshunsong (</span><span class="cls_021">高順松</span><span class="cls_013"> ) (acemetacin extended-release capsules)</span></div>
<div style="position:absolute;left:56.69px;top:550.34px" class="cls_002"><span class="cls_002">Acemetacin is a non-steroidal anti-inflammatory drug (NSAIDs) mainly used for the treatment</span></div>
<div style="position:absolute;left:56.69px;top:567.35px" class="cls_002"><span class="cls_002">of osteoarthritis, ankylosing spondylitis and rheumatoid arthritis. The overall sales of NSAIDs</span></div>
<div style="position:absolute;left:56.69px;top:584.35px" class="cls_002"><span class="cls_002">market are estimated to be over RMB13 billion in 2018 with a three-year CAGR of 15.64%,</span></div>
<div style="position:absolute;left:56.69px;top:601.35px" class="cls_002"><span class="cls_002">showing a steady growth in market size.</span></div>
<div style="position:absolute;left:56.69px;top:635.35px" class="cls_002"><span class="cls_002">Gaoshunsong is an exclusive generic drug in China. The Group is establishing a direct sales</span></div>
<div style="position:absolute;left:56.69px;top:652.35px" class="cls_002"><span class="cls_002">team and expanding end-user market in order to promote more patients to use the product.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 28 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:23828px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background29.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.72px" class="cls_013"><span class="cls_013">Enxi (</span><span class="cls_021">恩悉</span><span class="cls_013"> ) (pramipexole dihydrochloride tablets)</span></div>
<div style="position:absolute;left:56.69px;top:74.34px" class="cls_002"><span class="cls_002">Enxi is indicated for the treatment of signs and symptoms of adult idiopathic Parkinson’s</span></div>
<div style="position:absolute;left:56.69px;top:91.35px" class="cls_002"><span class="cls_002">disease, and is the first pramipexole dihydrochloride tablet passing the consistency evaluation</span></div>
<div style="position:absolute;left:56.69px;top:108.35px" class="cls_002"><span class="cls_002">in China. The number of patients with Parkinson’s disease increases about 100,000 annually</span></div>
<div style="position:absolute;left:56.69px;top:125.35px" class="cls_002"><span class="cls_002">and is expected to reach 4.94 million in 2030. In 2018, the sales of pramipexole accounted for</span></div>
<div style="position:absolute;left:56.69px;top:142.36px" class="cls_002"><span class="cls_002">approximately 41.2% of the overall domestic market for Parkinson’s disease drugs with rapid</span></div>
<div style="position:absolute;left:56.69px;top:159.36px" class="cls_002"><span class="cls_002">growth at a CAGR of 18%. Therefore, Enxi is expected to have a promising sales prospect.</span></div>
<div style="position:absolute;left:56.69px;top:193.36px" class="cls_002"><span class="cls_002">The Group will initiate clinical studies including comparison with the originator drug and</span></div>
<div style="position:absolute;left:56.69px;top:210.36px" class="cls_002"><span class="cls_002">combo study with butylphthalide for the treatment of vascular Parkinsonism/Parkinson’s</span></div>
<div style="position:absolute;left:56.69px;top:227.37px" class="cls_002"><span class="cls_002">syndrome. The Group will also enhance doctors’ diagnosis and treatment standard for</span></div>
<div style="position:absolute;left:56.69px;top:244.37px" class="cls_002"><span class="cls_002">Parkinson’s disease, strengthen patient education and increase the consultation rate of patients</span></div>
<div style="position:absolute;left:56.69px;top:261.37px" class="cls_002"><span class="cls_002">with Parkinson’s disease. Currently, the price of Enxi is only 47% of the originator product,</span></div>
<div style="position:absolute;left:56.69px;top:278.38px" class="cls_002"><span class="cls_002">which can significantly reduce patients’ financial burden as well as maximize its clinical value.</span></div>
<div style="position:absolute;left:56.69px;top:311.72px" class="cls_013"><span class="cls_013">Luoruite (</span><span class="cls_021">洛瑞特</span><span class="cls_013"> ) (erlotinib hydrochloride tablets)</span></div>
<div style="position:absolute;left:56.70px;top:346.34px" class="cls_002"><span class="cls_002">Erlotinib is a first-line drug for the treatment of patients with advanced EGFR mutation-</span></div>
<div style="position:absolute;left:56.70px;top:363.35px" class="cls_002"><span class="cls_002">positive lung cancer. It is the first generation EGFR-TKI drug and has been unanimously</span></div>
<div style="position:absolute;left:56.70px;top:380.35px" class="cls_002"><span class="cls_002">recommended by domestic and foreign guidelines. Luoruite is the first-to-market erlotinib</span></div>
<div style="position:absolute;left:56.70px;top:397.35px" class="cls_002"><span class="cls_002">generic in China with consistency evaluation passed and was included in category B of the</span></div>
<div style="position:absolute;left:56.70px;top:414.36px" class="cls_002"><span class="cls_002">national reimbursement drug list. With a lower price than the originator drug, it has a higher</span></div>
<div style="position:absolute;left:56.70px;top:431.36px" class="cls_002"><span class="cls_002">pharmacoeconomic value.</span></div>
<div style="position:absolute;left:56.70px;top:465.36px" class="cls_002"><span class="cls_002">Leveraging on the advantages of products and resources, the Group will compete in the first</span></div>
<div style="position:absolute;left:56.70px;top:482.36px" class="cls_002"><span class="cls_002">generation EGFR-TKI market so as to capture new patients and replace existing ones among</span></div>
<div style="position:absolute;left:56.70px;top:499.37px" class="cls_002"><span class="cls_002">the target population of patients with EGFR mutation-positive non-small cell lung cancer.</span></div>
<div style="position:absolute;left:56.70px;top:533.36px" class="cls_013"><span class="cls_013">Montelukast sodium tablets/chewable tablets</span></div>
<div style="position:absolute;left:56.70px;top:567.36px" class="cls_002"><span class="cls_002">Montelukast is mainly used for the prevention and long-term treatment of asthma. Asthma</span></div>
<div style="position:absolute;left:56.70px;top:584.36px" class="cls_002"><span class="cls_002">is one of the most common diseases in the world today. There are approximately 30 million</span></div>
<div style="position:absolute;left:56.70px;top:601.37px" class="cls_002"><span class="cls_002">asthma patients in China with prevalence of children at 3.02% and people over 14 years of</span></div>
<div style="position:absolute;left:56.70px;top:618.37px" class="cls_002"><span class="cls_002">age at</span></div>
<div style="position:absolute;left:96.79px;top:618.37px" class="cls_002"><span class="cls_002">1.24%, and the incidence is increasing at an alarming rate. Montelukast has a sales</span></div>
<div style="position:absolute;left:56.70px;top:634.70px" class="cls_002"><span class="cls_002">of RMB3.2 billion in China and has been included in the 1</span><span class="cls_022"><sup>st</sup></span><span class="cls_002"> batch of “4+7” pilot centralised</span></div>
<div style="position:absolute;left:56.70px;top:652.35px" class="cls_002"><span class="cls_002">procurement. The Group’s montelukast sodium tablets/chewable tablets are deemed as passing</span></div>
<div style="position:absolute;left:56.70px;top:669.35px" class="cls_002"><span class="cls_002">the consistency evaluation. The Group will commit to promoting the clinical use of the product</span></div>
<div style="position:absolute;left:56.70px;top:686.36px" class="cls_002"><span class="cls_002">and preparing for the next round of national centralised procurement.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 29 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:24679px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background30.jpg" width=595 height=841></div>
<div style="position:absolute;left:56.70px;top:39.60px" class="cls_013"><span class="cls_013">Sitagliptin phosphate tablets</span></div>
<div style="position:absolute;left:56.70px;top:73.60px" class="cls_002"><span class="cls_002">Sitagliptin is mainly used for the treatment of type</span></div>
<div style="position:absolute;left:361.51px;top:73.60px" class="cls_002"><span class="cls_002">2 diabetes. It is the first dipeptidyl</span></div>
<div style="position:absolute;left:56.70px;top:90.60px" class="cls_002"><span class="cls_002">peptidase-4</span></div>
<div style="position:absolute;left:123.01px;top:90.60px" class="cls_002"><span class="cls_002">(DPP-4) inhibitor in the market and has been fully recognised by domestic and</span></div>
<div style="position:absolute;left:56.70px;top:107.61px" class="cls_002"><span class="cls_002">overseas clinical guidelines. With increasing market recognition, sitagliptin gradually leads</span></div>
<div style="position:absolute;left:56.70px;top:124.61px" class="cls_002"><span class="cls_002">DPP-4 inhibitors to become one of the major players in the diabetic market. Ranking first in</span></div>
<div style="position:absolute;left:56.70px;top:141.62px" class="cls_002"><span class="cls_002">the world, the number of diabetic patients in China is 116 million, creating a huge market for</span></div>
<div style="position:absolute;left:56.70px;top:158.62px" class="cls_002"><span class="cls_002">diabetes drugs. Currently, the sales of sitagliptin have maintained rapid growth. It is expected</span></div>
<div style="position:absolute;left:56.70px;top:175.62px" class="cls_002"><span class="cls_002">that the Group’s sitagliptin will gain a certain market share after its approval.</span></div>
<div style="position:absolute;left:56.70px;top:209.62px" class="cls_013"><span class="cls_013">Nintedanib esilate soft capsules</span></div>
<div style="position:absolute;left:56.70px;top:243.62px" class="cls_002"><span class="cls_002">Nintedanib is mainly used for the treatment of interstitial lung disease associated with</span></div>
<div style="position:absolute;left:56.70px;top:260.62px" class="cls_002"><span class="cls_002">idiopathic pulmonary fibrosis or systemic sclerosis. It is recommended by the guidelines</span></div>
<div style="position:absolute;left:56.70px;top:277.62px" class="cls_002"><span class="cls_002">together with pirfenidone for treating pulmonary fibrosis, but with a higher safety. The Group</span></div>
<div style="position:absolute;left:56.70px;top:294.63px" class="cls_002"><span class="cls_002">will strive to launch this product as the first-to-market generic in China.</span></div>
<div style="position:absolute;left:28.56px;top:328.62px" class="cls_007"><span class="cls_007">Vitamin C Business</span></div>
<div style="position:absolute;left:28.35px;top:362.62px" class="cls_002"><span class="cls_002">In</span></div>
<div style="position:absolute;left:45.22px;top:362.62px" class="cls_002"><span class="cls_002">2019, the vitamin C business continued to build on its market strengths in terms of capacity,</span></div>
<div style="position:absolute;left:28.35px;top:379.62px" class="cls_002"><span class="cls_002">quality and production cost. Both sales volume and export market share were able to further increase</span></div>
<div style="position:absolute;left:28.35px;top:396.63px" class="cls_002"><span class="cls_002">even though already ranked the first place in the industry. However, the price decline has weakened</span></div>
<div style="position:absolute;left:28.35px;top:413.63px" class="cls_002"><span class="cls_002">the business performance during the year as compared to previous year. As it is expected that the</span></div>
<div style="position:absolute;left:28.35px;top:430.64px" class="cls_002"><span class="cls_002">overall supply of vitamin C will continue to be excessive for a long time, significant product price</span></div>
<div style="position:absolute;left:28.35px;top:447.64px" class="cls_002"><span class="cls_002">rebound is unlikely. In addition to continuously improving product quality and reducing production</span></div>
<div style="position:absolute;left:28.35px;top:464.64px" class="cls_002"><span class="cls_002">costs, the Group will keep focusing on the development of untapped market, optimizing customer</span></div>
<div style="position:absolute;left:28.35px;top:481.65px" class="cls_002"><span class="cls_002">mix, increasing number of end-user customers and reducing energy consumption in order to achieve</span></div>
<div style="position:absolute;left:28.35px;top:498.65px" class="cls_002"><span class="cls_002">continuous enhancement of overall market competitiveness of the business.</span></div>
<div style="position:absolute;left:28.57px;top:532.65px" class="cls_007"><span class="cls_007">Antibiotics Business</span></div>
<div style="position:absolute;left:28.36px;top:566.64px" class="cls_002"><span class="cls_002">The overall demand and prices of antibiotics have remained low as a result of the policy of</span></div>
<div style="position:absolute;left:28.36px;top:583.65px" class="cls_002"><span class="cls_002">restrictive use of antibiotics over the years, and the business performance remained weak in 2019.</span></div>
<div style="position:absolute;left:28.36px;top:600.65px" class="cls_002"><span class="cls_002">The Group will keep improving product quality, developing high-end market, striving for high-end</span></div>
<div style="position:absolute;left:28.36px;top:617.66px" class="cls_002"><span class="cls_002">registration as well as making use of the product chain advantage to improve market competitiveness.</span></div>
<div style="position:absolute;left:28.58px;top:651.65px" class="cls_007"><span class="cls_007">Other Businesses</span></div>
<div style="position:absolute;left:28.36px;top:685.65px" class="cls_002"><span class="cls_002">The functional food business</span></div>
<div style="position:absolute;left:200.34px;top:685.65px" class="cls_002"><span class="cls_002">(including caffeine additives and vitamin supplements) recorded</span></div>
<div style="position:absolute;left:28.36px;top:702.65px" class="cls_002"><span class="cls_002">a stable growth in</span></div>
<div style="position:absolute;left:136.53px;top:702.65px" class="cls_002"><span class="cls_002">2019. The market environment of caffeine has seen changes with increase in</span></div>
<div style="position:absolute;left:28.36px;top:719.66px" class="cls_002"><span class="cls_002">competitors and total supply. Thanks to the Group’s increased efforts in technology upgrade, cost</span></div>
<div style="position:absolute;left:28.36px;top:736.66px" class="cls_002"><span class="cls_002">reduction and market development, its share of the export market has greatly increased and a</span></div>
<div style="position:absolute;left:28.36px;top:753.66px" class="cls_002"><span class="cls_002">relatively good performance has been achieved.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 30 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:25530px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background31.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">Research and Development</span></div>
<div style="position:absolute;left:28.34px;top:73.60px" class="cls_002"><span class="cls_002">The Group firmly believes in the importance of investing in research and development so that the</span></div>
<div style="position:absolute;left:28.34px;top:90.60px" class="cls_002"><span class="cls_002">Group can have strong product and technology innovation capability as well as a rich pipeline of</span></div>
<div style="position:absolute;left:28.34px;top:107.61px" class="cls_002"><span class="cls_002">drugs under development. The R&D expenses for the year amounted to RMB2,000 million (charged</span></div>
<div style="position:absolute;left:28.34px;top:124.61px" class="cls_002"><span class="cls_002">to profit or loss statement), representing an increase of</span></div>
<div style="position:absolute;left:343.10px;top:124.61px" class="cls_002"><span class="cls_002">49.1% and accounting for approximately</span></div>
<div style="position:absolute;left:28.34px;top:141.62px" class="cls_002"><span class="cls_002">11.2% of the finished drug business revenue. At present, the Group has established four major R&D</span></div>
<div style="position:absolute;left:28.34px;top:158.62px" class="cls_002"><span class="cls_002">centres in China and overseas, owns ten core technology platforms and an R&D team with more</span></div>
<div style="position:absolute;left:28.34px;top:175.62px" class="cls_002"><span class="cls_002">than 1,800 people. There are more than 300 projects in the pipeline, of which over 40 are innovative</span></div>
<div style="position:absolute;left:28.34px;top:192.63px" class="cls_002"><span class="cls_002">small molecule drugs, over 50 are innovative macromolecule drugs and over 20 are drugs of new</span></div>
<div style="position:absolute;left:28.34px;top:209.63px" class="cls_002"><span class="cls_002">preparation, primarily focusing on the therapeutic areas of oncology, autoimmunity, psychiatry and</span></div>
<div style="position:absolute;left:28.34px;top:226.64px" class="cls_002"><span class="cls_002">neurology, digestion and metabolism, cardio-cerebrovascular system and anti-infectives. According</span></div>
<div style="position:absolute;left:28.34px;top:243.64px" class="cls_002"><span class="cls_002">to the evaluation results of the</span></div>
<div style="position:absolute;left:212.34px;top:243.64px" class="cls_002"><span class="cls_002">“National Enterprise Technology Centre</span></div>
<div style="position:absolute;left:443.83px;top:243.64px" class="cls_002"><span class="cls_002">(2019)” issued by the</span></div>
<div style="position:absolute;left:28.34px;top:260.64px" class="cls_002"><span class="cls_002">National Development and Reform Commission, the Group was ranked as “excellent”, proving the</span></div>
<div style="position:absolute;left:28.34px;top:277.65px" class="cls_002"><span class="cls_002">Group’s capabilities in R&D and innovation.</span></div>
<div style="position:absolute;left:28.34px;top:311.64px" class="cls_002"><span class="cls_002">The major R&D progress of the Group since the beginning 2019 is as follows:</span></div>
<div style="position:absolute;left:28.34px;top:345.64px" class="cls_002"><span class="cls_002">10 drugs were granted drug registration approval in China. Of which sunitinib malate capsules and</span></div>
<div style="position:absolute;left:28.34px;top:362.64px" class="cls_002"><span class="cls_002">dronedarone hydrochloride tablets are first-to-market generics, pramipexole hydrochloride tablets</span></div>
<div style="position:absolute;left:28.34px;top:379.65px" class="cls_002"><span class="cls_002">is the first generic passing consistency evaluation, and products like clopidogrel bisulfate tablets,</span></div>
<div style="position:absolute;left:28.34px;top:396.65px" class="cls_002"><span class="cls_002">ticagrelor tablets and rivaroxaban tablets have great market potentials. There are 27 drug candidates</span></div>
<div style="position:absolute;left:28.34px;top:413.66px" class="cls_002"><span class="cls_002">pending drug registration approval. As for international registration, 1 drug was granted U.S. NDA</span></div>
<div style="position:absolute;left:28.34px;top:430.66px" class="cls_002"><span class="cls_002">approval, 2 drugs granted U.S. ANDA approval and 6 drugs candidates are pending approval.</span></div>
<div style="position:absolute;left:28.34px;top:464.66px" class="cls_002"><span class="cls_002">During the year, the Group reached a peak in terms of application and approval for consistency</span></div>
<div style="position:absolute;left:28.34px;top:481.66px" class="cls_002"><span class="cls_002">evaluation, with</span></div>
<div style="position:absolute;left:127.00px;top:481.66px" class="cls_002"><span class="cls_002">17 products passing the evaluation and</span></div>
<div style="position:absolute;left:362.25px;top:481.66px" class="cls_002"><span class="cls_002">25 products submitted for approval</span></div>
<div style="position:absolute;left:28.34px;top:498.66px" class="cls_002"><span class="cls_002">application.</span></div>
<div style="position:absolute;left:28.34px;top:532.66px" class="cls_002"><span class="cls_002">16 new drug candidates, including</span></div>
<div style="position:absolute;left:231.80px;top:532.66px" class="cls_002"><span class="cls_002">7 innovative small molecule drug candidates,</span></div>
<div style="position:absolute;left:497.40px;top:532.66px" class="cls_002"><span class="cls_002">5 innovative</span></div>
<div style="position:absolute;left:28.34px;top:549.66px" class="cls_002"><span class="cls_002">macromolecule drug candidates and</span></div>
<div style="position:absolute;left:232.96px;top:549.66px" class="cls_002"><span class="cls_002">4 new preparations, were granted clinical trial approval, of</span></div>
<div style="position:absolute;left:28.34px;top:566.67px" class="cls_002"><span class="cls_002">which 12 in China and 4 in the U.S. and Australia, further enriching the clinical pipeline of new</span></div>
<div style="position:absolute;left:28.34px;top:583.67px" class="cls_002"><span class="cls_002">drugs. At present, the Group has 42 products under clinical trials, including 31 innovative drugs and</span></div>
<div style="position:absolute;left:28.34px;top:600.68px" class="cls_002"><span class="cls_002">11 new preparations.</span></div>
<div style="position:absolute;left:28.34px;top:634.67px" class="cls_002"><span class="cls_002">Apart from in-house research and development, the Group has also been proactively seeking external</span></div>
<div style="position:absolute;left:28.34px;top:651.68px" class="cls_002"><span class="cls_002">cooperation and acquisition opportunities. During the year, the Group has 1) entered into a licensing</span></div>
<div style="position:absolute;left:28.34px;top:668.68px" class="cls_002"><span class="cls_002">agreement with Hangzhou Innogate Pharma Co., Ltd. for 5 small molecule compounds; 2) acquired</span></div>
<div style="position:absolute;left:28.34px;top:685.68px" class="cls_002"><span class="cls_002">the entire equity interests in Yong Shun Technology Development Co., Ltd. and obtained its R&D</span></div>
<div style="position:absolute;left:28.34px;top:702.69px" class="cls_002"><span class="cls_002">platform of antibodies and product pipelines; 3) entered into a licensing agreement with Shanghai</span></div>
<div style="position:absolute;left:28.34px;top:719.69px" class="cls_002"><span class="cls_002">Institute of Materia Medica for</span></div>
<div style="position:absolute;left:206.77px;top:719.69px" class="cls_002"><span class="cls_002">4 small molecule compounds; 4) established a joint venture with</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 31 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:26381px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background32.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_002"><span class="cls_002">Shanghai Haihe Pharmaceutical Co., Ltd for the joint development of 5 new drug projects; 5) entered</span></div>
<div style="position:absolute;left:28.35px;top:56.61px" class="cls_002"><span class="cls_002">into a licensing agreement with Synermore Biologics (Suzhou) Co., Ltd. for omalizumab biosimilar;</span></div>
<div style="position:absolute;left:28.35px;top:73.61px" class="cls_002"><span class="cls_002">and 6) entered into a product transfer agreement with Shanghai Acebright Pharmaceuticals Group</span></div>
<div style="position:absolute;left:28.35px;top:90.62px" class="cls_002"><span class="cls_002">Co., Ltd. for erlotinib hydrochloride.</span></div>
<div style="position:absolute;left:28.35px;top:124.61px" class="cls_002"><span class="cls_002">The Group attaches great importance to the protection of intellectual property rights and actively</span></div>
<div style="position:absolute;left:28.35px;top:141.62px" class="cls_002"><span class="cls_002">files patent applications for its research and development projects. During the year, the Group</span></div>
<div style="position:absolute;left:28.35px;top:158.62px" class="cls_002"><span class="cls_002">has filed</span></div>
<div style="position:absolute;left:81.72px;top:158.62px" class="cls_002"><span class="cls_002">161 domestic patent applications (61 authorised) and 62 overseas patent applications (9</span></div>
<div style="position:absolute;left:28.35px;top:175.62px" class="cls_002"><span class="cls_002">authorised).</span></div>
<div style="position:absolute;left:28.35px;top:209.62px" class="cls_002"><span class="cls_002">In the next three years, the Group is expected to launch more than 50 new products, over 15 of</span></div>
<div style="position:absolute;left:28.35px;top:226.62px" class="cls_002"><span class="cls_002">which will be major products with a market potential of more than RMB1 billion each, providing</span></div>
<div style="position:absolute;left:28.35px;top:243.63px" class="cls_002"><span class="cls_002">strong support for the Group’s high-quality growth in the future.</span></div>
<div style="position:absolute;left:28.35px;top:277.62px" class="cls_002"><span class="cls_002">As a national innovative enterprise in China equipped with a strong R&D team and product</span></div>
<div style="position:absolute;left:28.35px;top:294.63px" class="cls_002"><span class="cls_002">pipelines, the Group will definitely take the lead in future market competition.</span></div>
<div style="position:absolute;left:28.57px;top:328.62px" class="cls_007"><span class="cls_007">Impact of Coronavirus Disease (COVID-19)</span></div>
<div style="position:absolute;left:28.36px;top:362.62px" class="cls_002"><span class="cls_002">Since the novel coronavirus outbreak in January</span></div>
<div style="position:absolute;left:304.42px;top:362.62px" class="cls_002"><span class="cls_002">2020, the close-off management throughout the</span></div>
<div style="position:absolute;left:28.36px;top:379.62px" class="cls_002"><span class="cls_002">country has severely affected the outpatient visits and hospitalization rate, marketing activities and</span></div>
<div style="position:absolute;left:28.36px;top:396.63px" class="cls_002"><span class="cls_002">drug distribution have also been hindered. Except for certain finished drug products related to the</span></div>
<div style="position:absolute;left:28.36px;top:413.63px" class="cls_002"><span class="cls_002">epidemic achieving sales above expectation, the sales of other finished drug products have been</span></div>
<div style="position:absolute;left:28.36px;top:430.64px" class="cls_002"><span class="cls_002">adversely affected to various degrees.</span></div>
<div style="position:absolute;left:28.36px;top:464.63px" class="cls_002"><span class="cls_002">During the epidemic, the Group, on one hand, actively responded to various prevention and control</span></div>
<div style="position:absolute;left:28.36px;top:481.64px" class="cls_002"><span class="cls_002">measures of the government, and ensured sufficient supply of products with urgent clinical needs</span></div>
<div style="position:absolute;left:28.36px;top:498.64px" class="cls_002"><span class="cls_002">such as arbidol. On the other hand, the new ways of doing academic promotion such as online</span></div>
<div style="position:absolute;left:28.36px;top:515.64px" class="cls_002"><span class="cls_002">academic meetings and lectures have generated good results, alleviating the impact on sales from the</span></div>
<div style="position:absolute;left:28.36px;top:532.65px" class="cls_002"><span class="cls_002">epidemic to a certain extent. Currently, the Group has fully resumed operation and business has been</span></div>
<div style="position:absolute;left:28.36px;top:549.65px" class="cls_002"><span class="cls_002">back to normal, except for Hubei Province. The Group will endeavour to make up for the epidemic’s</span></div>
<div style="position:absolute;left:28.36px;top:566.66px" class="cls_002"><span class="cls_002">impact on the business progress of the year.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 32 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:27232px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background33.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">FINANCIAL REVIEW</span></div>
<div style="position:absolute;left:28.34px;top:73.60px" class="cls_007"><span class="cls_007">Results</span></div>
<div style="position:absolute;left:371.49px;top:110.44px" class="cls_007"><span class="cls_007">2019</span></div>
<div style="position:absolute;left:456.54px;top:110.44px" class="cls_002"><span class="cls_002">2018</span></div>
<div style="position:absolute;left:528.02px;top:110.44px" class="cls_002"><span class="cls_002">Change</span></div>
<div style="position:absolute;left:341.42px;top:127.44px" class="cls_013"><span class="cls_013">RMB ‘000</span></div>
<div style="position:absolute;left:428.48px;top:127.44px" class="cls_003"><span class="cls_003">RMB ‘000</span></div>
<div style="position:absolute;left:28.34px;top:161.44px" class="cls_002"><span class="cls_002">Revenue:</span></div>
<div style="position:absolute;left:28.34px;top:178.44px" class="cls_002"><span class="cls_002">Finished drugs</span></div>
<div style="position:absolute;left:338.79px;top:178.44px" class="cls_007"><span class="cls_007">17,937,001</span></div>
<div style="position:absolute;left:423.84px;top:178.44px" class="cls_002"><span class="cls_002">13,503,386</span></div>
<div style="position:absolute;left:526.92px;top:178.44px" class="cls_002"><span class="cls_002">+32.8%</span></div>
<div style="position:absolute;left:28.35px;top:195.45px" class="cls_002"><span class="cls_002">Vitamin C</span></div>
<div style="position:absolute;left:345.26px;top:195.45px" class="cls_007"><span class="cls_007">1,921,704</span></div>
<div style="position:absolute;left:430.30px;top:195.45px" class="cls_002"><span class="cls_002">1,783,510</span></div>
<div style="position:absolute;left:533.38px;top:195.45px" class="cls_002"><span class="cls_002">+7.7%</span></div>
<div style="position:absolute;left:28.36px;top:212.45px" class="cls_002"><span class="cls_002">Antibiotics</span></div>
<div style="position:absolute;left:355.17px;top:212.45px" class="cls_007"><span class="cls_007">878,921</span></div>
<div style="position:absolute;left:430.32px;top:212.45px" class="cls_002"><span class="cls_002">1,086,725</span></div>
<div style="position:absolute;left:529.71px;top:212.45px" class="cls_002"><span class="cls_002">-19.1%</span></div>
<div style="position:absolute;left:28.38px;top:229.46px" class="cls_002"><span class="cls_002">Others</span></div>
<div style="position:absolute;left:345.28px;top:229.46px" class="cls_007"><span class="cls_007">1,365,566</span></div>
<div style="position:absolute;left:430.33px;top:229.46px" class="cls_002"><span class="cls_002">1,342,919</span></div>
<div style="position:absolute;left:533.41px;top:229.46px" class="cls_002"><span class="cls_002">+1.7%</span></div>
<div style="position:absolute;left:28.35px;top:266.43px" class="cls_002"><span class="cls_002">Total</span></div>
<div style="position:absolute;left:338.80px;top:266.43px" class="cls_007"><span class="cls_007">22,103,192</span></div>
<div style="position:absolute;left:423.85px;top:266.43px" class="cls_002"><span class="cls_002">17,716,540</span></div>
<div style="position:absolute;left:526.93px;top:266.43px" class="cls_002"><span class="cls_002">+24.8%</span></div>
<div style="position:absolute;left:28.35px;top:307.68px" class="cls_002"><span class="cls_002">Operating profit</span></div>
<div style="position:absolute;left:345.26px;top:307.68px" class="cls_007"><span class="cls_007">4,600,181</span></div>
<div style="position:absolute;left:430.30px;top:307.68px" class="cls_002"><span class="cls_002">3,822,962</span></div>
<div style="position:absolute;left:526.93px;top:307.68px" class="cls_002"><span class="cls_002">+20.3%</span></div>
<div style="position:absolute;left:28.36px;top:324.69px" class="cls_002"><span class="cls_002">Operating profit margin</span></div>
<div style="position:absolute;left:362.07px;top:324.69px" class="cls_007"><span class="cls_007">20.8%</span></div>
<div style="position:absolute;left:449.12px;top:324.69px" class="cls_002"><span class="cls_002">21.6%</span></div>
<div style="position:absolute;left:28.37px;top:341.69px" class="cls_002"><span class="cls_002">Profit attributable to shareholders</span></div>
<div style="position:absolute;left:345.28px;top:341.69px" class="cls_007"><span class="cls_007">3,714,106</span></div>
<div style="position:absolute;left:430.33px;top:341.69px" class="cls_002"><span class="cls_002">3,080,802</span></div>
<div style="position:absolute;left:526.95px;top:341.69px" class="cls_002"><span class="cls_002">+20.6%</span></div>
<div style="position:absolute;left:28.39px;top:376.50px" class="cls_002"><span class="cls_002">Finished drug business continued to be a major growth driver to the Group, with sales increasing by</span></div>
<div style="position:absolute;left:28.39px;top:393.51px" class="cls_002"><span class="cls_002">32.8% to RMB17,937 million in the current year. Innovative drugs, in particular, delivered a strong</span></div>
<div style="position:absolute;left:28.39px;top:410.51px" class="cls_002"><span class="cls_002">growth with sales reaching RMB12,975 million, representing a growth of</span></div>
<div style="position:absolute;left:447.11px;top:410.51px" class="cls_002"><span class="cls_002">48.4%. Revenue from</span></div>
<div style="position:absolute;left:28.39px;top:427.52px" class="cls_002"><span class="cls_002">innovative drugs as a proportion of total revenue of the Group further increased from 49.3% in 2018</span></div>
<div style="position:absolute;left:28.39px;top:444.52px" class="cls_002"><span class="cls_002">to 58.7% in the current year.</span></div>
<div style="position:absolute;left:28.39px;top:478.52px" class="cls_002"><span class="cls_002">Operating profit margin slightly decreased from 21.6% in 2018 to 20.8% in 2019. It is the mixed</span></div>
<div style="position:absolute;left:28.39px;top:495.52px" class="cls_002"><span class="cls_002">results of the following factors:</span></div>
<div style="position:absolute;left:210.16px;top:495.52px" class="cls_002"><span class="cls_002">(i) higher proportion of sales from innovative drugs which have</span></div>
<div style="position:absolute;left:28.39px;top:512.52px" class="cls_002"><span class="cls_002">a relatively higher profit margin;</span></div>
<div style="position:absolute;left:215.36px;top:512.52px" class="cls_002"><span class="cls_002">(ii) higher selling expense to revenue ratio of the finished drug</span></div>
<div style="position:absolute;left:28.39px;top:529.53px" class="cls_002"><span class="cls_002">business resulting from the Group’s increased efforts in market development;</span></div>
<div style="position:absolute;left:481.82px;top:529.53px" class="cls_002"><span class="cls_002">(iii) significant</span></div>
<div style="position:absolute;left:28.39px;top:546.53px" class="cls_002"><span class="cls_002">increase in research and development expenses; and (iv) decreased profitability of the vitamin C</span></div>
<div style="position:absolute;left:28.39px;top:563.54px" class="cls_002"><span class="cls_002">business due to lower selling prices.</span></div>
<div style="position:absolute;left:28.39px;top:597.53px" class="cls_007"><span class="cls_007">Selling and Distribution Expenses</span></div>
<div style="position:absolute;left:28.39px;top:631.53px" class="cls_002"><span class="cls_002">Selling and distribution expenses was RMB8,712 million in 2019 as compared to RMB6,185 million</span></div>
<div style="position:absolute;left:28.39px;top:648.53px" class="cls_002"><span class="cls_002">in 2018. The increase in selling and distribution expenses was primarily attributable to (i) expansion</span></div>
<div style="position:absolute;left:28.39px;top:665.54px" class="cls_002"><span class="cls_002">of sales force of the innovative drugs; (ii) increased efforts in marketing and academic promotion</span></div>
<div style="position:absolute;left:28.39px;top:682.54px" class="cls_002"><span class="cls_002">for the newly launched innovative drug product</span></div>
<div style="position:absolute;left:300.50px;top:682.54px" class="cls_002"><span class="cls_002">“Keaili”; and</span></div>
<div style="position:absolute;left:378.97px;top:682.54px" class="cls_002"><span class="cls_002">(iii) increased efforts in academic</span></div>
<div style="position:absolute;left:28.39px;top:699.54px" class="cls_002"><span class="cls_002">promotion for some generic drug products.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 33 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:28083px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background34.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_007"><span class="cls_007">Administrative Expenses</span></div>
<div style="position:absolute;left:28.35px;top:73.60px" class="cls_002"><span class="cls_002">Administrative expenses was RMB749 million in 2019 as compared to RMB657 million in 2018. The</span></div>
<div style="position:absolute;left:28.35px;top:90.60px" class="cls_002"><span class="cls_002">increase in administrative expenses was primarily attributable to the expanded scale of operation of</span></div>
<div style="position:absolute;left:28.35px;top:107.61px" class="cls_002"><span class="cls_002">the Group.</span></div>
<div style="position:absolute;left:28.35px;top:141.60px" class="cls_007"><span class="cls_007">Research and Development Expenses</span></div>
<div style="position:absolute;left:28.35px;top:175.60px" class="cls_002"><span class="cls_002">R&D expenses was RMB2,000 million in 2019 as compared to RMB1,342 million in 2018. The</span></div>
<div style="position:absolute;left:28.35px;top:192.60px" class="cls_002"><span class="cls_002">increase in R&D expenses was primarily attributable to</span></div>
<div style="position:absolute;left:347.52px;top:192.60px" class="cls_002"><span class="cls_002">(i) increased number of products under</span></div>
<div style="position:absolute;left:28.35px;top:209.61px" class="cls_002"><span class="cls_002">development; (ii) increased spending on ongoing and newly initiated clinical trials; (iii) increased</span></div>
<div style="position:absolute;left:28.35px;top:226.61px" class="cls_002"><span class="cls_002">spending on product collaboration projects; and</span></div>
<div style="position:absolute;left:301.36px;top:226.61px" class="cls_002"><span class="cls_002">(iv) increased spending on quality and efficacy</span></div>
<div style="position:absolute;left:28.35px;top:243.62px" class="cls_002"><span class="cls_002">consistency evaluation of generics.</span></div>
<div style="position:absolute;left:28.35px;top:277.61px" class="cls_007"><span class="cls_007">Liquidity and Financial Position</span></div>
<div style="position:absolute;left:28.35px;top:311.61px" class="cls_002"><span class="cls_002">For the financial year of 2019, the Group’s operating activities generated a cash inflow of RMB3,784</span></div>
<div style="position:absolute;left:28.35px;top:328.61px" class="cls_002"><span class="cls_002">million (2018: RMB3,795 million). Average turnover period of trade receivables (ratio of balance</span></div>
<div style="position:absolute;left:28.35px;top:345.62px" class="cls_002"><span class="cls_002">of trade receivables to sales, inclusive of value added tax for sales in China) slightly improved from</span></div>
<div style="position:absolute;left:28.35px;top:362.62px" class="cls_002"><span class="cls_002">37 days in 2018 to 35 days this year. Average turnover period of inventories (ratio of balance of</span></div>
<div style="position:absolute;left:28.35px;top:379.62px" class="cls_002"><span class="cls_002">inventories to cost of sales) decreased from 178 days in 2018 to 149 days this year. Current ratio of</span></div>
<div style="position:absolute;left:28.35px;top:396.63px" class="cls_002"><span class="cls_002">the Group was 2.2 as at 31 December 2019, higher than 1.9 a year ago. Capital expenditure for the</span></div>
<div style="position:absolute;left:28.35px;top:413.63px" class="cls_002"><span class="cls_002">year amounted to RMB2,185 million, which were mainly spent to construct production facilities and</span></div>
<div style="position:absolute;left:28.35px;top:430.64px" class="cls_002"><span class="cls_002">improve production efficiency.</span></div>
<div style="position:absolute;left:28.35px;top:464.63px" class="cls_002"><span class="cls_002">The Group’s financial position remained solid. As at 31 December 2019, cash and cash equivalents</span></div>
<div style="position:absolute;left:28.35px;top:481.64px" class="cls_002"><span class="cls_002">amounted to RMB4,118 million (2018: RMB4,336 million) and bank borrowings amounted to</span></div>
<div style="position:absolute;left:28.35px;top:498.64px" class="cls_002"><span class="cls_002">RMB23 million (2018: RMB71 million), resulting in a net cash position of RMB4,095 million (2018:</span></div>
<div style="position:absolute;left:28.35px;top:515.64px" class="cls_002"><span class="cls_002">RMB4,265 million).</span></div>
<div style="position:absolute;left:28.35px;top:549.64px" class="cls_002"><span class="cls_002">All of the Group’s borrowings are denominated in Renminbi. The Group’s sales revenue are</span></div>
<div style="position:absolute;left:28.35px;top:566.64px" class="cls_002"><span class="cls_002">denominated in Renminbi for domestic sales in China and in US dollars for export sales. The</span></div>
<div style="position:absolute;left:28.35px;top:583.65px" class="cls_002"><span class="cls_002">Group manages its foreign exchange risks by closely monitoring its foreign exchange exposures and</span></div>
<div style="position:absolute;left:28.35px;top:600.65px" class="cls_002"><span class="cls_002">mitigating the impact of foreign currency fluctuations by using appropriate hedging arrangements</span></div>
<div style="position:absolute;left:28.35px;top:617.66px" class="cls_002"><span class="cls_002">when considered necessary.</span></div>
<div style="position:absolute;left:28.35px;top:651.65px" class="cls_007"><span class="cls_007">Pledge of Assets</span></div>
<div style="position:absolute;left:28.35px;top:685.65px" class="cls_002"><span class="cls_002">As at 31 December 2019, structured bank deposits amounting to RMB195 million and buildings</span></div>
<div style="position:absolute;left:28.35px;top:702.65px" class="cls_002"><span class="cls_002">amounting to RMB34 million have been pledged to secure certain banking facilities of the Group.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 34 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:28934px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background35.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.35px;top:39.60px" class="cls_007"><span class="cls_007">Dividend Policy</span></div>
<div style="position:absolute;left:28.35px;top:73.60px" class="cls_002"><span class="cls_002">It is the present intention of the Board to provide shareholders with regular dividends with a normal</span></div>
<div style="position:absolute;left:28.35px;top:90.60px" class="cls_002"><span class="cls_002">target payout ratio of not less than 30 per cent of the Group’s core profit on a full year basis. The</span></div>
<div style="position:absolute;left:28.35px;top:107.61px" class="cls_002"><span class="cls_002">actual amount of dividends will depend on a number of factors including but not limited to financial</span></div>
<div style="position:absolute;left:28.35px;top:124.61px" class="cls_002"><span class="cls_002">results, financial position and funding needs of the Group.</span></div>
<div style="position:absolute;left:28.35px;top:158.61px" class="cls_007"><span class="cls_007">Employees</span></div>
<div style="position:absolute;left:28.35px;top:192.60px" class="cls_002"><span class="cls_002">As at 31 December 2019, the Group had approximately 17,300 employees. The majority of them are</span></div>
<div style="position:absolute;left:28.35px;top:209.61px" class="cls_002"><span class="cls_002">employed in mainland China. The Group will continue to offer competitive remuneration packages,</span></div>
<div style="position:absolute;left:28.35px;top:226.61px" class="cls_002"><span class="cls_002">share options, share awards and bonuses to staff based on the performance of the Group and</span></div>
<div style="position:absolute;left:28.35px;top:243.62px" class="cls_002"><span class="cls_002">individual employee.</span></div>
<div style="position:absolute;left:28.57px;top:277.61px" class="cls_007"><span class="cls_007">SUSTAINABLE DEVELOPMENT STRATEGIES</span></div>
<div style="position:absolute;left:28.35px;top:311.61px" class="cls_002"><span class="cls_002">The Group will continue to pursue the development strategies of (i) active development of innovative</span></div>
<div style="position:absolute;left:28.35px;top:328.61px" class="cls_002"><span class="cls_002">drug business; (ii) continuation of products internationalization; and (iii) consolidation of leadership</span></div>
<div style="position:absolute;left:28.35px;top:345.62px" class="cls_002"><span class="cls_002">in bulk drug business in order to achieve long-term sustainable growth.</span></div>
<div style="position:absolute;left:28.57px;top:379.61px" class="cls_007"><span class="cls_007">CORPORATE GOVERNANCE</span></div>
<div style="position:absolute;left:28.35px;top:413.61px" class="cls_002"><span class="cls_002">The Company has complied with all the code provisions in the Corporate Governance Code (the</span></div>
<div style="position:absolute;left:28.35px;top:430.61px" class="cls_002"><span class="cls_002">“Code”) contained in Appendix 14 of the Rules Governing the Listing of Securities on The Stock</span></div>
<div style="position:absolute;left:28.35px;top:447.62px" class="cls_002"><span class="cls_002">Exchange of Hong Kong Limited (the “Listing Rules”) throughout the year ended 31 December 2019</span></div>
<div style="position:absolute;left:28.35px;top:464.62px" class="cls_002"><span class="cls_002">except the deviation from code provision A.2.1 as set out below.</span></div>
<div style="position:absolute;left:28.35px;top:498.62px" class="cls_002"><span class="cls_002">Code provision A.2.1 of the Code stipulates that the roles of chairman and chief executive officer</span></div>
<div style="position:absolute;left:28.35px;top:515.62px" class="cls_002"><span class="cls_002">should be separate and should not be performed by the same individual. Mr. Cai Dongchen, the</span></div>
<div style="position:absolute;left:28.35px;top:532.62px" class="cls_002"><span class="cls_002">Company’s Chairman, has also assumed the role as the chief executive officer of the Company. The</span></div>
<div style="position:absolute;left:28.35px;top:549.63px" class="cls_002"><span class="cls_002">Company believes that vesting both roles in Mr. Cai will allow for more effective planning and</span></div>
<div style="position:absolute;left:28.35px;top:566.63px" class="cls_002"><span class="cls_002">execution of business strategies. As all major decisions are made in consultation with members of</span></div>
<div style="position:absolute;left:28.35px;top:583.64px" class="cls_002"><span class="cls_002">the Board, the Company believes that there is adequate balance of power and authority in place.</span></div>
<div style="position:absolute;left:28.57px;top:617.63px" class="cls_007"><span class="cls_007">REVIEW OF ANNUAL RESULTS</span></div>
<div style="position:absolute;left:28.35px;top:651.63px" class="cls_002"><span class="cls_002">The consolidated financial statements of the Company and its subsidiaries for the year ended</span></div>
<div style="position:absolute;left:28.35px;top:668.63px" class="cls_002"><span class="cls_002">31 December 2019 have been reviewed by the Audit Committee of the Company and audited by the</span></div>
<div style="position:absolute;left:28.35px;top:685.64px" class="cls_002"><span class="cls_002">Company’s auditor.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 35 —</span></div>
</div>
<div style="position:absolute;left:50%;margin-left:-297px;top:29785px;width:595px;height:841px;border-style:outset;overflow:hidden">
<div style="position:absolute;left:0px;top:0px">
<img src="8a54d082-839f-11ea-8b25-0cc47a792c0a_id_8a54d082-839f-11ea-8b25-0cc47a792c0a_files/background36.jpg" width=595 height=841></div>
<div style="position:absolute;left:28.56px;top:39.60px" class="cls_007"><span class="cls_007">CLOSURE OF REGISTER OF MEMBERS</span></div>
<div style="position:absolute;left:28.34px;top:73.60px" class="cls_002"><span class="cls_002">The register of members of the Company will be closed from Tuesday, 9 June 2020 to Monday, 15</span></div>
<div style="position:absolute;left:28.34px;top:90.60px" class="cls_002"><span class="cls_002">June 2020, both days inclusive, during which period no transfer of shares will be effected. In order to</span></div>
<div style="position:absolute;left:28.34px;top:107.61px" class="cls_002"><span class="cls_002">determine the identity of members who are entitled to attend and vote at the annual general meeting</span></div>
<div style="position:absolute;left:28.34px;top:124.61px" class="cls_002"><span class="cls_002">to be held on Monday, 15 June 2020, all share transfer documents accompanied by the relevant share</span></div>
<div style="position:absolute;left:28.34px;top:141.62px" class="cls_002"><span class="cls_002">certificates must be lodged with the Company’s share registrar, Tricor Secretaries Limited, at Level</span></div>
<div style="position:absolute;left:28.34px;top:158.62px" class="cls_002"><span class="cls_002">54, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong for registration not later than</span></div>
<div style="position:absolute;left:28.34px;top:175.62px" class="cls_002"><span class="cls_002">4:30 p.m. on Monday, 8 June 2020.</span></div>
<div style="position:absolute;left:28.34px;top:209.62px" class="cls_002"><span class="cls_002">The register of members of the Company will be closed from Monday, 22 June 2020 to Tuesday, 23</span></div>
<div style="position:absolute;left:28.34px;top:226.62px" class="cls_002"><span class="cls_002">June 2020, both dates inclusive, during which period no transfer of shares will be effected. In order</span></div>
<div style="position:absolute;left:28.34px;top:243.63px" class="cls_002"><span class="cls_002">to qualify for the proposed final dividend and issue of bonus shares, all share transfer documents</span></div>
<div style="position:absolute;left:28.34px;top:260.63px" class="cls_002"><span class="cls_002">accompanied by the relevant share certificates must be lodged with the Company’s share registrar,</span></div>
<div style="position:absolute;left:28.34px;top:277.64px" class="cls_002"><span class="cls_002">Tricor Secretaries Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong</span></div>
<div style="position:absolute;left:28.34px;top:294.64px" class="cls_002"><span class="cls_002">Kong, for registration not later than 4:30 p.m. on Friday, 19 June 2020.</span></div>
<div style="position:absolute;left:28.56px;top:328.64px" class="cls_007"><span class="cls_007">PURCHASE, SALE OR REDEMPTION OF THE COMPANY’S LISTED SECURITIES</span></div>
<div style="position:absolute;left:28.34px;top:362.63px" class="cls_002"><span class="cls_002">Neither the Company nor any of its subsidiaries had purchased, sold or redeemed any of the listed</span></div>
<div style="position:absolute;left:28.34px;top:379.64px" class="cls_002"><span class="cls_002">securities of the Company during the year.</span></div>
<div style="position:absolute;left:409.35px;top:413.63px" class="cls_002"><span class="cls_002">By order of the Board</span></div>
<div style="position:absolute;left:426.76px;top:430.64px" class="cls_007"><span class="cls_007">CAI Dongchen</span></div>
<div style="position:absolute;left:441.80px;top:447.64px" class="cls_003"><span class="cls_003">Chairman</span></div>
<div style="position:absolute;left:28.34px;top:464.64px" class="cls_002"><span class="cls_002">Hong Kong, 30 March 2020</span></div>
<div style="position:absolute;left:28.34px;top:498.64px" class="cls_003"><span class="cls_003">As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG</span></div>
<div style="position:absolute;left:28.34px;top:515.64px" class="cls_003"><span class="cls_003">Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei,</span></div>
<div style="position:absolute;left:28.34px;top:532.65px" class="cls_003"><span class="cls_003">Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as</span></div>
<div style="position:absolute;left:28.34px;top:549.65px" class="cls_003"><span class="cls_003">non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam,</span></div>
<div style="position:absolute;left:28.34px;top:566.66px" class="cls_003"><span class="cls_003">Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.</span></div>
<div style="position:absolute;left:275.59px;top:800.70px" class="cls_002"><span class="cls_002">— 36 —</span></div>
</div>

</body>
</html>
